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Antigénios Thomsen-Friedenreich em cancro de 
bexiga: avaliação do seu valor prognóstico 
 
Resumo 
Introdução. O cancro de bexiga é uma patologia comum que representa o 6° e o 5° 
cancro mais incidente em Portugal e na Itália, respetivamente. Em mais de metade dos 
casos ocorre reincidência durante o primeiro ano, requerendo acompanhamento clínico ao 
longo da vida. A instilação intravesical de Bacillus Calmette-Guérin (BCG)  
(uma estirpe atenuada do Mycobacterium bovis) representa uma imunoterapia eficaz no 
combate ao cancro de bexiga, no entanto, muitos aspetos da interação de BCG com as 
células tumorais bem como com as células do sistema imunitário permanecem por 
desvendar. As células tumorais de bexiga expressam frequentemente as formas sialiladas 
dos antigénios de Thomsen-Friedenreich (TF), i.e., sialil-T (sT) e sialil-Tn (sTn).  
Contudo ainda se desconhece o significado da sua expressão na malignidade tumoral e se 
afeta a eficácia da terapêutica BCG. Objetivo do estudo. Investigar o papel dos 
antigénios sT e sTn no fenótipo maligno de células de cancro de bexiga bem como na 
resposta mediada pelo sistema imunitário à terapia com BCG. Metodologia. Para tal, 
foram utilizadas as linhas celulares de cancro da bexiga HT1376 e MCR, geneticamente 
modificadas por transdução com vetores codificantes para as sialiltransferases ST3GAL1 
ou ST6GALNAC1, de forma a expressar homogeneamente os antigénios sT ou sTn 
respetivamente. Estes modelos celulares foram estudados após confronto com BCG.  
O nível de BCG internalizado foi avaliado por citometria de fluxo. O perfil global de 
expressão genética dos modelos celulares antes e após incubação com BCG foi analisado 
pela tecnologia de microarray. O perfil de citocinas secretadas pelos modelos celulares 
após incubação com BCG, bem como de macrófagos estimulados pelo secretoma de 
células de cancro de bexiga que por sua vez foram estimuladas previamente por BCG,  
foi estudado pelo sistema multiplex de “imuno-esferas”. Resultados. A análise do 
transcritoma dos modelos celulares revelou que grupos de genes envolvidos em funções 
específicas foram modulados em paralelo nos dois modelos celulares, após transdução, 
independentemente da sialiltransferase expressa. Ou seja, em células que expressavam a 
sialiltransferase ST3GAL1 ou ST6GALNAC1, os genes envolvidos na regulação da 
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segregação cromossómica e na reparação do DNA foram consistentemente regulados 
negativamente. Genes descritos na literatura como marcadores para o cancro de bexiga 
foram também modulados. A incubação com BCG resultou numa tendência ao aumento 
da expressão de genes relevantes na preservação e estabilidade genómica e menor 
malignidade, no entanto, apenas em células que expressavam sT ou sTn. Entre as dez 
citocinas testadas, apenas a IL-6 e IL-8 foram expressas pelas linhas celulares de cancro 
da bexiga, com indução destas após estimulação com BCG, e principalmente em células 
que expressavam ST3GAL1 ou ST6GALNAC1. Em macrófagos, citocinas inflamatórias, 
tais como IL-1β, IL-6 e TNFα, e a citocina anti-inflamatória IL-10, foram induzidas 
apenas pelo secretoma de células de cancro da bexiga confrontadas com BCG, com maior 
relevância quando estas expressavam ST3GAL1 ou ST6GALNAC1, prevendo a 
estimulação de macrófagos semelhantes aos de tipo M1 e uma melhor resposta à terapia 
com BCG. Conclusões. O efeito geral da expressão destas sialiltransferases e dos 
produtos enzimáticos sT ou sTn nas células de cancro de bexiga conduz a um fenótipo de 
maior malignidade. Contudo, a maior avidez de estas na produção de citocinas 
inflamatórias após confronto com BCG, bem como a maior capacidade de estimulação de 
macrófagos, predirá uma resposta à terapia com BCG mais eficaz em tumores que 
expressem os antigénios de TF sialilados. Tais conclusões são totalmente concordantes 
com os nossos mais recentes dados clínicos obtidos em colaboração, que mostram que em 
doentes com cancro de bexiga que expressam sTn respondem melhor a terapia BCG. 
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Antigeni Thomsen-Friedenreich nel cancro della 
vescica: valutazione del valore prognostico 
 
Riassunto 
Introduzione. Il cancro della vescica è una patologia comune che rappresenta la 6ª e la 5ª 
neoplasia a maggiore incidenza  in Portogallo ed in Italia, rispettivamente. Più della metà 
dei casi presentano una recidiva entro un anno, richiedendo quindi il monitoraggio a vita. 
L’instillazione intravescicale di Bacillus Calmette Guerin (BCG)  
(un ceppo attenuato di Mycobacterium bovis) rappresenta una immunoterapia efficace 
contro il cancro alla vescica, ma molti aspetti dell’interazione del BCG con le cellule 
tumorali e con le cellule del sistema immunitario sono ancora da comprendere.  
Le cellule tumorali di vescica spesso esprimono le forme sialilate degli antigeni  
Thomsen-Friedenreich (TF), i.e., sialil-T (sT) e sialil-Tn (sTn). Però il significato 
biologico della loro espressione e nel determinare l’efficacia terapeutica del BCG è 
ancora sconosciuto. Obiettivo dello studio. Studiare il ruolo degli antigeni sT e sTn nel 
determinare il fenotipo maligno delle cellule tumorali della vescica e la risposta 
immunitaria alla terapia con BCG. Metodologia. Sono state utilizzate le linee cellulari di 
cancro alla vescica HT1376 e MCR, geneticamente modificate mediante trasduzione 
genica con vettori codificanti le sialiltrasferasi ST3GAL1 o ST6GALNAC1, allo scopo di 
ottenere l’espressione omogenea degli antigeni sT o sTn. Questi modelli cellulari sono 
stati studiati dopo l’incubazione col BCG. Il livello di internalizzazione di BCG è stato 
valutato mediante citometria a flusso. Il  profilo di espressione genica delle linee cellulari 
prima e dopo incubazione col BCG è stato studiato mediante tecnologia microarray. 
Mediante un sistema immunobiglie multiplex, è stato possibile studiare simultaneamente 
l’espressione di numerose citochine secrete o dalle cellule di cancro della vescica dopo 
incubazione con BCG e o dai macrofagi stimulati dal secretoma delle cellule tumorali di 
vescica dopo incubazione col BCG, . Risultati. Le analisi del trascrittoma delle linee 
cellulari hanno rivelato che vi erano gruppi di geni accomunati dal fatto di svolgere una 
analoga funzione, che venivano regolati in parallelo nelle due linee cellulari dopo 
trasduzione con l’una o l’altra sialiltrasferasi. In particolare, in cellule che esprimevano 
ST3GAL1 o ST6GALNAC1, molti geni coinvolti nella corretta segregazione cromosomica 
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e nella riparazione del DNA erano costantemente sottoespressi. Inoltre, geni descritti in 
letteratura come marcatori del cancro della vescica venivano modulati nelle  cellule 
trasdotte con l’una o l’altra sialiltrasferasi. L’incubazione col BCG induceva una tendenza 
alla sovraespressione di geni coinvolti nel mantenimento della stabilità genomica e nella 
riduzione della malignità, ma soltanto in cellule che esprimevano sT o sTn. Tra le dieci 
citochine analizzate, solo IL-6 e IL-8 erano secrete dalle linee cellulari. Il contatto con 
BCG ne stimolava la secrezione, in particolare nelle cellule che esprimevano ST3GAL1 o 
ST6GALNAC1. Nei macrofagi, la secrezione delle citochine infiammatorie IL-1β, IL-6 e 
TNFα e della citochina antinfiammatoria IL-10 veniva indotta solo se il secretoma di 
cellule di cancro della vescica proveniva da cellule trattate con  BCG, in particolare 
quando le cellule esprimevano gli antigeni sT o sTn, prevedendo la stimolazione dei 
macrofagi simili ai macrofagi di tipo M1 e una migliore risposta alla terapia con BCG. 
Conclusioni. L’espressione delle due sialiltrasferasi e dei loro prodotti, gli antigeni sT o 
sTn, nelle cellule tumorali della vescica sembra indurre un fenotipo più maligno. Tuttavia, 
la maggiore capacità delle cellule tumorali che esprimono queste sialiltrasferasi di  
secernere delle citochine infiammatorie dopo contatto con BCG, così come la loro 
maggiore capacità di stimolare i macrofagi, fa prevedere che la risposta al BCG sia più 
efficace nei tumori che esprimono questi antigeni TF sialilati. Ciò è perfettamente in 
accordo con i nostri più recenti dati clinici ottenuti in collaborazione, che dimonstrano che 
i pazienti con cancro della vescica che esprimono sTn rispondono meglio alla terapia con 
BCG. 
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Thomsen-Friedenreich antigens in bladder cancer: 
evaluation of their prognostic value 
 
Abstract 
Background. Bladder cancer is a common malignancy representing the 6
th
 and the 5
th
 
most incident cancer in Portugal and in Italy, respectively. More than half of the cases 
relapse within one year, requiring though a lifelong follow-up. Intravesical instillation of 
Bacillus Calmette-Guérin (BCG) (an attenuated strain of Mycobacterium bovis) 
represents an effective immunotherapy of bladder cancer, although many aspects of the 
interaction of BCG with cancer cells and host immune cells remain obscure. Bladder 
cancer cells often express the sialylated forms of the Thomsen-Friedenreich (TF),  
i.e., sialil-T (sT) e sialil-Tn (sTn). However, it’s still unknown the sense of such 
expression in tumour malignancy and in the BCG therapy efficacy.  
Aim of the study. To investigate the role of the sT and sTn antigens on the malignant 
phenotype of bladder cancer cells and the immune mediated response to BCG therapy. 
Experimental. We have utilized populations of the bladder cancer cell lines HT1376 and 
MCR, genetically modified by transduction with the sialyltransferases ST3GAL1 or 
ST6GALNAC1 to express homogeneously sT or sTn antigens. The level of BCG 
internalized was assessed by flow cytometry. The whole gene expression profile of  
BCG-challenged or unchallenged bladder cancer cell lines was studied by microarray 
technology. The profile of cytokines secreted by BCG-challenged bladder cancer cells 
and that of macrophages challenged by the secretome of BCG-challenged bladder cancer 
cells was studied by multiplex immune-beads assay. Results. Transcriptome analysis of 
the sialyltransferase-transduced cells revealed that groups of genes involved in specific 
functions were regulated in parallel in the two cell lines, regardless the sialyltransferase 
expressed. Namely, in sialyltransferase-expressing cells, genes involved in the proper 
chromosomal segregation and in the DNA repair were consistently down-regulated, while 
genes reported in literature as markers for bladder cancer were modulated.  
BCG-challenging induced a tendency to up-regulation of the genes preserving genomic 
stability and reducing malignancy, but only in cells expressing either sT or sTn.  
Among the ten cytokines tested, only IL-6 and IL-8 were expressed by bladder cancer cell 
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lines and up-regulated by BCG-challenging, mainly in sialyltransferases-expressing cells. 
In macrophages, inflammatory cytokines, such as IL-1β, IL-6 and TNFα, and the 
antinflammatory IL-10 were induced only by the secretome of BCG-challenged bladder 
cancer cells, particularly when expressing either sialyltransferase, predicting the 
stimulation of M1-like macrophages and a better response to BCG therapy.  
Conclusions. The general effect of the expression of the two sialyltransferases and their 
products in the bladder cancer cells is toward a more malignant phenotype.  
However, the stronger ability of sialyltransferase expressing cells to produce 
inflammatory cytokines upon BCG-challenging and to stimulate macrophages predicts a 
more effective response to BCG in tumours expressing the sialylated TF antigens.  
This is fully consistent with our recent clinical data obtained in collaboration, showing 
that patients with bladder cancer expressing sTn respond better to BCG therapy. 
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and MCRsTn, respectively. Boxed expression data are the same reported in Figure 3.4 and are 
repeated here for comparison. 
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Figure 3.6. Time course of BCG internalization by bladder cancer cell lines. a) Analysis by 
FACS of the internalization of Connaught-BCG, RIVM-BCG or Pasteur-BCG by HT1376NC cells 
(light orange bars), HT1376sT cells (orange bars), MCRNC cells (light blue bars) and MCRsTn cells 
(dark blue bars), after 2 or 6 h of incubation with BCG. Internalization values were normalized 
with the respective controls incubated at 4 ºC. Data are the mean ± SD of 3 experiments.  
* p < 0.05. b) and c) An example of time-dependent Connaught-BCG internalization by MCRsTn 
cells MFI2h = 7, MFI6h = 13 and MFI24h = 23. Black line: internalization at 4 ºC. Over longer 
periods of time, internalization of BCG displayed a two slope curve with tendency to saturation. 
OCT stands for orange cell tracker. 
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Figure 3.7. Gene signatures in HT1376 cells. Expression variation of relevant genes in  
a) HT1376sT cells vs. HT1376NC cells, in b) HT1376NC cells and in c) HT1376sT cells after  
BCG-challenging. Genes were grouped in “bladder cancer markers” and “caretaker” categories, 
according to putatively increased or decreased malignant phenotypes. Only variations greater then 
± 0.5 were considered. Data are the mean of 3 experiments. * p < 0.05. 
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Figure 3.8. Modulation of MHC genes by BCG internalization in HT1376 cells. Percentage of 
expression variation of MHC related genes in a) HT1376NC, b) HT1376sT, after BCG-challenging. 
Only variations greater then ± 0.5 were considered. Data are the mean of 3 experiments. * p ≤ 0.05. 
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Figure 3.9. Gene signatures in MCR cells. Expression variation of relevant genes in a) MCRsTn 
cells vs. MCRNC cells in b) MCRNC cells and in c) MCRsTn cells after BCG-challenging.  
Genes were grouped in "BC markers" and "caretaker" according to their putative effect on 
malignancy. Only differential variations greater then ± 0.5 were considered. Data are the mean of  
3 experiments. * p < 0.05. 
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Figure 3.10. Modulation of MHC genes by BCG internalization. Percentage of expression 
variation of MHC genes in a) MCRNC, b) MCRsTn cells after BCG-challenging. Only variations 
greater then ± 0.5 were considered. Data are the mean of 3 experiments. * p ≤ 0.05. 
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Figure 3.11. Cytokine secretion by HT1376 cells. An induction of both IL-6 and IL-8 was found 
in both HT1376NC (pink bars) and HT1376sT (orange bars) 12 h after BCG-challenging. IL-8 
induction in HT1376sT cells was stronger than in HT1376NC cells. Data are the mean ± SD of  
3 experiments. *** p < 0.0001; * p < 0.05. 
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Figure 3.12. Cytokine secretion by MCR cells. Twelve hours after BCG-challenging, a 
significant induction of both IL-6 and IL-8 secretion was observed in MCRsTn (dark blue bars), but 
not in MCRNC (light blue bars). Data are the mean ± SD of 3 experiments. *** p < 0.0001;  
** p < 0.001. 
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Figure 3.13. Cytokine secretion by macrophages stimulated by HT1376 secretome. Secretome 
from BCG-challenged HT1376sT (dark orange bars) induced stronger secretion than that of 
HT1376NC (pink bars) of all cytokines except IL-8. Gray bars represent cytokine secretion by 
unstimulated macrophages. Data are the mean ± SD of 3 experiments. *** p < 0.0001;  
** p < 0.001; * p < 0.05. 
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Figure 3.14. Cytokine secretion by Macrophages stimulated by MCR secretome. Secretome 
from unchallenged MCRsTn (dark blue bars) or MCRNC (light blue bars) cells induced little 
secretion of IL-6 and TNFα and higher levels of IL-8. Secretome from BCG-challenged MCR cells 
induced all five cytokines with stronger induction of IL-10, IL-1β, IL-6 and TNFα when secretome 
from MCRsTn was tested. Gray bars represent cytokine secretion by unstimulated macrophages. 
Data are the mean ± SD of 3 experiments. *** p < 0.0001; ** p < 0.001; * p < 0.05. 
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Figure 3.15. Phagocytosis of apoptotic bladder cancer cell lines by macrophages. a) 
Phagocytosis of apoptotic BCG-challenged or unchallenged HT1376NC (pink bars) or HT1376sT 
(orange bars) cells. Phagocytosis was not affected by BCG-challenging but was higher with 
HT1376sT cells. b) Phagocytosis of apoptotic BCG-challenged or -unchallenged MCRNC  
(light blue) or MCRsTn cells (dark blue). Phagocytosis was not affected either by BCG-challenging 
or sTn expression. Data are the mean ± SD of 3 experiments. * p < 0.05. 
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Supplement I  
Figure I.1. Genes showing up- or down-regulation in HT1376sT cells compared with 
HT1376NC cells. Heat-maps are presented for the 2log expression ratio (≤ -0.9 in green or ≥ 0.9 in 
red) between HT1376sT cells and HT1376NC cells. Constitutive expression of ST3GAL1 induced 
significant (p ≤ 0.05) over-expression of 197 genes and down-regulation of 107 genes. Data are the 
mean of 3 experiments. 
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Figure I.2. Genes showing up- or down-regulation in both HT1376NC and HT1376sT after 
BCG-challenging. Heat-maps are presented for the 2log expression ratio (≤ -0.5 in green or ≥ 0.5 
in red) between BCG-challenged and unchallenged HT1376 (NC and sT) cell lines.  
BCG-challenging induced down-regulation of 18 genes and up-regulation of 68 genes. p ≤ 0.05. 
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Figure I.3. Genes showing differential modulation after BCG-challenging in HT1376NC or 
HT1376sT cells. Heat-maps are presented for the 2log expression ratio (≤ -1.0 in green or ≥ 1.0 in 
red) between BCG-challenged HT1376NC or HT1376sT cells and unchallenged cells. a) Group of 
genes modulated by BCG-challenging in HT1376NC, but not in HT1376sT cells. b) Group of genes 
modulated by BCG-challenging in HT1376sT, but not in HT1376NC cells. Twenty five genes 
showed modulation (12 up-regulation, 13 down-regulation) in HT1376NC, cells, but not in 
HT1376sT. On the contrary, 107 genes displayed modulation in HT1376sT cells but not in 
HT1376NC. Of these, 27 displayed up-regulation and 80 down-regulation. Data are the mean of  
3 experiments. p ≤ 0.05. 
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Figure I.4. Genes showing up- or down-regulation in MCRsTn cells compared with MCRNC. 
Heat-maps are presented for the 2log expression difference (≤ -0.9 in green or ≥ 0.9 in red) 
between MCRsTn cells and MCRNC cells. In MCRsTn cells, constitutive ST6GALNAC1 
overexpression induced the down-regulation of 114 genes and the up-regulation of 83 genes.  
Data are the mean of 3 experiments. p ≤ 0.05. 
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Figure I.5. Genes showing up- or down-regulation in both MCRNC and MCRsTn after  
BCG-challenging. Heat-maps are presented for the 2log expression ratio (≤ -0.5 in green or ≥ 0.5 
in red) between BCG-challenged and unchallenged MCR (NC and sTn) cell lines.  
BCG-challenging, 24 genes are down-regulated and 25 genes are significantly up-regulated.  
Data are the mean of 3 experiments. p ≤ 0.05. 
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Figure I.6. Genes showing differential modulation after BCG-challenging in MCRNC or 
MCRsTn cells. Heat-maps are presented for the 2log expression difference (≤ -1.0 in green or ≥ 1.0 
in red) between BCG-challenged MCRNC or MCRsTn cells and their respective unchallenged cells. 
a) Group of genes modulated by BCG-challenging in MCRNC, but not in MCRsTn cells. b) Group of 
genes modulated by BCG-challenging in MCRsTn, but not in MCRNC cells. In MCRsTn bladder 
cancer cells, after BCG-challenging, a) 17 genes failed to respond to BCG whether in MCRNC 
these responded negatively (11 genes) or positively (6 genes). On the other hand b) 38 new genes 
differentially respond to BCG-challenging (29 genes were up-regulated and 9 were  
down-regulated). Data are the mean of 3 experiments. p ≤ 0.00). 
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List of Abbreviations 
 
BC Bladder cancer  
BCG Bacillus Calmette-Guérin (an attenuated strain of Mycobacterium bovis) 
C1GALT1 Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (or core 1 
synthase) 
C1GALT1C1 C1GALT1-specific chaperone 1 (or Cosmc) 
CD4 Cluster of differentiation 4 molecule 
CD8 Cluster of differentiation 8 molecule 
Fuc Fucose 
Gal Galactose 
GalNAc N-acetylgalactosamine 
Glc Glucose 
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GU Genomic unstable bladder cancer molecular subtype 
HT1376 Bladder cancer cell line isolated from a 58 year old Caucasian woman with invasive 
TCC 
HT1376NC HT1376 cell line mock-transduced with the virapower lentiviral expression system  
HT1376ST3G1 HT1376 cell line ST3GAL1-transduced with the virapower lentiviral expression system 
(heterogeneously expressing sT) 
HT1376sT HT1376 cell line ST3GAL1-transduced with the virapower lentiviral expression system 
(homogeneously expressing sT) 
IL-1β/6/8/10 Interleukin 1 beta/ 6 / 8 / 10 
INFγ Interferon gamma 
MAA Maackia amurensis lectin 
MCR Bladder cancer cell line isolated from a subcutaneous metastatic lesion of a 51 year old 
male diagnosed with invasive TCC 
MCRNC MCR cell line mock-transduced with the virapower lentiviral expression system  
MCRST6GN1 MCR cell line ST6GALNAC1-transduced with the virapower lentiviral expression 
system (heterogeneously expressing sTn) 
MCRsTn MCR cell line ST6GALNAC1-transduced with the virapower lentiviral expression 
system (homogeneously expressing sTn) 
MHC Major histocompatibility complex  
MUC Mucin 
NMIBC Non-muscle invasive bladder cancer 
PNA Peanut lectin 
s6T Galβ1,3(Siaα2,6)GalNAc TF related antigen 
SCCL Squamous cell cancer-like bladder cancer molecular subtype 
Sia  Sialic acid 
SNA Sambucus nigra lectin 
sT Sialyl-T antigen 
ST3GAL1  ST3 beta-galactoside alpha-2,3-sialyltransferase 1 
ST6GALNAC1  ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide 
alpha-2,6-sialyltransferase 1 
sTn Sialyl-Tn antigen 
T Galα1,3GalNAc-O-Ser/Thr TF related antigen (or core 1 structure) 
TCC Transitional cell carcinoma  
TF Thomsen Friedenreich antigens 
Tis Bladder carcinoma in situ  
Tn GalNAc-O-Ser/Thr TF related antigen 
TNFα Tumour necrosis factor 
TUR Transurethral resection  
Uro A Urobasal A bladder cancer molecular subtype 
Uro B Urobasal B bladder cancer molecular subtype 
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I.1 Bladder Cancer 
 
Epidemiology 
Bladder cancer (BC) is a common malignancy in the world (Figure 1.1a), presenting the 
8
th
 highest incidence in 2008, with more than 10/100 000 new cases. Particularly high 
incidence rates are observed in Southern and Western Europe (Figure 1.1b) with more 
than 20/100 000 new cases. In Portugal (Figure 1.1c) and in Italy (Figure 1.1d),  
bladder cancer represents the 6
th
 and the 5
th
 most incident cancer  
(Ferlay, Shin et al. 2010). 
 
a) 
 
c) 
 
 
b) 
 
 
 
d) 
 
 
  Figure 1.1. Incidence and mortality rates per 
100 000 for Bladder Cancer. a) Bladder cancer 
is the 8
th
 most incident cancer in the world,  
b) showing high incidence rates in Southern and 
Western Europe. Bladder cancer is c) the 6
th
 
most frequent in Portugal and d) the 5
th
 in Italy. 
From GLOBOCAN database available at 
http://globocan.iarc.fr (Ferlay, Shin et al. 2010). 
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Women have approximately a 4-fold lower incidence and mortality rate for bladder 
cancer (Fajkovic, Halpern et al. 2011). A decreasing trend in mortality has been evident 
in most European countries over the last decades (Ferlay, Randi et al. 2008). Still, bladder 
cancer displays the highest recurrence rates among solid tumours with a significant 
percentage of progression to muscle invasion (Jacobs, Lee et al. 2010). More than half of 
the cases relapse within one year, requiring though a lifelong follow-up (Babjuk, 
Oosterlinck et al. 2011). Bladder cancer shows also the highest prevalence rates, 
representing the 5
th
 and 4
th
 most prevalent cancer in Portugal (Figure 1.2a) and in Italy 
(Figure 1.2b) respectively (Bray, Ren et al. 2012). 
 
a) b) 
  
Figure 1.2. Prevalence rates per 100 000 of the ten most prevalent cancers in a) Portugal, and  
b) in Italy. Bladder cancer is the 5
th
 most prevalent cancer in Portugal and the 4
th
 In Italy. From EUCAN 
database available at http://eco.iarc.fr/ (Bray, Ren et al. 2012). 
 
Aetiology and risk factors 
There are multiple risk factors associated with the development and progression of 
bladder cancer. Tobacco smoking is the principal risk factor (relative risk of about 4, 
according to a follow-up occurring between 1995 and 2006), being responsible for 
approximately 50% of death caused by bladder cancer (Freedman, Silverman et al. 2011).  
The incidence of bladder cancer is directly related to the lifetime tobacco use and the 
number of cigarettes smoked per day (Brennan, Bogillot et al. 2000). A recent study 
showed that bladder cancer in smokers displayed a younger age of diagnosis, larger 
tumours, a higher tumour stage and a higher grade than in never smokers (van Roekel, 
Cheng et al. 2013). The precise mechanism by which cigarette smoking causes bladder 
cancer has yet to be determined (Zeegers, Kellen et al. 2004). It seems most likely that  
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the risk of this cancer is related to the large number of chemicals present in smoke, such 
as 4-aminobiphenyl, polycyclic aromatic hydrocarbons (PAH), N-nitroso compounds, 
heterocyclic amines, arylamines and various epoxides agents (Zeegers, Tan et al. 2000). 
Variability in susceptibility for chemically induced urinary bladder cancer is due to the 
individual genetic background (Roos 2008). The initial step in chemically induced 
bladder carcinogenesis formation of reactive and DNA-affecting metabolites from bladder 
procarcinogens occurs via the catalytic activity of cytochromes P450 (CYP).  
For instances, cigarette smoking leads to an increase in exfoliated urothelial cells 
expressing CYP1A1 cytochrome which catalyses the formation of reactive metabolites 
from PAH (Dorrenhaus, Muller et al. 2007). The induction of CYP1A1 can be regarded as 
an indicator of cancer initiation. Moreover, Roos suggested that some individuals with 
different CYP alleles background may present different susceptibility to bladder 
carcinogenesis (Roos 2008). A clear polymorphism-dependent effect on bladder cancer 
susceptibility is known for two phase II enzymes though, namely N-acetyltransferase 2 
(NAT2), which is involved in arylamine metabolism (Golka, Prior et al. 2002) and 
glutathion S-transferase M1 (GSTM1) (Dong, Potter et al. 2008). In addition, bladder 
cancer was the first cancer to be related to certain occupations.  
An increased risk for bladder cancer was observed among workers in the industries of dye, 
printing, rubber, transportation and in the electrical/gas/sanitary services. Some 
compounds related to professional exposure, such as o-toluidine, aniline, nitrobenzene, 
4,4’-methylenebis(2-chloroaniline) and the aromatic amines 2-naphthylamine,  
4-aminobiphenyl and benzidine (Samanic, Kogevinas et al. 2008, Sorahan 2008, de Vocht, 
Sobala et al. 2009, Talaska, Gaultney et al. 2012, Burger, Catto et al. 2013) are 
responsible for the majority of occupational bladder cancer cases. An increased risk of 
bladder cancer has been reported in people living in areas close to industrial  
waste-treatment spots (Garcia-Perez, Fernandez-Navarro et al. 2013). The ingestion of 
water with high levels of arsenic or nitrate, or the intake of some drugs, such as 
cyclophosphamide, analgesics containing phenacetin are also associated with the risk of 
developing bladder tumours (Guo, Chiang et al. 1997, Letasiova, Medve'ova et al. 2012, 
Wang, Fan et al. 2012). In addition, several studies reported a correlation between the 
ingestion of food such as barbecued meat, salted meat, fried eggs and fat meals, and an 
increased risk for bladder cancer. On the other hand, the ingestion of fruits and vegetables 
was reported to exert a protective effect (Steinmaus, Nunez et al. 2000, Balbi, Larrinaga 
et al. 2001). However, this latter conclusion was recently challenged by a  
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multicentre cohort study with 521468 subjects who showed no statistically significance 
between fruit and vegetable consumption and a lower risk for bladder cancer  
(Buchner, Bueno-de-Mesquita et al. 2011).  
Gender is also a risk factor for bladder cancer. Interestingly Jiang et al reported in a study 
on 1586 women a lower risk of invasive high-grade bladder cancers in those who 
experienced multiple infections. This could be due to the immune response triggered by 
the bladder infection and/or to the infection therapy (Jiang, Castelao et al. 2009).  
For this reason, the lower risk in women for bladder cancer might be directly correlated 
with the higher risk in women for bladder infection. In some parts of Africa and the 
Middle East, higher rates of squamous cell carcinoma of the bladder, rather than TCC, 
were correlated though to high prevalence of the parasitic chronic infection with 
Schistosoma haematobium (IARC 1994, Michaud 2007). 
As occurs for other solid tumours, the incidence of bladder cancer increases with age 
(Ferlay, Shin et al. 2010) (Figure 1.3). In fact, tumours of the bladder rarely occur before 
the age of 40-50, arising most commonly in the seventh decade of life (Shariat, Milowsky 
et al. 2009). Individuals older than 65 years have a 3-fold increase in the incidence of 
bladder cancer, and the mean age of newly diagnosed cases is approximately 66, 69, 69 
and 72 years in the World, Europe, Portugal and Italy respectively (Ferlay, Shin et al. 
2010). The relative late onset of bladder cancer has been hypothesized to be the result of 
the accumulation of exposures to a variety of carcinogens over time, mainly cigarette 
smoking and occupational exposure. However, other factors may also be involved.  
For instance, urothelial enzymes responsible for inactivation of carcinogens may 
deteriorate over time, effectively increasing exposure of the urothelium to active 
carcinogens, or in general physiologic and immunological changes that occur with aging 
(Shariat, Milowsky et al. 2009). 
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Figure 1.3. Bladder cancer incidence rates by age in Europe according to GLOBOCAN database 
(Ferlay, Shin et al. 2010). 
 
Classification and pathological staging 
The most common histological types of bladder tumours (90% of cases) are originated in 
the urothelial epithelial cells, and are referred to as transitional cell carcinoma (TCC) 
(Jacobs, Lee et al. 2010). Approximately 5% are squamous cell carcinoma, and less than 
2% are adenocarcinoma (Jacobs, Lee et al. 2010). Bladder cancer can be classified into 
different stages, depending on the level of invasion. The TNM (tumour, node, metastasis) 
classification system takes into consideration the depth of the bladder wall reached by the 
tumour (T), the invasion of lymph nodes (N) and the metastatic spread to other parts of 
the body (M) (Table 1.1 and Figure 1.4) (Babjuk, Oosterlinck et al. 2011). 
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Table 1.1: 2009 TNM classification of urinary bladder cancer (Babjuk, Oosterlinck et al. 2011). 
T – Primary tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Ta Non-invasive papillary carcinoma 
Tis Carcinoma in situ: ‘flat tumour’ 
T1 Tumour invades subepithelial connective tissue 
T2 Tumour invades muscle 
 T2a Tumour invades superficial muscle (inner half) 
 T2b Tumour invades deep muscle (outer half) 
T3 Tumour invades perivesical tissue 
 T3a Microscopically 
 T3b Macroscopically (extravesical mass) 
T4 Tumour invades any of the following: prostate, uterus, vagina, pelvic wall, abdominal wall 
 T4a Tumour invades prostate, uterus or vagina 
 T4b Tumour invades pelvic wall or abdominal wall 
N – Lymph nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lode metastasis 
N1 Metastasis in a single lymph node in the true pelvis (hypogastric, obturator, external iliac, or 
presacral) 
N2 Metastasis in a multiple lymph nodes in the true pelvis (hypogastric, obturator, external iliac, or 
presacral) 
N3 Metastasis in common iliac lymph node(s) 
M – Distant metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
 
 
Figure 1.4. Representation of the anatomy of a male bladder and the different stages of bladder 
cancer according to the TNM classification. In the left is represented the anatomy of the human male 
bladder and prostate, and in the right is represented a small portion of the epithelium containing al states of 
bladder cancer. This figure was elaborated by both the author and the MSc Filipe Miguel Severino. 
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At diagnosis, more than 75% of TCC cases are non-muscle invasive (NMIBC), including 
those that are superficial papillary tumours (Ta), invasive tumour of the subepithelial 
connective tissue (T1), and carcinoma in situ (Tis), which are rarely lethal, but show a 
high recurrence rate of 50-70%. In about 10-20% of patients with Ta/T1 TCC, the disease 
progresses to muscle-invasion (≥T2 lesions), which can lead to metastasis and death 
(Jacobs, Lee et al. 2010). The level of differentiation (inversely related with grade) of a 
tumour is also an important parameter for the prognosis assessment and treatment 
strategies. According to the World Health Organization (WHO) 2004 bladder cancer 
grading, it can be distinguished in flat lesions (hyperplasia – flat lesion without atypia or 
papillary, reactive atypia – flat lesion with atypia, atypia of unknown significance, 
Urothelial dysplasia and Urothelial – Tis) and papillary lesions (urothelial papilloma – 
which is a completely benign lesion, papillary urothelial neoplasm of low malignant 
potential – PUNLMP, low-grade papillary urothelial carcinoma and high-grade papillary 
urothelial carcinoma) (Babjuk, Oosterlinck et al. 2011). Over time, great efforts have 
been done toward a better molecular characterization of bladder cancer (Lindgren, 
Sjodahl et al. 2012, Sjodahl, Lovgren et al. 2013). Recently, Sjödahl et al elaborated a 
more precise classification of bladder cancer based on several RNA and protein molecular 
markers. Tree major molecular subtypes of bladder cancer have been defined; urobasal A 
and B (Uro A and B), genomically unstable (GU), and squamous cell cancer-like (SCCL), 
in which Uro A tumours are associated with a good prognosis, and UroB and SCCL 
tumours with the worst outcome (Sjodahl, Lovgren et al. 2013). 
 
Diagnosis, prognosis and therapy 
Haematuria is the most common symptom in NMIBC. Lower urinary tract symptoms may 
appear in patients with Tis. Diagnosis of bladder cancer depends mainly on urine 
cytology, cystoscopic examination of the bladder and histological evaluation of multiple 
tissue biopsies (Babjuk, Oosterlinck et al. 2011). Like in any other cancer, the 
identification of specific biomarkers allowing the screening of the patients has been a 
principal goal of several research groups (Tilki, Burger et al. 2011). Reliable biomarkers 
allow early diagnosis and help in the choice of therapeutic options. The assessment of 
such biomarkers is of extreme importance to establish non-invasive alternative diagnostic 
strategies, as well as reliable surveillance markers. Interpatient and intratumour 
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heterogeneity provide overwhelming odds against the existence of a single marker with 
the sensitivity and specificity desired for diagnosis and prognosis of bladder cancer 
(Stenzl, Cowan et al. 2009).  Still, the use of multiple biomarkers can be used to improve 
the detection and classification of the disease (Catto, Abbod et al. 2010, Guo, Che et al. 
2011). Until now, six urine markers have been approved for clinical use in the detection 
of bladder cancer. Based on these, commercial urine tests were developed, namely the 
bladder tumour antigen (BTA) stat test (which measures complement factor H and related 
glycoprotein), nuclear matrix protein 22 test, ImmunoCyt (detecting a high molecular 
weight form of carcinoembryonic antigen and two bladder tumour cell-associated mucins 
in exfoliated urothelial cells) and the UroVysion (a fluorescence in situ hybridization 
(FISH) assay that detects chromosomal aneuploidy and the loss of the p16 tumour 
suppressor gene) (Van Tilborg, Bangma et al. 2009, Mowatt, Zhu et al. 2010, Tilki, 
Burger et al. 2011). Urine markers are highly sensitive, however, less specific than urine 
cytology (Lokeshwar, Habuchi et al. 2005, van Rhijn, van der Poel et al. 2009).  
Photodynamic diagnosis (PDD) based on blue-light cystoscopy (BLC) after intravesical 
instillation of 5-aminolevulinic acid or hexaminolaevulinic acid, is the most recent 
endoscopic technique used for detection of bladder lesions. BLC at the time of 
transurethral resection (TUR) facilitates a more complete resection and prolongs 
recurrence-free survival (Cheung, Sahai et al. 2013). At diagnosis, classically patients 
with TaT1 tumours are categorized into low-, intermediate-, and high-risk groups of both 
recurrence and progression according to the European Organisation for Research and 
Treatment of Cancer (EORTC) scoring system. Further treatment strategy of bladder 
cancer depends largely on its risk classification and invasive status (Figure 1.5).  
The primary approach to the management in cases of low risk of recurrence and 
progression is the TUR of the bladder tumour followed by one immediate instillation of 
chemotherapy. This procedure reduces the odds of recurrence when compared with TUR 
alone (Gudjonsson, Adell et al. 2009). Intravesical chemotherapy is usually approached 
with the instillation of mitomycin C, epirubicin or doxorubicin drugs that show equivalent 
efficacies (Sylvester, Oosterlinck et al. 2004). More recently gemcitabine has been 
introduced as a chemotherapeutic agent for metastatic bladder cancer (Shelley, Cleves et 
al. 2011). Owing to the likelihood of recurrence and/or progression in patients diagnosed 
with bladder cancer, the need for further adjuvant intravesical therapy is usually taken 
into account depending on the patient’s prognosis (Babjuk, Oosterlinck et al. 2011).  
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In tumours evaluated with higher risk for progression (solid lesions, positive urine 
cytology), other than an immediate chemotherapy intravesical instillation, a subsequent 
intravesical immunotherapy with the bacillus Calmette-Guérin (BCG, an attenuated strain 
of Mycobacterium bovis) is an essential treatment option (Babjuk, Oosterlinck et al. 
2011). Invasive forms are more likely treated by cystectomy (Kaufman, Shipley et al. 
2009). 
Aggressive therapy can also be considered for those patients who are at high risk of 
progression and failure of BCG treatment (Raj, Herr et al. 2007). Therapeutic approaches 
in elderly have been discussed by several research groups, since the elderly and, in 
particular, the octogenarian have a worse tolerance to aggressive therapies (Destefanis, 
Bisconti et al. 2010). Is important to note that innate and adaptive immunity deteriorate 
with age (Gomez, Nomellini et al. 2008), resulting in a hypothetical less durable response 
to BCG therapy. In a retrospective analysis of 805 patients with multiple or recurrent 
high-grade Ta, T1, and/or Tis, it was reported that age did not affect the initial response to 
BCG therapy (Herr 2007) but patients older than 70 were less likely to maintain that 
response and remain free of tumour recurrence (Joudi, Smith et al. 2006). Moreover, the 
potential side effects or complications of intravesical BCG may not be well tolerated in 
elderly individuals (Herr 2007). The decision to undergo treatment for cancer is a trade 
off between loss of function and/or independence and extension of life. Comorbid 
medical conditions, functional declines and “frailty”, family dynamics, and social and 
psychological issues are important when deciding for the bladder cancer therapy (Shariat, 
Sfakianos et al. 2010). In general, quality of life tended to be better in patients with 
preservation of the bladder (Miyanaga, Akaza et al. 1999). Cystectomy patients reported 
more fatigue, appetite loss and decreased role functioning (Singer, Ziegler et al. 2012).  
In a large single centre study of 1054 patients treated uniformly with radical cystectomy 
and pelvic lymph node dissection for invasive bladder cancer, the recurrence-free and 
overall survival was 68% and 66% at 5 years and 60% and 43%, at 10 years, respectively 
(Stein, Lieskovsky et al. 2001). The 10-year disease-specific and overall survival rates in 
node-positive patients after cystectomy have been reported to be 28% and 21%, 
respectively (Gschwend, Dahm et al. 2002). In another study, 5-year recurrence-free 
survival was 76% in patients with T1 tumours, 74% for T2, 52% in T3, and 36% in T4 
tumours (Madersbacher, Hochreiter et al. 2003).  
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According to a multi-institutional database of 888 consecutive patients undergoing 
cystectomy and lymphadenectomy for bladder cancer the outcome at 5 years was 58% for 
a mean recurrence-free survival and 66% for bladder cancer-specific survival  
(Shariat, Karakiewicz et al. 2006).  
Owing to its anatomy, the bladder offers advantages to adjuvant therapy because it allows 
high local concentrations of either BCG or any chemotherapeutic drug (Bevers, Kurth et 
al. 2004). BCG and/or chemotherapeutic agent instillations are important to reduce the 
risk for recurrence and progression of NMIBC (Sylvester, Oosterlinck et al. 2008).  
The efficacy of BCG in preventing recurrences of TaT1 tumours has been confirmed, 
having a long lasting effect. The advantages of BCG were also observed in patients with 
intermediate-risk tumours, being more effective than other agents (Malmstrom, Sylvester 
et al. 2009, Sylvester, Brausi et al. 2010). Moreover, BCG therapy has been correlated 
with prevention of tumour progression, fewer metastases, a better overall and  
disease-specific survival (Sylvester, Brausi et al. 2010).  In cases of recurrence, 
maintenance schedule of BCG therapy showed an optimal efficacy (Houghton, Chalasani 
et al. 2012). BCG instillations are classically given according to the empirical 6-weekly 
induction schedule, and different maintenance schedules have been used with up to 30 
instillations given over 3 years (Lamm, Blumenstein et al. 2000). Regarding cases of Tis, 
there are no reliable prognostic factors that can be used to predict the course of the 
tumour (Babjuk, Oosterlinck et al. 2011). Tis cannot be resolved by endoscopic procedure 
alone, being necessary histological evaluation followed by further treatment, either 
intravesical instillations or radical cystectomy. Yet no consensus exists about whether 
conservative therapy (intravesical BCG instillations) or aggressive therapy (cystectomy) 
should be performed (Sylvester, van der Meijden et al. 2005). Recent in vitro studies on 
bladder cancer cell lines suggests that different commercial BCG trains could exert 
different anti-tumour activities (Secanella-Fandos, Luquin et al. 2013). However, data 
from a meta-analysis of the published data of 24 randomized clinical trials with 
progression information on 4863 patients suggests that at least the five most commonly 
used BCG strains, i.e. Tice, Pasteur, Connaught, RIVM and A. Frappier strains; do not 
differ in terms of preventing tumour progression (Sylvester, van der Meijden et al. 2002). 
A recent prospective comparative study on 129 patients with Ta/T1 and Tis that 
underwent intravesical BCG therapy with the Tokyo or Connaught strains, also reported 
no outcome differences in terms of the rates of complete response (CR), recurrence-free 
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survival (RFS) or adverse events (Sengiku, Ito et al. 2013). Nevertheless, up to 90% of all 
patients will experience some sort of side effect of BCG therapy among which common 
cystitic symptoms are by far the most frequent. Sepsis and even death following 
intravesical BCG have been reported (Witjes, Palou et al. 2008). For this, full acceptance 
of this therapy is still debated. In addition, despite BCG therapy success, patients either 
fail to respond to the intravesical pharmacotherapy or recur in 50-70% of the cases, being 
10-15% of these patients prone to develop progression of the disease to muscle invasion 
within a 5-years period (Witjes and Hendricksen 2008). A continuous follow-up  
of bladder cancer patients is though required due to high recurrence rates  
(Babjuk, Oosterlinck et al. 2011).  
 
Bladder cancer burden 
The social and economic burden of bladder cancer is expected to increase dramatically 
with the increase of the life expectancy (Shariat, Milowsky et al. 2009). Bladder cancer 
has the highest lifetime treatment costs per patient of all cancers. The high recurrence rate 
and ongoing invasive monitoring requirement are the key contributors to the economic 
and human toll of this disease (Sievert, Amend et al. 2009). The bladder cancer burden is 
highest in developed communities but with the increasing age and exposure to risk factors 
of the population in the developing Countries, it is expected an increase in such Countries 
in the forthcoming years (Ploeg, Aben et al. 2009). Long-term cost benefits can be 
achieved through reduced tumour recurrence and potentially reduced progression rates 
(Sievert, Amend et al. 2009). 
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I.2 Insights into Glyco-Oncology 
 
Introduction to Glycobiology 
Glycosylation is one of the most frequent modifications of proteins and lipids.  
This process consists in the covalent attachment of one or more glycans to a protein or a 
lipid, forming a glycoconjugate (Figure 1.5) (Varki, Kannagi et al. 2009). Unlike the 
biosynthesis of nucleic acids and proteins, which are deterministic, template-driven 
processes, glycosylation is a stochastic process, regulated mainly by the relative 
abundance, cellular localization and specificities of biosynthetic enzymes 
(glycosyltransferases) and catabolic enzymes (glycosidases). The stochastic nature of the 
glycosylation process is at the basis of the phenomenon known as microheterogeneity, 
which means that the structure of the sugar chains attached to a specific glycosylation site 
in a given glycoconjugate displays a certain degree of variability (Nairn, York et al. 2008, 
Lauc, Rudan et al. 2010). The synthesis of glycoconjugates occurs mainly in the lumen of 
the endoplasmic reticulum (ER) and in the Golgi apparatus (Li and Richards 2010) and is 
mediated by glycosyltransferases, a family of enzymes which transfer a sugar residue 
from a donor, which is frequently a nucleotide-sugar (e.g. GDP-fucose, UDP-galactose or 
CMP-sialic acid) to an acceptor which can be a sugar, an amino acid or a lipid. 
Glycosyltransferases are classified on the basis of the sugar they transfer  
(e.g. fucosyltransferases, galactosyltransferases, sialyltransferases). Moreover, members 
of each glycosyltransferase family are distinguished on the basis of the structure they 
recognize as acceptor and of the isomeric linkage they form. Glycoconjugates can be 
grouped in glycolipids, proteoglycans and glycoproteins. In glycolipids, the sugar portion 
is usually attached through a glucose (Glc) residue to the hydrophilic portion of a 
membrane lipid, which is often ceramide. In this case the glycolipid is referred to as 
glycosphingolipid. Usually, a galactose (Gal) residue is 1,4-linked to Glc. Based on their 
basic glycan structures, glycosphingolipids are classified into four groups, namely,  
globo-series, lacto-series, neolacto-series and ganglio-series, classified according to the 
sugar types linked to the (Gal) residue (Schnaar, Suzuki et al. 2009). The basic structure 
of proteoglycans is comprised of a core protein and one or more covalently attached 
glycosaminoglycan (GAG) side chains. GAGs are polysaccharides composed of repeating 
disaccharide units formed by an amino sugar (N-acetylglucosamine (GlcNAc) in  
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heparan sulphate or N-acetylgalactosamine (GalNAc) in chondroitin sulphate) linked to  
D-glucuronic acid (GlcA) or L-iduronic acid (IdoA). The linkage of GAGs to the protein 
core involves a specific trisaccharide composed of two Gal and one xylose (Xyl) sugars 
(GAG-GalGalXyl-O-CH2-protein). GAGs exist also as free molecules, as is the case of 
hyaluronan (Esko and Lindahl 2001). In glycoproteins, the two types of glycans attached 
to the peptide are the N- and O-glycans, which may co-exist in the same protein.  
The N-linked chains are attached through a GlcNAc residue to the asparagine residue of 
the sequence N-X-S/T (X represents any amino acid, except proline), while the O-linked 
chains are usually linked through a GalNAc residue to serine or threonine.  
The biosynthesis of N-linked chains requires the assembly of an oligosaccharide precursor 
comprised of two GlcNAc, nine mannose (Man) and three Glc residues associated to the 
membrane lipid dolichol-phosphate. This structure is then transferred en bloc to an 
asparagine residue of a the nascent polypeptide chain (Kornfeld and Kornfeld 1985). 
Successively, the protein-linked oligosaccharide first undergoes trimming of the glucose 
and of some of the mannose residues. Then GlcNAc, Gal, sialic acid (Sia) and fucose 
(Fuc) residues are added forming "complex type" glycans. The trisaccharide units 
comprised of Sia-Gal-GlcNAc are referred to as branches or antennae. When a GlcNAc 
residue is β1,4-linked to the innermost Man residue is referred to as “bisecting GlcNAc” 
and is not elongated further. The presence of a Fuc residue α1,6-linked to the innermost 
GlcNAc of the core is referred to as “core fucosylation” (Takahashi, Kuroki et al. 2009). 
O-linked glycans are attached to the hydroxyl group of serine or threonine in the Golgi 
apparatus, through the stepwise addition of single monosaccharides. After the addition of 
the first GalNAc residue, the addition of other sugars is a stepwise process which 
accompanies the maturation of the glycoprotein (Brockhausen 1999). In the ‘mucin-type’ 
O-glycans, the first GalNAc is further extended with Gal, GlcNAc, and Sia. There are 
also several types of non-mucin O-glycans, in which the peptide-bound sugar can be  
O-Fuc, or O-Xyl, O-Man or O-GlcNAc (Varki, Kannagi et al. 2009). In this thesis,  
the term O-glycan will refer to “mucin type” O-glycans. 
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Figure 1.5. Glycoconjugates in mammalian cells. a) Glycans can be attached to proteins as in 
glycoproteins and proteoglycans. Glycoproteins are decorated with N- and/or O-glycans and proteoglycan 
with glycosaminoglycans (GAG). Glycosphingolipids are mainly associated with membranes and are 
formed by a glycan attached to the lipid moiety ceramide. A ganglioside contains one or more residues of 
sialic acid (Sia). The glycan structures presented for each N-linked, O-linked, glycosaminoglycan (GAG) 
and glycosphingolipids exemplify one of the possible structures (Severino, Silva et al. 2012).  
b) The electron micrograph of the surface of a lymphocyte stained with ruthenium red emphasizes the thick 
carbohydrate layer surrounding the cell, a.k.a. glycocalyx (Alberts, Johnson et al. 2002). 
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A large number of complex carbohydrates of animals and microorganisms are terminated 
by Sia. This sugar exists in various chemical forms linked as monomers or polymers in an 
outstanding position, rendering them versatile modulators in cell biology and pathology 
(Schauer 2009). Sialic acid structures are involved in many cellular functions, both in 
physiological and pathological processes (Varki and Varki 2007). The addition of sialic 
acid to glycoconjugates is mediated by sialyltransferases. These enzymes transfer sialic 
acid from the donor substrate CMP-Sia to the terminal positions of the oligosaccharide 
chains of glycoproteins and glycolipids in different linkages. Sia can be linked through 
α2,3- or α2,6- linkages to a βGal residues, α2,6-linkage to βGalNAc or to βGlcNAc 
residues, or even α2,8- linkage to other sialic acid residues in ganglioside or polysialic 
acid chains (Harduin-Lepers, Vallejo-Ruiz et al. 2001). Sialyltransferases constitute a 
family of over 20 enzymes usually associated with the membrane of the Golgi apparatus. 
Their expression is strongly dependent on the tissue, the cell type or the developmental 
stage (Harduin-Lepers, Vallejo-Ruiz et al. 2001). 
Glycoconjugates are involved in many physiological and pathological processes, 
including differentiation, migration and cell signalling, host-pathogen interactions, 
tumour invasion and metastasis (Ghazarian, Idoni et al. 2011, Dall'olio, Malagolini et al. 
2012). The expression of glycan structures, which are usually cell type-dependent, are 
profoundly modified in cancers (Varki, Kannagi et al. 2009). These modifications 
contribute to determine the phenotype of cancer cells, including their aberrant growth, 
adhesion to endothelia, angiogenesis and the ability to escape apoptotic death and 
immune recognition (Dall'olio, Malagolini et al. 2012). The alteration of glycosylation is 
an early step in the process of tumour invasion and metastasis and is therefore regarded as 
a "quasi-universal" modification in tumour cells (Reis, Osorio et al. 2010).  
Aberrant glycosylation in tumour cells include either a loss or a gain of expression of 
certain glycan structures, the appearance of truncated structures or even new structures. 
Up-regulation and/or down-regulation of specific glycosyltransferases are often 
responsible for these changes (Dall'Olio, Malagolini et al. 1989, Malagolini, Dall'Olio et 
al. 1989, Videira, Amado et al. 2007, Videira, Correia et al. 2009, Dall'olio, Malagolini et 
al. 2012). Frequently, glycosyltransferases are under the control of signal transduction 
pathways whose alteration in cancer cells leads to altered glycosyltransferase expression 
(Dall'olio, Malagolini et al. 2012). Examples of this mechanism are provided by GlcNAc 
transferase-V and sialyltransferase ST6GAL1. The first is under the control of oncogenes 
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SRC (Buckhaults, Chen et al. 1997), HER2 (Chen, Zhang et al. 1998) and HRAS (Lu and 
Chaney 1993), through transcription factor ETS1 (Ko, Miyoshi et al. 1999). The second is 
controlled by the Ras pathway (Easton, Bolscher et al. 1991, Le Marer, Laudet et al. 1992, 
Dalziel, Dall'Olio et al. 2004). Often, the carbohydrate structures formed by cancer cells 
resemble those expressed by the corresponding normal tissue during the foetal life  
(onco-developmental regulation) and are largely tissue-specific (Dall'olio, Malagolini et 
al. 2012). Still, some structures appear to be widely expressed by cancers of different 
histological origin. This is probably due to two main reasons: first, their biosynthesis is 
strictly controlled by the mechanism altered in cell transformation (i.e. activation of 
oncogenes, inactivation of tumour-suppressor genes, altered pattern of epigenetic 
regulation etc); second, their expression provides cancer cells with growth advantage, 
resulting in the selection of cells expressing a given antigen during tumour growth 
(Dall'olio, Malagolini et al. 2012). The relevance of epigenetic changes in cancer 
progression is increasingly recognized (Murr 2010). Many “glycogenes”, including 
glycosyltransferases, galectins, enzymes involved in the biosynthesis of sugar nucleotides, 
transporters, are aberrantly regulated in cancer by epigenetic mechanisms (Zoldos, Horvat 
et al. 2013). Altered glycosyltransferase expression generates a flow of information from 
the nucleus to the cell surface (inside-out) altering the structure of cell membrane 
glycoproteins. Many cell membrane receptors are crucially involved in the regulation of 
cell adhesion, such as integrins (Seales, Jurado et al. 2005) or cadherins  
(Zhao, Nakagawa et al. 2006, Pinho, Seruca et al. 2011), or of cell growth, such as 
growth factor receptors (Lau and Dennis 2008). These receptors are indeed glycoproteins 
and their aberrant glycosylation can result in inappropriate signaling. This altered flow of 
information from the cell membrane to the nucleus (outside-in) can support the growth of 
cancer cells, fuelling a vicious loop (Dall'olio, Malagolini et al. 2012). Tumour-associated 
carbohydrate structures allow tumour cells to invade and metastasize (Schultz, Swindall 
et al. 2012, Tsuboi, Hatakeyama et al. 2012). One of the best examples of relationship 
between expression of a cancer-associated carbohydrate structure and metastasis 
formation is provided by the β1,6-branching, which consists in the presence of an antenna 
β1,6-linked to the trimannosyl-core of N-linked chains. Although the mechanism(s) 
linking this structure with metastasis have not been completely elucidated, the conclusive 
evidence about the causative role played by this structure in metastasis formation came 
from mouse studies in which the enzyme responsible for this modification, β1,6 GlcNAc 
transferase V (GnT5, product of the MGAT5 gene) was knocked down (MGAT5
-/-
).  
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Mice expressing the polyomavirus middle T antigen (PyMT) from a transgene in 
mammary epithelium spontaneously develop mammary tumours. When these mice were 
crossed with MGAT5
-/-
 mice, the tumours grew slower than in the PyMT-transgenic 
littermate expressing MGAT5 and metastasis formation was almost completely inhibited 
(Granovsky, Fata et al. 2000). Another example of glycosylation-metastasis relationship 
is provided by ganglioside GD3 which enhances in vivo growth and metastasis formation 
through interactions with the growth factor receptor c-Met (Cazet, Lefebvre et al. 2010). 
One of the most important cancer-associated glycosylation change is the incomplete 
glycosylation of O-glycans, leading to the formation of truncated oligosaccharides and 
consequently to the increased expression of the Thomsen Friedenreich (TF) related 
antigens (Ju, Wang et al. 2013). These glycosidic antigens include the T and Tn antigens, 
and their sialylated forms sialyl-T (sT) and sialyl-Tn (sTn) antigens (Figure 1.6).  
The Tn antigen (GalNAc-O-Ser/Thr) is the precursor of the T antigen  
(Galα1,3GalNAc-O-Ser/Thr), also known as core 1 structure. Its biosynthesis is catalysed 
by core 1 β1,3N-galactosyltransferase (C1GALT1) or T synthase present in most tissues. 
This enzyme is peculiar because it requires the presence of a molecular chaperone, the 
product of the gene C1GALT1C1 (coding for Cosmc) (Ju, Lanneau et al. 2008) which, in 
the endoplasmic reticulum, binds to T synthase preventing its ubiquitin-mediated 
proteosomal degradation.  
 
 
Figure 1.6. Structures of Thomsen-Friedenreich related antigens. Glycan structures and the main 
enzymes responsible for their synthesis are shown. 
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The T antigen (Yu 2007) accumulates in breast (Hanisch and Baldus 1997) and colon 
cancer (Cao, Karsten et al. 1995), while in normal colon its expression is masked by 
sialylation (Campbell, Finnie et al. 1995).  In breast cancer, despite the overexpression of 
the T antigen, sialyltransferase ST3GAL1 which synthesizes the alternative sT antigen, is 
usually elevated (Burchell, Poulsom et al. 1999). Overexpression of ST3GAL1 in 
epithelial breast cells of a murine model of breast carcinogenesis, leads to the 
development of breast tumours with a short latency, independently on the expression of 
the cognate product, the sT antigen. This unexpected result has been interpreted 
suggesting that ST3GAL1 acts as a tumour promoter (Picco, Julien et al. 2010). 
Interestingly, an elevation of ST3GAL1 mRNA was reported also in bladder cancer 
specimens (Videira, Correia et al. 2009), even though the role of this modification in the 
biology of bladder cancer remains to be established. sTn antigen is expressed by cancers 
of the stomach (Conze, Carvalho et al. 2010), liver (Cao, Karsten et al. 1999), pancreas 
(Itzkowitz, Kjeldsen et al. 1991) and other tissues. In breast cancer its expression 
correlates with a poorly differentiated state (Cho, Sahin et al. 1994) and resistance to 
adjuvant therapy in node-positive patients (Miles, Happerfield et al. 1994), while in colon 
cancer, it  correlates with a worse prognosis (Cao, Karsten et al. 1995). The impact of sTn 
overexpression has been studied by over expressing sialyltransferase ST6GALNAC1, 
which is the major sTn synthase (Marcos, Pinho et al. 2004), in different cellular model 
systems. In murine carcinoma cells overexpressing ST6GALNAC1, a major carrier of sTn 
antigen are β1-integrins. These cells displayed major morphological changes and  reduced 
ability to migrate on extracellular matrix components (Clement, Rocher et al. 2004).  
In human breast cancer cell lines overexpressing ST6GALNAC1, a major carrier of sTn 
antigen were mucin 1 (MUC1) and other high molecular weight glycoproteins.  
These cells exhibited reduced cell adhesion and increased cell migration (Julien, 
Adriaenssens et al. 2006). sTn was recently reported by our group to be also 
overexpressed in bladder cancer carried by MUC1 and CD44. The relationship between 
sTn and bladder cancer is the subject of a recent study  (Ferreira, Videira et al. 2013). 
Both sT and sTn and their synthesis enzymes will be discussed thoroughly in the 
Discussion and Conclusions section. In different epithelial tissues, the carriers of T and 
sTn antigens are different. In fact, they are carried mainly by a high molecular weight 
splice variant of CD44 (Singh, Campbell et al. 2001) and MUC1 (Storr, Royle et al. 2008) 
in colon cancer, by MUC2 in gastric cancer (Conze, Carvalho et al. 2010)  
and by MUC1 in breast cancer (Storr, Royle et al. 2008).  
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The somatic inactivation of the gene C1GALT1C1 is associated with the expression of Tn 
and sTn antigens in colon cancer and melanoma cell lines (Ju, Lanneau et al. 2008), 
indicating a general mechanism of regulation of the biosynthesis of these structures.  
It was previously reported that the expression of the T antigen increased Natural Killer 
(NK) cells susceptibility of cancer cells (Sotiriadis, Shin et al. 2004), and that peptides 
containing the T antigen were able to elicit a specific and major histocompatibility 
complex  (MHC) class-I-restricted anti-tumour cytotoxic T lymphocyte response  
(Xu, Gendler et al. 2004, Heimburg, Yan et al. 2006). These findings supported the idea 
of the T antigen as a possible target for cell-mediated anti cancer immunity.  
Initial insights into the unique repertoire of glycans expressed on tumour cells emerged 
from the increased ability of tumours to bind a range of plant carbohydrate-binding 
proteins, the lectins (Raedler and Schreiber 1988). In fact, a large number of the studies 
on the alterations of glycosylation in cancer has been performed using lectins as probes  
(Wu, Lisowska et al. 2009). Lectins exhibit a typical protein folding that defines the 
carbohydrate-binding protein families and bind defined monosaccharide or 
oligosaccharide structures with good specificity (Wu, Lisowska et al. 2009) in a  
‘lock-and-key’ fashion (Weis and Drickamer 1996, Gabius, Andre et al. 2011).  
The carbohydrate-binding proteins are divided into several types depending on their 
structures and the nature of the interaction they establish (Wu, Lisowska et al. 2009). 
Long before the role of carbohydrate-protein interactions had been explored, many lectins 
were identified, characterized and applied as useful tools in studying glycoconjugates. 
Therefore, lectins have been widely used for preparative and analytical purposes in 
biochemistry, cell biology, immunology, oncology, pathology and related areas  
(Wu, Lisowska et al. 2009). 
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Glyco-Oncology of bladder cancer 
Several reports showed drastic changes in the glycosylation of lipids in bladder tumours 
and correlated these modifications with tumour invasiveness and progression.  
For instance, while NMIBC shows an accumulation of GM3 ganglioside and a decrease 
of Gb3 and Gb4 glycolipids, invasive tumours show a decreased expression of GM3 and 
an accumulation of Gb3 and Gb4 (Kawamura, Ohyama et al. 2001, Guan, Handa et al. 
2009). Also ABH and Lewis blood group systems, a group of carbohydrate structures 
expressed at the terminal part of both glycoproteins (O- and N-glycans) and glycolipids 
on red blood cells, endothelial and epithelial cells (Magnani, Nilsson et al. 1982, 
Shimodaira, Nakayama et al. 1997), were correlated with bladder cancer.  
The loss of ABH structures and the increased expression of Lewis related antigens are the 
most evident changes, among the blood group antigens, related with poor prognosis in 
bladder cancer, suggesting a pathophysiological role in bladder cancer progression 
(Hegele, Mecklenburg et al. 2010). The glycosylation of epithelial cadherin (E-cadherin), 
the main constituent of the adherens junctions, critically regulates its biological properties 
(Pinho, Seruca et al. 2011). It’s down-regulation was reported in malignant human 
urothelium and found associated with tumour recurrence, progression and poor survival 
(Clairotte, Lascombe et al. 2006). High levels of the proteolytic cleavage product of the  
E-cadherin (sE-cadherin) can be found in serum of patients with TCC and are detectable 
also in urine (Matsumoto, Shariat et al. 2003, Shariat, Matsumoto et al. 2005).  
Integrins are also important glycoproteins that are involved in cell growth and 
differentiation, proliferation and migration, tissue organization, recruiting of lymphocytes 
and inflammation, cancer invasion and metastasis (Cox, Brennan et al. 2010).  
The integrin α3β1 was shown to take part in the bladder cancer T24 cell line migration on 
fibronectin being proposed that its function may be altered by glycosylation  
(Pochec, Litynska et al. 2006). MUC1, is a heavily glycosylated high-molecular-mass 
glycoprotein from the Mucin family that can be present both in membrane-bound and 
secreted forms, representing a major component of mucus (Hollingsworth and Swanson 
2004). Radioactively labelled anti-MUC1 antibodies, when intravenously administrated
 
to 
TCC patients, stained tumour tissues in a stage dependent manner (Hughes, Perkins et al. 
2001, Scholfield, Simms et al. 2003). MUC7 is also atypically expressed in exfoliated 
cells expelled in the urine of patients with bladder cancer (Okegawa, Kinjo et al. 2003). 
Invasion by tumour cells involves also the alteration of cell-matrix interactions  
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(Fuster and Esko 2005). For example, the expression of the hyaluronic acid (HA), a  
non-sulfated GAG comprised of a repeating disaccharide (GlcA-GlcNAc), has been 
implicated in promoting tumour cell proliferation, invasion and metastasis and represents 
an accurate diagnostic marker for bladder cancer. The measurement of HA and of its 
degrading enzyme hyaluronidase (HAase) in urine has been applied as a  
commercial urinary test, the HA-HAase test, to the screening of bladder cancer  
(Lokeshwar, Schroeder et al. 2002).  
Some lectins were found to be useful in differentiating bladder tumours from normal 
urothelium. Lectins like Ricinus communis agglutinin (RCA, recognizing 
Galβ1,4GlcNAcβ1-R) and wheat germ lectin (WGA, recognizing 
GlcNAcβ1,4GlcNAcβ1,4GlcNAc-R) can bind to all urothelial cells in the normal tissue, 
while some lectins like peanut agglutinin (PNA recognizing Gal1,3GalNAc), 
concanavalin A (ConA, recognizing branched α-mannosidic structures and biantennary 
complex type N-Glycans) and soybean lectin (SBA, recognizing GalNAc) show little 
binding (Ward, Stewart et al. 1987). Initially, by using cell suspensions from transitional 
cell carcinoma, it was found that aneuploid cells bound PNA more extensively and were 
less reactive with WGA than diploid cell population (Langkilde, Wolf et al. 1992).  
Drugs or delivery systems modified by lectins have been thought as potential tools for 
more efficient, local adjuvant intravesical treatment for bladder cancer (Neutsch, Plattner 
et al. 2011). The calcium-independent galactose-specific lectins, the galectins, represent a 
family of carbohydrate-binding proteins widely distributed in all living organisms  
(Lahm, Hoeflich et al. 2000), that play a number of important roles in cancer by 
contributing to tumourigenesis, proliferation, angiogenesis, and metastasis  
(Liu and Rabinovich 2005). This group of lectins are the best characterized  
carbohydrate-binding proteins in bladder cancer (Cindolo, Benvenuto et al. 1999). 
A glycopeptide decorated with a trisaccharide similar, if not identical, with sT was 
identified in the urine of patients affected by interstitial cystitis, a painful disease caused 
by thinning or denudation of bladder epithelium. This molecule, which is referred to as 
antiproliferative factor (APF) exerts a strong anti-proliferative activity on bladder cells 
and is involved in the pathogenesis of interstitial cystitis (Keay, Szekely et al. 2004).  
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I.3 BCG Immunotherapy 
 
Adhesion and Internalization of BCG 
The intravesical therapy with the bacillus Calmette-Guérin is commonly used in the 
treatment of non-muscle invasive urothelial carcinomas. BCG is a sub-attenuated strain of 
Mycobacterium bovis, developed between 1908 and 1921, by Calmette and Guérin, in 
order to generate a vaccine against human tuberculosis (TBC). The notion that TBC could 
have some anti-tumour effect born in the early twentieth century, when Raymond Pearl 
reported a low frequency of cancer in patients with TBC. However, the use of BCG as 
anti-tumour therapy began later. In 1976 Alvaro Morales carried out the first intravesical 
instillation of BCG to treat superficial bladder cancer, and since then BCG 
immunotherapy for superficial bladder cancer underwent few modifications.  
This therapeutic procedure begins one to three weeks after transurethral resection (TUR) 
of the bladder, and consists of a weekly intravesical instillation for six weeks.  
After six weeks, a maintenance therapy can be continued, depending on the grade and the 
stage of the tumour (Brandau and Suttmann 2007, Kresowik and Griffith 2009). 
Following instillation, BCG accumulates near the wall of the bladder, allowing the 
establishment of non-specific and specific contacts, with urothelial cells. The lumen of 
the bladder is covered with a hydrophilic layer of highly sulfated glycosaminoglycans 
(GAGs), which protects the bladder from pathogens and toxic compounds. The fact that 
both the GAGs layer and BCG cell wall are negatively charged allows BCG local 
accumulation, without adherence, at a close docking distance to the bladder wall.  
In normal conditions, BCG would only reversibly adsorb to the bladder wall, nevertheless, 
when GAG layer is damaged, like for instance in a case of neoplastic tissue, this will 
allow an increased BCG docking and adherence (Bevers, Kurth et al. 2004).  
Interestingly, it was reported that medications that inhibit fibrin clot formation diminished 
the side effects of BCG therapy but also adversely affected efficacy (Boorjian, Berglund 
et al. 2009). Recent in vitro findings support the notion that the fibronectin attachment 
protein (FAP) from BCG has an important role in BCG targeting to cells (Coon, Crist et 
al. 2011). After intravesical instillation, BCG is internalised and processed by tumour 
cells, triggering an inflammatory response (Bevers, Kurth et al. 2004).  
Glycoproteins and lipoproteins from degraded and processed BCG by tumour cells are 
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presented at the cell surface. This process induces phenotypic alterations in tumour cells 
which eventually trigger an immune reaction against the tumour (Bevers, Kurth et al. 
2004). It has been reported that the interaction of BCG with urothelial malignant cells 
causes the activation of multiple signaling pathways, contributing to the transcription of 
early genes, including genes encoding the inhibitor of cyclin-dependent kinase p21 and 
interleukin 6 (IL-6), leading to cell cycle arrest in G1 phase and to the induction of 
necrosis of urothelial cells (Chen, Zhang et al. 2009). Activation of these pathways also 
promotes the secretion of several intracellular proteins (Chen, Zhang et al. 2009, See, 
Zhang et al. 2009). However it has been suggested that BCG might trigger also the 
formation of metastasis via the secretion of vascular endothelial growth factor (VEGF) 
(Ping, Wu et al. 2012). 
 
Immune response triggered by BCG 
BCG mycobacteria have a characteristic outer cell wall consisting of various complex 
structural biomolecules. The immunologically active components of these biomolecules 
are nowadays referred to as pathogen-associated molecular patterns (PAMPs).  
PAMPs on the mycobacterial cell wall include peptidoglycan, mycolic acids, lipomannan 
and lipoarabinomannan (Brennan 2003). The precise mechanisms responsible for BCG  
anti-tumour effect have not been fully elucidated, but a massive, complex and local 
activation of the immune system has been well documented (Bevers, Kurth et al. 2004, 
Videira, Calais et al. 2009). BCG interacts with urothelial cells which, after  
BCG-challenging, produce various proinflammatory cytokines, including IL-6, IL-8 and 
TNFα, which trigger the activation and the recruitment of inflammatory cell populations 
into the urothelium. Cell populations which respond to this stimulus infiltrating the wall 
of the urothelium, include neutrophils, monocytes and macrophages. Neutrophils and 
macrophages produce additional cytokines and chemokines which attract to the bladder 
several lymphocyte populations, including CD4 T lymphocytes and later  
CD8 T lymphocytes (Kresowik and Griffith 2009). 
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Purpose of the work 
 
The present work is based on the following premises: 
1) Although BCG therapy represents a very effective approach for the treatment of 
bladder cancer and one of the few examples of effective cancer immunotherapy,  
its mechanism of action remains partially obscure; 
2) Thomsen-Friedenreich related antigens are aberrantly expressed in bladder cancer and 
some of them are related with malignancy but the role they play in bladder cancer biology 
remains to be established. In particular, it is not clear whether and how the expression of a 
given TF related antigen affects the response to BCG.    
 
To investigate these two points, it has been taken advantage from the availability of the 
cellular models established in recent years by the collaboration of the two supervisors. 
The model is comprised of the bladder cancer cell lines HT1376 and MCR, retrovirally 
transduced with the cDNA of sialyltransferases ST3GAL1 and ST6GALNAC1, 
respectively. As a consequence, the transduced HT1376 cells expressed the sialyl-T (sT) 
antigen and reduced expression of T antigen, while transduced MCR cells expressed the 
sialyl-Tn (sTn) antigen. However, the cell lines originated by transduction turned out to 
express heterogeneously the desired antigens. Thus, this work begins with a preliminary 
purification step of cell populations expressing homogeneously the desired antigen.   
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The objectives of this work are the following: 
1) The refinement of the cellular model of bladder cancer: 
1a. Isolation of cell populations expressing homogeneously the desired carbohydrate 
antigens sT and sTn 
1b.Characterization of the cell population by FACS analysis and for the expression of 
sialyltransferase activities and mRNA 
2) The study of the response of bladder cancer cell lines to BCG: 
2a. Study of BCG internalization 
2b. Effect of sialyltransferase expression and BCG interaction on the whole gene 
expression profile and on cytokine secretion 
3) The study of the response of macrophages to BCG-challenged BC cell lines: 
3a. Cytokine secretion by macrophages in response to the secretome of  
BCG-challenged bladder cancer cells 
3b. Phagocytosis of apoptotic BCG-challenged bladder cancer cell lines by 
macrophages 
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Cell lines 
The HT1376 cell line was initially isolated from a 58 year old Caucasian woman with 
invasive transitional cell cancer (TCC) of the bladder (Rasheed, Gardner et al. 1977) 
while the MCR cell line was isolated from a subcutaneous metastatic lesion of a 51 year 
old male diagnosed with invasive TCC (Zoli, Ricotti et al. 2004). Cells were grown in  
25 cm
2
 flasks with DMEM (4.5 g.L
-1
 glucose, Sigma), 10% Foetal Calf Serum  
(FCS – Sigma), 2 mM L-glutamine (Sigma) and 100 μg.mL
-1
 penicillin/streptomycin 
(Sigma) in a 5% CO2 humidified atmosphere. Culture media were renewed twice a week, 
washing the cells when necessary with sterile phosphate buffered saline (PBS) solution 
(1.47 mM of KH2PO4, 4.29 mM of Na2HPO4.7H2O, 137 mM of NaCl and 2.68 mM of 
KCl, pH 7.3, in ultrapure water). Cells were routinely passaged when approximately 80% 
confluent by trypsin/EDTA (Sigma) treatment. 
 
Flow cytometry 
Peanut (PNA), Maackia amurensis (MAA) and Sambucus nigra (SNA) lectins (Sigma) 
were conjugated with Fluorescein Isothiocyanate (FITC) as previously described 
(Hoebeke, Foriers et al. 1978). Briefly, 10 µg of FITC (Invitrogen) dissolved in acetone 
was added to 1 mg of lectin dissolved in 1 mL of Na2CO3 1 M (pH 10). Each Lectin-FITC 
preparation was incubated overnight at 4 °C and dialyzed extensively against PBS.  
The anti-sTn antibody (TKH2 hybridoma clone) was kindly provided by Professor Celso 
Reis. Labelled cells were analysed in a FACSAria flow cytometer (Becton Dickinson). 
Fluorescence-activated cell sorting (FACS) data were processed with the Flowing 
Software v.2.3.3 (by Perthu Terho, Turku Centre for Biotechnology, Finland). 
For lectin staining, cells were incubated with 1:20 diluted PNA-FITC, 1:40 diluted  
MAA-FITC or 1:25 diluted SNA-FITC at 4 ºC for 15 min in the dark. For anti-sTn 
staining, cells were incubated with 1:50 diluted TKH2 supernatant for 45 min at 4 ºC, and 
then with 1:100 diluted polyclonal anti-Ig-FITC (Dako) for 15 min at 4 ºC in the dark. 
After a washing by centrifugation, cells were FACS analysed. 
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Preparation of cell lines constitutively expressing sialyltransferases 
HT1376 and MCR cells were previously transduced with a retroviral vector generated 
with the ViraPower Lentiviral Expression System (Invitrogen), according to 
manufacturer’s instructions. The whole coding regions of human ST3GAL1  
(cDNA isolated from the 5637 bladder cancer line) or of ST6GALNAC1 (kindly provided 
by Professor Celso Reis, IPATIMUP, University of Porto, Portugal) were PCR amplified 
and cloned in the pLenti6/V5 Directional TOPO cloning vector. The vector drives the 
expression of inserted genes through the cytomegalovirus promoter and contains the 
selectable marker for blasticidin. A negative control vector was prepared with an empty 
plasmid. After transduction with mock- or sialyltransferase-expressing  
vectors, HT1376 and MCR cells were selected with 4 g.mL
-1
 blasticidin.  
Pooled blasticidin-resistant cells were used for successive studies. 
 Isolation of cell populations homogeneously expressing sialylated antigens 
To obtain cell populations homogeneously expressing sialylated antigens from the 
heterogeneous cell populations which resulted from the transduction steps, two different 
approaches were used for HT1376 and MCR cells. 
  HT1376 cells expressing sT antigen – HT1376sT 
HT1376 cells homogeneously negative for PNA expression (HT1376sT) were obtained by 
selection of individual clones. About 100 transduced HT1376 cells were seeded in a  
10 cm Petri dish. Fifty percent of the growing medium was renewed every 3 to 5 days. 
After approximately one month, individual colonies were observed and collected with an 
inoculation loop. Nine colonies were randomly selected and the presence of the T antigen 
(Galβ1-3GalNAcα1-Ser/Thr) was detected by PNA-FITC staining and FACS analysed.  
  MCR cells expressing sTn antigen – MCRsTn 
The transduced MCR cells were enriched in their sTn positive population, using a 
commercial system for cell separation from MACS Technology (Miltenyi Biotec)  
as recommended by the manufacturer. Briefly, cells were incubated with 1:50 diluted  
anti-sTn antibody (HB-STn1 clone, Dako) for 45 min at room temperature. After washing 
with Beads Buffer (0.5% bovine serum albumin and 2 mM ethylenediaminetetraacetic 
acid in PBS) by centrifugation at 1000 x g for 5 min, cells were resuspended in Beads 
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Buffer and incubated with anti-mouse IgG Microbeads for 30 min at 4 ºC. After washing, 
cells were resuspended in Beads Buffer and dispensed into a MS column attached to the 
MiniMAC magnetic support. Unlabelled cells were washed out with Beads Buffer.  
After this step, the column was removed from the magnetic support, and the positive 
fraction of cell suspension was collected by flushing out with Beads Buffer. Cells of the 
sTn-positive fraction were grown and their sTn expression was evaluated by FACS. 
 
Sialyltransferase activity assays 
Cell pellets, stored at -80 °C, were homogenized in water. The protein concentration of 
the homogenates was determined by Lowry method (Lowry, Rosebrough et al. 1951). 
Sialyltransferase activities of these homogenates were measured according to the 
protocols described below, in the range of linearity with regard to time and substrate 
concentrations. Homogenates were conserved at -80 °C.  
  ST3GAL1 activity 
ST3GAL1 activity was assayed as previously described by Piller et al (Piller, Piller et al. 
1990) with some modifications. The reaction mixture contained in a 25 μL volume:  
50 mM of 2-(N-morpholino)ethanesulphonic acid (MES) buffer pH 6.5, 0.5% Triton  
X-100, 23.5 µg of Galβ1,3GalNAcα1-O-benzyl (benzyl-T; Sigma) as acceptor substrate, 
15 μM (640 Bq) of CMP-[
14
C]Sia (Amersham) and 50 µg of lysate proteins. Endogenous 
controls were prepared in the absence of the acceptor substrate. The enzyme reactions 
were incubated at 37 ºC for 2 h and then the products were isolated by hydrophobic 
chromatography in SepPak C18 Classic Cartridge (Waters), eluted and measured in a 
liquid scintillation counter. The incorporation on endogenous substrates was subtracted. 
  ST6GALNAC1 activity 
ST6GALNAC1 activity was assayed as previously described by Dall’Olio et al 
(Dall'Olio, Mariani et al. 1997) with some modifications. The reaction mixture contained 
in a 50 μL volume: 80 mM sodium cacodylate buffer pH 6.5, 0.5% Triton X-100 (Sigma), 
0.3 mg of asialo bovine submaxillary mucin (asialo-BSM, prepared by acid desialylation 
of BSM) as acceptor substrate, 30 μM (1280 Bq) of CMP-[
14
C]Sia (Amersham) and  
0.1 mg of homogenate. Endogenous controls were prepared in the absence of acceptor 
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substrate. The enzyme reactions were incubated at 37 ºC for 2 h and the radioactivity of 
the pellets was measured in a Wallac Guardian 1414 Liquid Scintillation Counter  
(Perkin Elmer) as previously described (Dall'Olio, Mariani et al. 1997). The incorporation 
on endogenous substrates was subtracted.  
 
Neuraminidase treatment 
Cells were treated with 20 mU of Clostridium perfringens sialidase (Roche Diagnostics) 
for 90 min at 37 °C. After a wash with PBS, cells were stained with lectins or antibodies 
and analysed as described above. 
 
Growth of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) 
Different available strains of BCG were studied, namely the laboratory Pasteur strain 
(kindly provided by Professor Yi Luo, Harvard Medical School, Boston), and the 
commercial strains RIVM (RIVM-BCG – Medac, Germany) and Connaught  
(Connaught-BCG – ImmuCyst, Sanofi Pasteur SA, France). 
Pasteur-BCG was maintained as described previously by Luo et al (Luo, Szilvasi et al. 
1996). In short, Pasteur-BCG was grown in 25 mL of Middlebrook 7H9 (Sigma) 
supplemented with 0.22% glycerol (Sigma), 0.05% Tween 80 (Sigma), 10% of Albumin 
Dextrose Catalase medium (ADC, Sigma) and 30 µg.mL
-1
 kanamycin (Sigma) for 
approximately one week. The number of colony forming units (CFU) was monitored 
daily through the formula CFU.mL
-1
 = A600 x 3.2 x 10
7
. When the density of the culture 
reached 1 unit of optical density (O.D.), BCG was recultured with a starting O.D. of 0.1, 
or stored in growing medium at -80 ºC. Aliquots were cultured in blood agar plates for 
24-48 h at 37 ºC to search for the presence of contaminating microorganisms. 
Commercial BCG strains were resuspended in PBS with 0.05% of Tween 80 and stored at 
-80 ºC. Before each assay, BCG aggregates were eliminated by centrifugation (300 x g for 
5 min). When required, about 1 unit of O.D.600nm of single cell BCG was labelled with  
2 µg.mL
-1
 of orange cell tracker dye (OCT – CMTMR, Invitrogen) for 2 h in growth 
conditions, and incubated for other 2 h in one volume of growing medium. 
Materials and Methods 
Paulo Severino | Thomsen-Friedenreich antigens in bladder cancer: evaluation of their prognostic value 61 
 
 
BCG internalization by cell lines 
BCG internalization by bladder cancer cell lines was accomplished by co-incubating cell 
lines with different strains of OCT-stained BCG in a cell:bacteria proportion of 
approximately 1:10. Cell lines, seeded in 24 wells plates, were incubated with  
0.25 O.D.600nm units of BCG, for 2, 4, 6 or 12 h. Internalization of BCG-OCT by cell lines 
was evaluated by FACS.  
 
Real time RT-PCR 
Total RNA was isolated using either the GenElute Mammalian Total RNA Purification kit 
and DNase treatment (Sigma), according to the manufacturer's instructions, or by the 
guanidinium thiocyanate-method described by Chomczynski and Sacchi (Chomczynski 
and Sacchi 1987). The purity of RNA was determined by A260/A280 and 
Abs260nm/Abs230nm, absorbance ratios. Only samples with ratios between 1.9 and 2.1 were 
used. The absence of genomic DNA was confirmed by electrophoresis in 1% of agarose 
gel (Invitrogen). 
Approximately 1 μg of total RNA was reverse transcribed, using the  
random-primers-based High Capacity cDNA Archive Kit (Applied Biosystems).  
Briefly, 50 µL of reaction mixture, containing 2x of random primers, 8 mM of 
deoxynucleotides solution, 250 U of reverse transcriptase, 2x of buffer and ultrapure 
water, was added to RNA samples in a 1:1 ratio. The expression levels of the set of 
sialyltransferases selected (Table 2.1) were evaluated with the TaqMan assay system 
(Applied Biosystems). Real time PCR was performed in a 7500 Fast Real-Time PCR 
System (Applied Biosystems) using the TaqMan Universal PCR Master Mix Fast 
(Applied Biosystems) as described previously by Videira et al (Videira, Calais et al. 
2009). Briefly, each reaction mixture of 10 µL contained 1x of TaqMan Universal PCR 
Master Mix Fast, 1.8 µL of cDNA reverse transcribed previously, 1x of each probe and 
nuclease-free ultrapure water in a 96-well microplate (Fast Optical 96-Well Reaction). An 
initial denaturation step (95 °C, 20 s) was followed by 40 cycles of denaturation (95 °C, 
30 s) and annealing (60 °C, 30 s). During cDNA exponential amplification the product 
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formation was proportional to the fluorescence emission resulting from the TaqMan probe 
degradation (van der Velden, Hochhaus et al. 2003, Wong and Medrano 2005).  
The mRNA levels relative to the expression of ACTB, which was taken as a suitable 
endogenous control for bladder cancer cells (Videira, Calais et al. 2009).  
Results were analysed using ∆∆Ct method (Livak and Schmittgen 2001). 
 
Table 2.1. Set of housekeeping gene and sialyltransferases gene assays ID from Applied Biosystems. 
Gene Gene Assay ID 
ACTB Hs00355741_m1 
ST3GAL1 Hs00161688_m1 
ST3GAL2 Hs00199480_m1 
ST3GAL3 Hs00196718_m1 
ST3GAL4 Hs00272170_m1 
ST3GAL5 Hs00187405_m1 
ST3GAL6 Hs00196086_m1 
ST6GAL1 Hs00174599_m1 
ST6GALNAC1 Hs00300842_m1 
ST6GALNAC2 Hs00197670_m1 
ST6GALNAC3 Hs00541761_m1 
ST6GALNAC4 Hs00205241_m1 
ST6GALNAC5 Hs00229612_m1 
ST6GALNAC6 Hs00203739_m1 
 
Whole transcriptome analysis by expression microarray 
Total RNA was prepared as described above, converted to labelled single strand DNA 
(ssDNA) by the commercial Whole Transcript Expression kit (Ambion) and hybridized 
into a GeneChip Human Gene 1.0 ST Array (Affymetrix) according to the manufacturer’s 
instructions. In short, 250 ng of sample RNA were spiked-in with the same quantity of 
control poly-A RNA and converted into cDNA in two steps. The first was important for 
an accurate synthesis of the first DNA strand with an incorporated T7 promoter;  
the second was important for the synthesis of the second DNA strand and for the removal 
of the initial RNA template. After this, an in vitro transcription of complementary RNA 
(cRNA) was performed. cRNA samples were purified from nucleotides, salts and 
enzymes in a magnetic platform (Affymetrix), by taking advantage of the affinity of RNA 
for nucleic acid binding beads. From pure cRNA, a complementary ssDNA was obtained 
by reverse transcription of only the first strand. ssDNA sequences are equivalent to the 
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RNA sequences existing in the original samples. Samples of ssDNA were purified from 
nucleotides, salts and enzymes as above. ssDNA sequences with incorporated uracil 
nucleotides were fragmented by the activities of the uracil-DNA glycosylase (UDG) and 
the apurinic/apyrimidinic endonuclease 1 (APE1), and labelled at the 3’ end with a 
proprietary biotin-labelled deoxynucleotide analogue using the Terminal 
Deoxynucleotidyl Transferase (TdT). Labelled ssDNA fragments virtually covering the 
whole transcriptome of transduced bladder cancer cell lines were then hybridized in a 
Human Transcriptome Array 2.0 overnight. Fluorescences were read in a GeneChip 
Scanner 3000 7G (Affymetrix). Raw data were background-subtracted, normalised and 
summarised with the robust multi-array average (RMA) algorithm implemented in the 
affy package of Bioconductor (http://www.bioconductor.org). Differential genes between 
query and control assay were selected by a modified t-test implemented in limma 
package, with p = 0.05 cut-off. Array data were analysed by the ArrayStar v2.0 software 
(DNASTAR).  
 
Preparation of monocyte derived macrophages 
Macrophages were obtained by differentiation of peripheral human monocytes as follows. 
Blood from the blood collection service of the Pizzardi Hospital of Bologna was diluted 
one fold with PBS and centrifugated at 200 x g for 30 min at 20 ºC. The interface, 
containing the majority of the white blood cells, was diluted two folds with PBS and 
gently stratified in Ficoll-Hypaque (GE Healthcare) in a proportion of 5:3.7. Stratified 
preparations were centrifuged at 1200 x g for 30 min at 20 ºC and the white interface was 
carefully collected. This phase, containing the mononuclear cells, was washed abundantly 
with PBS and resuspended in RPMI 1640 (Sigma) medium supplemented with 20% FCS, 
2 mM L-glutamine (Sigma) and 100 μg.mL
-1
 penicillin/streptomycin (Sigma). 
Mononuclear cells were dispensed in plastic Petri dishes and incubated in growth 
conditions. Medium was daily renewed. After 7 days, monocyte derived macrophages 
were detached with a cell scraper and dispensed in 24 well plates at approximately 50% 
of confluence for further assays. 
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Induction of cytokine secretion 
 Stimulation in bladder cancer cell lines 
Bladder cancer cell lines were incubated with BCG for 2 h at 37 °C. Then the medium 
was removed, cells were washed twice with PBS and incubated with fresh medium 
without BCG for 16 h. Conditioned media were collected and stored at -80 for further 
analysis. Cells were washed, harvested and used for RNA preparation. The media and 
cells mock treated in parallel without BCG were used as controls. 
 Stimulation in macrophages 
The response of macrophages to components secreted by BCG-treated cell lines was 
assessed by incubating macrophages with conditioned media from BCG-challenged or 
unchallenged cell lines obtained as described above. After 24 h, conditioned media were 
removed and stored at -80 °C for cytokine expression analysis. 
 
Detection of secreted cytokines 
Conditioned media from cell lines challenged or unchallenged with BCG and those from 
macrophages incubated with media conditioned by cell lines were characterized for their 
cytokine content by enzyme-linked immunosorbent assay (ELISA) and multiplex 
immune-beads assay (MIBA). IL-6 was detected with a commercial 96 wells ELISA kit 
(Raybiotech) as recommended by manufacturer instructions. In short, ELISA plates 
coated with anti-IL-6 were incubated at room temperature for 2.5 h with 3:10 diluted 
supernatants and successively with biotin-conjugated anti-IL-6 (biotin-anti-IL-6) for 1 h 
with horseradish peroxidase conjugated streptavidin (HRP-streptavidin) for 45 min and 
with 3,3’,5,5’-Tetramethylbenzidine (TBM) substrate solution for 30 min. At the end, an 
acidic stop solution was added and colorimetric results were read at 450 nm in a  
multi-channel reader (Multiskan EX, Labsystems). After evaluation of IL-6,  
ten interleukins (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17, IFNγ and TNFα) were 
evaluated in a 96-well strip plate from a commercial MIBA kit (Bio-Rad) as 
recommended by manufacturer’s instructions. In short, a mix of colour-coded micro 
beads coated with each specific antibody recognizing each studied cytokine were 
incubated with each supernatant sample in a filtered bottom 96 wells MIBA plate for  
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30 min at room temperature. Further steps of incubation with a mix of antibodies for  
30 min and with Phycoerythrin-streptavidin (PE-streptavidin) for 10 min at room 
temperature were performed. Fluorescences were read in a Luminex 100 Bio-Plex Liquid 
Array Multiplexing System reader (Bio-Rad) and the data were analysed with the  
Bio-Plex Manager v5 software (Bio-Rad). 
 
Phagocytosis assay 
Phagocytosis was evaluated by incubating apoptotic BCG-challenged and unchallenged 
cell lines with macrophages as follows. Apoptosis was induced by incubation with  
100 M (for HT1376) or 200 µM (for MCR) of the zinc chelator TPEN  
(N,N,N’,N’-tetrakis-(2-pyridylmethyl)ethylenediamine, Sigma) for 48 h. Apoptotic cells 
were harvested and resuspended in prewarmed serum-free DMEM with 1 µg.mL
-1
 of 
OCT and incubated for 1 h under growth conditions. Dye solution was then replaced by 
supplemented DMEM, cells were incubated for another hour under growth conditions, 
washed with PBS and resuspended in supplemented medium. The same procedure of 
labelling was carried out on adherent macrophages but with the green cell tracker dye 
(GCT – CMFDA, Invitrogen). Labelled apoptotic cells were incubated with macrophages 
in a 2:1 proportion in 24 wells plates and incubated for 2 h in growth conditions.  
At the end, the medium was removed and wells were washed with PBS.  
Macrophages were detached with a cell scraper, resuspended in 500 µL of PBS and FACS 
analysed. The percentage of double labelled macrophages was taken as a measure of the 
macrophage population which phagocytosed apoptotic cells. 
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III.1 Cellular Models of Bladder Cancer (BC) 
 
FACS characterization of cells highly expressing sT or sTn antigens 
To investigate the role of Thomsen-Friedenreich related antigens on bladder cancer, 
cellular models were prepared earlier by our research group (Ferreira, Videira et al. 
2013). As discussed before, HT1376 and MCR cell lines, derived from patients with TCC 
of the bladder, were chosen because they presented originally low expression of the  
sialyl-T (sT) or sialyl-Tn (sTn) antigens and ST3GAL1 or ST6GALNAC1 
sialyltransferases respectively (Videira, Correia et al. 2009). Cell lines resulting from 
transduction with the cDNA of the two sialyltransferases and successive cloning or 
enrichment steps, were characterized for the presence of carbohydrate antigens, 
expression of sialyltransferase mRNA and enzymatic activities. 
After the transduction step, the ST3GAL1-transduced HT1376ST3G1 and the 
ST6GALNAC1-transduced MCRST6GN1 cell lines were composed by populations of cells 
expressing heterogeneously the sT or sTn antigens respectively (Figure 3.1).  
The induction of sT antigen expression was indirectly deduced from the decreased 
labelling with PNA. In fact, this lectin recognizes the T antigen (Galβ1,3GalNAc), which 
is masked and no longer bound by the lectin after the addition of α2,3-linked sialic acid.  
On the other hand, sTn expression was directly assessed by the labelling with the 
antibody anti-sTn. 
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a)         HT1376  
 
Figure 3.1. Flow Cytometry analysis of transduced cells.  
a) T antigen expression by HT1376 cells. Mock-transduced 
HT1376NC cells (green line) were strongly reactive for PNA 
because of the large number of Gal1,3GalNAc termini.  
The ST3GAL1-transduced HT1376ST3G1 cell line presented a 
bimodal reactivity for PNA (blue line). b) Sialyl Tn expression 
by MCR cells. sTn expression on mock-transduced MCRNC 
cells (green line) was negligible, while sTn expression on 
ST6GALNAC1-transduced MCRST6GN1 cells was bimodal  
(blue line) with a minority of sTn negative cells.  
Black line: unlabelled cell lines or isotype control antibody 
when labelling with lectins or antibodies was used, 
respectively. 
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To obtain cell populations homogeneously expressing sT or sTn antigens, we adopted two 
different strategies: clone selection for HT1376ST3G1 cells and magnetic sorting on 
MCRST6GN1 cells. In fact, we first attempted to sort HT1376ST3G1 clones, by negative 
magnetic selection, but as we still failed to obtain homogeneous populations of  
PNA-negative HT1376ST3G1 cells and therefore we opted for clone selection to obtain a 
PNA-positive population. The new cell models (hereafter named HT1376sT and MCRsTn 
cells) were highly homogeneous, being comprised of more than 95% of cells either not 
showing PNA reactivity (Figure 3.2 – blue framed histograms) or expressing sTn  
(Figure 3.2 – orange framed histograms), respectively. The pattern of carbohydrate 
structures induced by the expression of the two sialyltransferases was also investigated by 
flow cytometry using two lectins specific for α2,3-linked sialic acid (Maackia amurensis 
lectin, MAA) or for α2,6-linked sialic acid (Sambucus nigra lectin, SNA) (Figure 3.2). 
ST3GAL1 overexpression in HT1376 cells induced a slight increase of MAA reactivity 
while reactivity for SNA remained unchanged. ST6GALNAC1 overexpression in MCR 
cells induced, beside the expected effect on sTn antigen expression, also a substantial 
decrease of the T antigen expression (Figure 3.2 – gray framed histograms).  
This effect was likely due either to the block by the addition of β1,3-linked galactose to 
the GalNAc (Tn antigen), since it is already linked by sialic acid (sTn antigen), or to the 
lack of recognition by PNA of sialyl-6-T antigen [Galβ1,3(Siaα2,6)GalNAc]. Reactivity 
for SNA consistently augmented, as predicted by the known specificity of SNA for sTn 
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antigen (Shibuya, Goldstein et al. 1987). Mock-transduced and ST6GALNAC1-transduced 
MCR variants showed similar reactivity with MAA. No sTn antigen was detectable in 
HT1376 cells (Figure 3.2 – gray framed histograms). 
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Figure 3.2. Characterization of transduced bladder cancer cell lines by Flow Cytometry.  
Bladder cancer cell lines were labelled with PNA-FITC, MAA-FITC, SNA-FITC and anti-sTn  
(labelled with anti-Ig-FITC) before (red line) or after (grey line) sialidase treatment. Black line: unlabelled 
cell lines or isotype control antibody when labelling with lectins or antibodies was used, respectively. 
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Sialidase treatment of the HT1376sT clone reverted its PNA-reactivity to the same high 
level of HT1376NC cells, confirming that α2,3-linked sialic acid was responsible for the 
masking of the Galβ1,3GalNAc structures. By contrast, sialidase treatment had no effect 
on PNA-reactivity of HT1376NC cells. Together, these results indicate that in HT1376 
cells the T antigen is masked only by α2,3-sialylation. Sialidase treatment slightly 
reduced the MAA reactivity of both HT1376NC and HT1376sT cells and, although at a 
lesser extent, their SNA reactivity. Sialidase treatment induced a remarkable increase of 
PNA-reactivity in MCRNC cells and a much higher increase in MCRsTn cells.  
Altogether, these data suggest that in MCRNC cells, the T antigen is partially masked by 
the α2,3-sialylation of galactose (sT antigen), thus explaining the increase of PNA 
reactivity after sialidase treatment. mRNA expression data (see below, Figure 3.5), show 
that of the three α2,3 sialyltransferases which can synthesize the sT structure  
(ST3GAL1, ST3GAL2 and ST3GAL4), the second and the third are expressed, albeit at a 
low level, in MCR cells, supporting the notion that a percentage of T antigen molecules 
are α2,3-sialyl substituted. In MCRsTn cells, in which the level of mRNA expression of 
transduced ST6GALNAC1 is about 1000 fold higher than that of ST3GAL2 and ST3GAL4 
(Figure 3.5), the level of PNA reactivity is very low, indicating that α2,6 sialylation 
strongly contributes to mask (or inhibit the biosynthesis) of the T antigen.  
The higher decrease in PNA reactivity observed in MCRsTn, suggests that the T antigen is 
present but almost completely masked by α2,6-sialylation (Figure 3.3). This is consistent 
with the reported substrate specificity of the cloned human ST6GALNAC1  
(Ikehara, Kojima et al. 1999) which indicates that the enzyme can act not only on Tn, but 
also on T and sT structures. 
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Figure 3.3. Different PNA reactivity in mock- or ST6GALNAC1-transduced MCR cells. PNA reactivity 
data indicate that the number of accessible T structures is much lower in MCRsTn cells than in MCRNC cells. 
This is due to the fact that ST6GALNAC1 acts not only on Tn antigen but also on T and sT structures, 
resulting in an almost complete masking of the T antigen by α2,6-linked sialic acid.   
GalNAc: yellow square; Gal: yellow circle; Sia: purple diamond. 
 
Sialyltransferase expression by selected cell populations 
The activities and the mRNA levels of the two sialyltransferase of the new HT1376sT and 
MCRsTn cell variants were measured to confirm the success of transduction and 
enrichment steps. The transfer of sialic acid on exogenous acceptors catalysed by cell 
homogenates was measured by using benzyl-T or asialo-BSM as acceptors for ST3GAL1 
or ST6GALNAC1 sialyltransferases, respectively. Enzyme activities of  
sialyltransferase-transduced cell lines were much higher than that of untransduced or 
mock-transduced cell lines (which were just above the background). HT1376sT cells 
presented a 40 fold increase of enzyme activity (Figure 3.4a) and MCRsTn a 20 fold 
increase of enzyme activity (Figure 3.4c). The specificity of the two acceptor substrates 
used for the two sialyltransferase assays was not absolute. Although sialyltransferases 
other than ST3GAL1 can act on benzyl-T, the fact that a high activity was detectable only 
in ST3GAL1-transduced cells, and not in control cells, strongly suggested that 
incorporation on benzyl-T was due to this enzyme. Also asialo-BSM can be sialylated by 
sialyltransferases other than ST6GALNAC1, but the fact that a high activity was 
detectable only in ST6GALNAC1-transduced cells strongly suggested that incorporation 
on asialo-BSM was due to ST6GALNAC1 activity. As expected, the mRNA level of 
ST3GAL1 (Figure 3.4b) and ST6GALNAC1 (Figure 3.4d) was also increased.  
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Expression of ST3GAL1 in HT1376sT cells was 156‰ that of β-actin, while in HT1376NC 
cells it was undetectable. In the same way, in MCRsTn cells the expression of 
ST6GALNAC1 was about 7000‰ that of β-actin, about 720 fold the expression of this 
sialyltransferase in MCRNC cells. These results are consistent with flow cytometry 
analysis. 
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Figure 3.4. ST3GAL1 and ST6GALNAC1 expression. Incorporation of radioactive sialic acid ([
3
H]-Sia) 
into a) benzyl-T by HT1376 cell homogenates or into c) asialo-BSM by MCR cell homogenates.  
The sialyltransferase activity was negligible in untransduced HT1376 or MCR, and in mock-transduced 
HT1376NC or MCRNC cells. Both selection procedures led to increase the respective sialyltransferase 
activities. Consonant expression of b) ST3GAL1 in HT1376sT cells and of d) ST6GALNAC1 in MCRsTn cells 
was found. Data are the mean ±SD of 3 experiments. ** p < 0.001; * p < 0.05. 
  
The level of mRNA expression of several sialyltransferases in ST3GAL1- and 
ST6GALNAC1- transduced cell lines and in their respective negative controls was 
accomplished by Real-time PCR (Figure 3.5).  
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Figure 3.5. Sialyltransferase mRNA expression in transduced cells. Relative mRNA levels of several 
sialyltransferases were analysed in a) HT1376NC (pink bars), HT1376sT (orange bars) and b) MCRNC  
(light blue bars) and MCRsTn (dark blue bars) cells by RT-qPCR. Results were normalized for  
1000 molecules of the endogenous control β-actin. High levels of ST3GAL1 and ST6GALNAC1 mRNA 
were detected in MCRsTn and in HT1376sT respectively, while the expression of other sialyltransferases 
were low or undetectable e was not interfered significantly after transduction. Data are the mean ±SD of 3 
experiments. Student’s t test revealed that sialyltransferases ST3GAL1 and ST6GALNAC1 were the only 
statistically modulated in HT1376sT and MCRsTn, respectively. Boxed expression data are the same reported 
in Figure 3.4 and are repeated here for comparison. 
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In both HT1376NC and HT1376sT cells, low levels (usually lower than 10‰ of β-actin) of 
the sialyltransferases ST3GAL3, ST3GAL6, ST6GALNAC2, ST6GALNAC4 and 
ST6GALNAC6 mRNA were detected, while sialyltransferases ST3GAL2, ST3GAL4, 
ST3GAL5, ST6GAL1, ST6GALNAC1, ST6GALNAC3 and ST6GALNAC5 mRNA were 
nearly undetectable. In both MCRNC and MCRsTn cells, low levels (usually lower than 
10‰ of β-actin) of the sialyltransferases ST3GAL2, ST3GAL3, ST3GAL4 ST3GAL5, 
ST3GAL6, ST6GALNAC2, ST6GALNAC4 and ST6GALNAC6 were detected, while 
ST3GAL1, ST6GAL1, ST6GALNAC3 and ST6GALNAC5 mRNA were nearly 
undetectable. Apparently, the expression of ST3GAL1 and ST6GALNAC1 did not interfere 
significantly on the expression of other sialyltransferases. In general, the above reported 
results indicate that, apart from the expression of the transduced genes and their cognate 
structures, the mock-transduced and the sialyltransferase-transduced cell lines showed to 
be similar, if not identical, allowing to establish clear cause-effect relationships between 
phenotype and sialyltransferases expression. 
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III.2 Response of BC cell lines to BCG 
 
As previously mentioned, attenuated Mycobacterium bovis Bacillus Calmette-Guérin 
(BCG) is used in the therapy of TCC of the bladder. For a better understanding of the role 
of sialyl Thomsen-Friedenreich antigens in tumour progression, we analysed several steps 
of the interactions between BCG and bladder cancer cells. Each step was analysed with 
regard to presence/absence of the sialylated Thomsen-Friedenreich related antigens.  
In this section, we will describe the effects of the interactions of bladder cancer cell lines 
expressing sT or sTn antigens with BCG. In particular, we will analyse BCG 
internalization, cytokine secretion and whole transcriptome changes in bladder cancer cell 
lines. 
 
BCG Internalization 
BCG therapy consists in the intravesical instillation of BCG for 2 hours. Internalization of 
BCG by bladder cancer cells was studied by using three different BCG strains 
(Connaught-BCG, RIVM-BCG and Pasteur-BCG). In Figure 3.6 is shown the time course 
of internalization of the three BCG strains by transduced HT1376sT and MCRsTn cell lines 
and the respective mock-transduced cell lines. Over long times, the process of BCG 
internalization displayed obvious time dependence (Figure 3.6b and 3.6c), while no 
significant differences among different BCG strains or different cell lines were observed. 
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Figure 3.6. Time course of BCG internalization by bladder cancer cell lines. a) Analysis by FACS of 
the internalization of Connaught-BCG, RIVM-BCG or Pasteur-BCG by HT1376NC cells (light orange bars), 
HT1376sT cells (orange bars), MCRNC cells (light blue bars) and MCRsTn cells (dark blue bars), after 2 or  
6 h of incubation with BCG. Internalization values were normalized with the respective controls incubated 
at 4 ºC. Data are the mean ± SD of 3 experiments. * p < 0.05. b) and c) An example of time-dependent 
Connaught-BCG internalization by MCRsTn cells MFI2h = 7, MFI6h = 13 and MFI24h = 23.  
Black line: internalization at 4 ºC. Over longer periods of time, internalization of BCG displayed a two 
slope curve with tendency to saturation. OCT stands for orange cell tracker. 
 
According to these results, BCG internalization might be independent from sT or sTn 
Thomsen-Friedenreich antigens since no significant differences were observed in BCG 
internalisation among sialyltransferase- and mock-transduced cell lines. Nonetheless the 
strain RIVM of BCG showed a tendency to be more internalized by HT1376sT or MCRsTn. 
In successive experiments the Connaught-BCG strain was used with an incubation time of 
2 hours, mimicking the instillation time in therapy. 
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Transcriptome analysis of bladder cancer cell lines 
The overall impact of the expression of ST3GAL1 or ST6GALNAC1 sialyltransferases and 
of BCG-challenge on our models was evaluated by analysing by expression microarray 
technology the global modulation of gene expression. This technology used over than  
6 million probes covering coding transcripts and non-coding transcripts. In a first step, the 
analysis was focused on genes displaying modulation as a response to  
sialyltransferase-transduction, regardless BCG-challenging. In a second step, we focused 
on the set of genes modulated by BCG-challenging regardless sialyltransferase 
expression. All significant modulations are presented as heat-maps in Supplement I 
section. After that, based on the literature, gene signatures of “bladder cancer markers” 
and “caretaker genes” were identified and are presented in Figures 3.7 and 3.9. 
Transcripts that showed a tendency for modulation in the context of the same gene 
signatures were also included. 
 
Effect of ST3GAL1 expression – Gene Signatures of HT1376 cells 
ST3GAL1 expression in HT1376 cells impacts several genes involved in specific cell 
functions (Figure 3.7a). In particular, a group of genes whose products affect mitotic 
fidelity and chromosomal stability show a consistent down-regulation. If the analysis is 
restricted to genes showing modulation by at least a factor 2 (i.e. whose expression in 
HT1376sT cells is at least double or half that of HT1376NC cells), genes ORC1L, SPC24, 
BUB1B, CENPI, FRY, KIFC1, HAUS7, CCNF and CDCA5, which are involved in the 
accuracy of chromosomal segregation during mitosis, show down-regulation in HT1376sT 
cells. Some genes crucially involved in the mechanism of repair of double strand breaks 
known as homologous recombination repair (HR), such as FANCA, FANCC, FANCD2, 
FANCG, RAD54L and KIF4A, also show down-regulation in HT1376sT cells. Other genes 
involved in HR, such as BRCA2, BRIP1, XRCC3, EME1, as well as genes involved in 
other mechanisms of DNA repair, like base excision repair (BER) and nucleotide excision 
repair (NER) (APEX2 and ERCC2, respectively) display down-regulation in HT1376sT 
cells, although at a lower extent. It can be hypothesized that, owing to the general  
down-regulation of the genes preserving chromosome number and integrity, which can be 
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collectively defined as “caretaker genes”, HT1376sT cells are more prone to display 
alterations of chromosome number and structure. HT1376sT cells display decreased 
expression of ADAM12, a protease involved in Notch signaling and of SERPINE1, but 
increased expression of SERPINE2. The two latter genes encode protease inhibitors with 
pleiotropic functions. Moreover, HT1376sT cells display decreased expression of two 
genes affecting cell growth, such as cyclin D1 (CCND1) and lysyl oxidase-like 4 
(LOXL4), which inhibits Ras/ERK signaling. The genes encoding trombospondin 1 
(THBS1) and keratin 5 (KRT5) also display down-regulation. In an attempt to predict the 
putative functional consequences of the gene modulation, we performed a literature 
search for the individual contribution of the modulated genes to the bladder neoplastic 
phenotype. This search revealed that the modulation of 46 genes was toward a more 
malignant phenotype while only 5 genes were modulated toward a less malignant 
phenotype. Sixteen of the genes modulated toward increased malignancy were reported in 
the literature as bladder cancer markers (CD24, SERPINE2, POLI, PTGS2, TMPRSS4, 
VEGFA, CTSH, CTSB, H19 and MMP14 genes were up-regulated, while ARID1A, 
FGFR3, CCND1, LOXL4, THBS1 and KRT5 genes were down-regulated), On the other 
hand, 5 genes reported as “bladder cancer markers” moved toward decreased malignancy 
(MTSS1 and TIMP3 genes were up-regulated, and BIRC3, ADAM12 and SERPINE1 
genes were down-regulated). The challenging with BCG appears to affect poorly the gene 
expression profile of HT1376NC cells whereas in HT1376sT cells we observed a tendency 
to up-regulation of the genes preserving genomic stability, although their changes is 
usually lower than a factor 2 (Figures 3.7b and 3.7c). A group of genes encoding 
proteases or their inhibitors also display a slight modulation in HT1376sT cells.  
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a) Genes modulated by ST3GAL1 expression  
in HT1376 cells 
 
b) Genes modulated by BCG-challenging  
in HT1376NC cells 
 
c) Genes modulated by BCG-challenging  
in HT1376sT cells 
 
 
Figure 3.7. Gene signatures in HT1376 cells. 
Expression variation of relevant genes in  
a) HT1376sT cells vs. HT1376NC cells, in  
b) HT1376NC cells and in c) HT1376sT cells after 
BCG-challenging. Genes were grouped in 
“bladder cancer markers” and “caretaker” 
categories, according to putatively increased or 
decreased malignant phenotypes. Only variations 
greater then ± 0.5 were considered. Data are the 
mean of 3 experiments. * p ≤ 0.05. 
 
In Tables 3.1 to 3.3 are presented the selected signature genes presented in figure 3.7 with 
gene description, hosting chromosome, GenBank code and a short outline of the function. 
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Table 3.1. Description of up- or down-regulated genes of HT1376sT cells vs. HT1376NC cells. 
Gene Signatures modulated by ST3GAL1 expression 
    
Symbol Description Chr 
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en
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13
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Lo
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E
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T
13
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(s
T
-N
C
) 
Function Ref 
  Changes increasing malignancy – Bladder Cancer markers 
    CD24 CD24 molecule 6 
N
M
_0
13
23
0 5,0 6,4 1,4 mucin-type 
glycoprotein, 
prognostic marker 
(BC) 
(Choi, Lee et al. 
2007, Lee, Kim et al. 
2009, Fenner 2012, 
Liu, Zheng et al. 
2013) 
    SERPINE2 serpin peptidase 
inhibitor; clade E 
(nexin; 
plasminogen 
activator 
inhibitor type 1); 
member 2 
2 
N
M
_0
01
13
65
29
 7,4 8,5 1,1 serine peptidase 
inhibitor, pleiotropic 
functions besides 
haemostasis 
(Bergeron, Lemieux 
et al. 2010, 
Nagahara, 
Nakayama et al. 
2010, Xu, McKee et 
al. 2010) 
    POLI polymerase 
(DNA directed) 
iota 
18 
N
M
_0
07
19
5 9,0 9,9 0,9 overexpressed 
POLI contributes to 
hypermutagenesis 
(BC) 
(Yuan, Xu et al. 
2013) 
    PTGS2 prostaglandin-
endoperoxide 
synthase 2 
(prostaglandin 
G/H synthase 
and 
cyclooxygenase) 
1 
N
M
_0
00
96
3 9,8 10,6 0,8 prostaglandins 
production (BC) 
(Czachorowski, 
Amaral et al. 2012, 
Ke, Tu et al. 2012, 
Tabriz, Olfati et al. 
2013) 
    TMPRSS4 transmembrane 
protease; serine 
4 
11 
N
M
_0
19
89
4 7,9 8,7 0,8 highly expressed in 
pancreatic, thyroid, 
colon and other 
cancer tissues (C) 
(Kim, Kuppireddy et 
al. 2012, Cheng, 
Kong et al. 2013, 
Cheng, Liang et al. 
2013, Min, Lee et al. 
2013) 
    VEGFA vascular 
endothelial 
growth factor A 
6 
N
M
_0
01
02
53
6 6 10,3 11,0 0,7 stimulates the 
formation of new 
blood vessels and 
tumour growth (BC) 
 
 
(Fauconnet, 
Bernardini et al. 
2009, Zaravinos, 
Volanis et al. 2012, 
Kopparapu, Boorjian 
et al. 2013) 
    CTSH cathepsin H 15 
N
M
_0
04
39
0 9,9 10,6 0,7 overexpression and 
release by 
cancerous tissues; 
degradation of 
extracellular matrix 
components (BC) 
(Staack, Koenig et 
al. 2002, Staack, 
Tolic et al. 2004) 
    CTSB cathepsin B 8 
N
M
_1
47
78
0 9,5 10,1 0,6 overexpression and 
release by 
cancerous tissues; 
degradation of 
extracellular matrix 
components (BC) 
(Eijan, Sandes et al. 
2003, Staack, Tolic 
et al. 2004, Svatek, 
Karam et al. 2008, 
Kotaska, Dusek et 
al. 2012) 
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Table 3.1. Description of up- or down-regulated genes of HT1376sT cells vs. HT1376NC cells 
(continued). 
    H19 H19, imprinted 
maternally 
expressed 
transcript (non-
protein coding) 
11 
N
R
_0
02
19
6
 10,4 11,0 0,6 a long non-coding 
RNA induced in 
bladder cancer 
(BC) 
(Matouk, DeGroot et 
al. 2007, Luo, Li et 
al. 2013, Luo, Li et 
al. 2013) 
    MMP14 matrix 
metallopeptidase 
14 (membrane-
inserted) 
14 
N
M
_0
04
99
5 9,4 10,0 0,6 degradation of 
basal membranes 
and of the 
extracellular matrix 
(BC) 
(Chaffer, Dopheide 
et al. 2005, 
Mohammad, Ismael 
et al. 2010, Reis, 
Leite et al. 2012) 
    ARID1A AT rich interactive 
domain 1A (SWI-
like) 
1 
N
M
_0
06
01
5 8,8 8,3 -0,5 actin dependent 
regulator of 
chromatin 
structure, acting as 
a tumour 
suppressor (BC) 
(Gui, Guo et al. 
2011, Balbas-
Martinez, 
Rodriguez-Pinilla et 
al. 2013, Guo, 
Zhang et al. 2013) 
    FGFR3 fibroblast growth 
factor receptor 3 
4 
N
M
_0
00
14
2 7,6 7,0 -0,6 regulation of cell 
growth and division 
(BC) 
(van Rhijn, van der 
Kwast et al. 2012, 
Gust, McConkey et 
al. 2013, Sjodahl, 
Lovgren et al. 2013) 
    CCND1 cyclin D1 11 
N
M
_0
53
05
6 9,0 7,6 -1,4 G(1)-phase cell 
cycle regulatory 
molecule (BC) 
(Pantazis, Soulitzis 
et al. 2011, Sjodahl, 
Lovgren et al. 2013) 
    THBS1 thrombospondin 1 15 
N
M
_0
03
24
6 7,7 5,9 -1,8 antiangiogenic 
factor (BC) 
(Goddard, Sutton et 
al. 2002, Brunner 
and Tzankov 2007, 
Donmez, Sullu et al. 
2009, Shariat, 
Youssef et al. 2010) 
    KRT5 keratin 5 12 
N
M
_0
00
42
4 10,4 8,6 -1,9 KRTs are 
differentially 
expressed during 
epithelial tissue 
differentiation (BC) 
(Volkmer, Sahoo et 
al. 2012, Balbas-
Martinez, 
Rodriguez-Pinilla et 
al. 2013, Sjodahl, 
Lovgren et al. 2013) 
    LOXL4 lysyl oxidase-like 4 10 
N
M
_0
32
21
1 7,1 5,7 -1,4 act as tumour 
suppressor by 
inhibiting the 
Ras/ERK signaling 
pathway (BC) 
(Wu, Guo et al. 
2007) 
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Table 3.1. Description of up- or down-regulated genes of HT1376sT cells vs. HT1376NC cells 
(continued). 
  Changes increasing malignancy – caretaker genes 
    XRCC6 X-ray repair 
complementing 
defective repair in 
Chinese hamster 
cells 6 
22 
N
M
_0
01
46
9 10,6 10,1 -0,5 plays an essential role 
in the DNA double-
strand break (DSB) 
repair pathway, i.e., 
non homologous 
DNA-end-joining 
(NHEJ) 
(Koike, Yutoku et 
al. 2011, Chang, 
Ke et al. 2012, 
Hsu, Yang et al. 
2013, Xu, Zou et 
al. 2013) 
    BRCA2 breast (C) 2, early 
onset 
13 
N
M
_0
00
05
9 8,8 8,3 -0,6 important role in the 
homologous 
recombination 
pathway for double-
strand DNA repair and 
in the G2 checkpoint 
following DNA-
damage (BC) 
(Goode, Ulrich et 
al. 2002, Wild, 
Catto et al. 2007, 
Catto, Abbod et 
al. 2010) 
    CHEK2 CHK2 checkpoint 
homolog (S. pombe) 
22 
N
M
_0
01
00
57
35
 6,9 6,3 -0,6 key cell cycle control 
gene encoding a 
pluripotent kinase that 
can cause arrest or 
apoptosis in response 
to unrepaired DNA 
damage (BC) 
(Slojewski, 
Zlowocka et al. 
2008, Zlowocka, 
Cybulski et al. 
2008) 
    SGOL1 shugoshin-like 1 (S. 
pombe) 
3 
N
M
_0
01
01
24
10
 8,5 7,9 -0,6 is required for 
maintenance of 
centromeric cohesion 
from prophase to the 
metaphase‑anaphase 
transition 
(Diaz-Martinez, 
Gimenez-Abian et 
al. 2007, Pouwels, 
Kukkonen et al. 
2007, Kang, 
Chaudhary et al. 
2011) 
    FANCD2 Fanconi anemia, 
complementation 
group D2 
3 
N
M
_0
33
08
4 8,5 7,9 -0,6 required to prevent 
accumulation of 
replication-associated 
DNA double-strand 
breaks and 
maintenance of 
normal chromosome 
stability (BC) 
(Neveling, Kalb et 
al. 2007, Wilson, 
Yamamoto et al. 
2008) 
    APEX2 APEX nuclease 
(apurinic/apyrimidinic 
endonuclease) 2 
X 
N
M
_0
14
48
1 8,3 7,7 -0,6 apurinic/apyrimidinic 
endonuclease 
participating in the 
base excision repair 
(BER) system 
(Nakabeppu, 
Tsuchimoto et al. 
2004, Grunda, 
Fiveash et al. 
2010, Al-Safi, 
Odde et al. 2012) 
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Table 3.1. Description of up- or down-regulated genes of HT1376sT cells vs. HT1376NC cells 
(continued). 
    FANCA Fanconi anemia, 
complementation 
group A 
16 
N
M
_0
00
13
5 8,4 7,7 -0,6 required to prevent 
accumulation of 
replication-associated 
DNA double-strand 
breaks and 
maintenance of 
normal chromosome 
stability (BC) 
(Neveling, Kalb et 
al. 2007) 
    FANCC Fanconi anemia, 
complementation 
group C 
9 
N
M
_0
00
13
6 7,6 6,9 -0,7 required to prevent 
accumulation of 
replication-associated 
DNA double-strand 
breaks and 
maintenance of 
normal chromosome 
stability (BC) 
(Neveling, Kalb et 
al. 2007) 
    HAUS8 HAUS augmin-like 
complex, subunit 8 
19 
N
M
_0
33
41
7 6,4 5,7 -0,7 HAUS disruption 
results in the 
destabilization of 
kinetochore 
microtubules and the 
eventual formation of 
multipolar spindles 
(Lawo, Bashkurov 
et al. 2009) 
    INCENP inner centromere 
protein antigens 
135/155kDa 
11 
N
M
_0
01
04
06
9 4 8,6 7,9 -0,7 playing a role in the 
regulation of sister 
chromatid separation 
in mitosis 
(Pouwels, 
Kukkonen et al. 
2007, Kang, 
Chaudhary et al. 
2011) 
    ERCC2 excision repair 
cross-
complementing 
rodent repair 
deficiency, 
complementation 
group 2 
19 
N
M
_0
00
40
0 7,5 6,7 -0,8 plays a critical role in 
nucleotide excision 
repair (NER) and 
basal transcription 
(BC) 
(Fontana, Bosviel et 
al. 2008, Stern, Lin 
et al. 2009, 
Gangawar, Ahirwar 
et al. 2010) 
    XRCC3 X-ray repair 
complementing 
defective repair in 
Chinese hamster 
cells 3 
14 
N
M
_0
01
10
01
19
 6,9 6,2 -0,8 plays an important 
role in the repair of 
DNA double-strand 
breaks by 
homologous 
recombination (BC) 
(Fontana, Bosviel et 
al. 2008, Sun, Qiao 
et al. 2010, Li, Li et 
al. 2011, Mittal, 
Gangwar et al. 
2012) 
    BRIP1 BRCA1 interacting 
protein C-terminal 
helicase 1 
17 
N
M
_0
32
04
3 8,7 7,9 -0,8 BRCA1-associated 
DNA helicase that 
contributes to 
homologous 
recombination and 
cross-link repair (BC) 
(Figueroa, Malats et 
al. 2007) 
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Table 3.1. Description of up- or down-regulated genes of HT1376sT cells vs. HT1376NC cells 
(continued). 
    CENPF centromere 
protein F, 
350/400ka 
(mitosin) 
1 
N
M
_0
16
34
3 10,0 9,2 -0,8 centromeric protein, 
important role in the 
fidelity of 
chromosome 
segregation 
(Pouwels, 
Kukkonen et al. 
2007, Cheeseman, 
Hori et al. 2008) 
    CDC20 cell division cycle 
20 homolog (S. 
cerevisiae) 
1 
N
M
_0
01
25
5 11,3 10,4 -0,8 mediating the 
association of the 
mitotic spindle 
checkpoint protein 
MAD1L1 with the 
cyclosome/anaphase-
promoting complex 
(Kops, Kim et al. 
2005, Famulski, 
Vos et al. 2008) 
    HAUS6 HAUS augmin-
like complex, 
subunit 6 
9 
N
M
_0
17
64
5 7,9 7,1 -0,8 HAUS disruption 
results in the 
destabilization of 
kinetochore 
microtubules and the 
eventual formation of 
multipolar spindles 
(Lawo, Bashkurov 
et al. 2009) 
    CENPM centromere 
protein M 
22 
N
M
_0
24
05
3 8,4 7,5 -0,9 centromeric protein, 
important role in the 
fidelity of 
chromosome 
segregation 
(Foltz, Jansen et al. 
2006) 
    EME1 essential meiotic 
endonuclease 1 
homolog 1 (S. 
pombe) 
17 
N
M
_1
52
46
3 7,3 6,4 -0,9 catalyses with MUS81 
coordinate bilateral 
cleavage of model 
Holliday-junction 
structures 
(Forment, Blasius et 
al. 2011, Zhao, Liu 
et al. 2013) 
    FANCG Fanconi anemia; 
complementation 
group G 
9 
N
M
_0
04
62
9 8,2 7,2 -1,0 required to prevent 
accumulation of 
replication-associated 
DNA double-strand 
breaks and 
maintenance of 
normal chromosome 
stability (BC)  
(Neveling, Kalb et 
al. 2007, Wilson, 
Yamamoto et al. 
2008) 
    RAD54L RAD54-like (S. 
cerevisiae) 
1 
N
M
_0
03
57
9 8,5 7,5 -1,0 recombination protein 
associated with 
RAD51, involved in 
NER of double-strand 
break and in meiotic 
recombination 
(Li, Frazier et al. 
2006, Nowacka-
Zawisza, Brys et al. 
2006, Romanowicz-
Makowska and 
Smolarz 2006) 
    BUB1B budding 
uninhibited by 
benzimidazoles 1 
homolog beta 
(yeast) 
15 
N
M
_0
01
21
1 9,8 8,7 -1,1 important role in the 
spindle checkpoint, 
reduction of BUB1B 
results in premature 
chromatid separation 
and aneuploidy 
(Hernando, Orlow et 
al. 2001, Bohers, 
Sarafan-Vasseur et 
al. 2008, Izumi, 
Matsumoto et al. 
2009) 
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Table 3.1. Description of up- or down-regulated genes of HT1376sT cells vs. HT1376NC cells 
(continued). 
    ORC1L origin 
recognition 
complex, 
subunit 1-like 
(yeast) 
1 
N
M
_0
04
15
3 8,2 7,1 -1,1 localized in the 
centrosomes preventing 
Cyclin E-dependent 
reduplication of 
centrioles and 
centrosomes during the 
cell division 
(Hemerly, Prasanth 
et al. 2009, 
Ferguson, Pascreau 
et al. 2010, Hossain 
and Stillman 2012) 
    CCNF cyclin F 16 
N
M
_0
01
76
1 9,0 7,9 -1,1 fine-tunes centrosome 
duplication and DNA 
synthesis, by promoting 
the elimination of RRM2 
and by inducing CP110 
degradation, it prevents 
chromosome instability 
(D'Angiolella, 
Donato et al. 2012, 
D'Angiolella, 
Esencay et al. 
2013, Li, 
D'Angiolella et al. 
2013) 
    CDCA5 cell division 
cycle 
associated 5 
11 
N
M
_0
80
66
8 8,5 7,4 -1,1 is involved in 
maintenance of 
cohesion in response to 
the spindle checkpoint 
(Diaz-Martinez, 
Gimenez-Abian et 
al. 2007, Dreier, 
Bekier et al. 2011, 
Wu, Nguyen et al. 
2011) 
    SPC24 SPC24, NDC80 
kinetochore 
complex 
component, 
homolog (S. 
cerevisiae) 
19 
N
M
_1
82
51
3 8,4 7,3 -1,1 required to establish 
and maintain 
kinetochore-microtubule 
attachment 
(McCleland, Kallio 
et al. 2004, Wei, 
Schnell et al. 2006) 
    KIFC1 kinesin family 
member C1 
6 
N
M
_0
02
26
3 9,4 8,1 -1,2 plays an essential role 
for bipolar microtubule 
organizing centres 
(MTOC) formation and 
maintaining 
chromosomal stability 
during mitosis 
(Kim and Song 
2013) 
    FRY furry homolog 
(Drosophila) 
13 
N
M
_0
23
03
7 9,1 7,9 -1,2 FRY mediated activation 
of STK38 is crucial for 
the fidelity of mitotic 
chromosome alignment 
(Chiba, Ikeda et al. 
2009, Kohler, 
Schmitz et al. 2010) 
    CENPI centromere 
protein I 
X 
N
M
_0
06
73
3 8,6 7,4 -1,2 centromeric protein, 
important role in the 
fidelity of chromosome 
segregation 
(Liu, Hittle et al. 
2003, Izuta, Ikeno 
et al. 2006, 
Cheeseman, Hori et 
al. 2008) 
    HAUS7 HAUS augmin-
like complex, 
subunit 7 
X 
N
M
_2
07
10
7 7,9 6,5 -1,3 HAUS disruption results 
in the destabilization of 
kinetochore 
microtubules and the 
eventual formation of 
multipolar spindles 
(Lawo, Bashkurov 
et al. 2009) 
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Table 3.1. Description of up- or down-regulated genes of HT1376sT cells vs. HT1376NC cells 
(continued). 
    KIF4A kinesin family 
member 4A 
X 
N
M
_0
12
31
0 9,3 8,0 -1,3 associates with 
BRCA2, upon 
nucleus-specific laser 
micro-irradiation, 
Kif4A was rapidly 
recruited to sites of 
DNA damage 
(Wu and Chen 
2008, Wu, Zhou et 
al. 2008, Gao, Sai 
et al. 2011) 
  Changes decreasing malignancy – Bladder Cancer markers 
    MTSS1 metastasis 
suppressor 1 
8 
N
M
_0
14
75
1 6,2 7,0 0,7 cytoskeletal scaffold 
protein (BC) 
(Wang, Liu et al. 
2007, Du, Ye et al. 
2011, Xie, Ye et al. 
2011) 
    TIMP3 TIMP 
metallopeptidase 
inhibitor 3 
22 
N
M
_0
00
36
2 9,0 9,7 0,6 tissue inhibitor of 
metalloproteinase 
(BC) 
(Hoque, Begum et 
al. 2008, 
Kandimalla, van 
Tilborg et al. 2013, 
Wieczorek, Reszka 
et al. 2013) 
    BIRC3 baculoviral IAP 
repeat-containing 
3 
11 
N
M
_0
01
16
5 9,8 9,2 -0,6 regulator of apoptosis; 
its overexpression 
may make tumours 
resistant to apoptosis 
(BC) 
(Che, Yang et al. 
2012, He, Wang et 
al. 2012) 
    ADAM12 ADAM 
metallopeptidase 
domain 12 
10 
N
M
_0
03
47
4 8,6 7,0 -1,5 a disintegrin and 
metalloprotease,  
multifunctional zinc-
dependent metzincin 
protease (BC) 
(Frohlich, 
Albrechtsen et al. 
2006, Kogure, 
Takawa et al. 2013) 
    SERPINE1 serpin peptidase 
inhibitor; clade E 
(nexin; 
plasminogen 
activator inhibitor 
type 1); member 
1 
7 
N
M
_0
00
60
2 9,6 7,3 -2,3 serine peptidase 
inhibitor, pleiotropic 
functions besides 
haemostasis (BC) 
(Chen, Henry et al. 
2009, Litlekalsoy, 
Hostmark et al. 
2012, Rosser, Ross 
et al. 2013) 
Log2E stands for the base 2 logarithm of a given expression value. 
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Table 3.2. Description of up- or down-regulated genes by BCG-challenging in HT1376NC cells. 
Genes modulated by BCG-challenging in HT1376NC cells 
    
Symbol Description Chr 
G
en
B
an
k 
Lo
g2
E
 
(H
T
13
76
N
C
) 
Lo
g2
E
 
(a
fte
r 
B
C
G
) 
D
iff
er
en
ce
 
(B
C
G
-N
C
) 
Function Ref 
  Changes decreasing malignancy – Bladder Cancer markers 
    SERPINE1 serpin peptidase 
inhibitor; clade E 
(nexin; 
plasminogen 
activator inhibitor 
type 1); member 1 
7 
N
M
_0
00
60
2 9,6 9,0 -0,6 serine peptidase 
inhibitor, 
pleiotropic 
functions besides 
haemostasis 
(BC) 
(Chen, Henry et 
al. 2009, 
Litlekalsoy, 
Hostmark et al. 
2012, Rosser, 
Ross et al. 2013) 
    ADAM12 ADAM 
metallopeptidase 
domain 12 
10 
N
M
_0
03
47
4 8,6 7,7 -0,9 a disintegrin and 
metalloprotease,  
multifunctional 
zinc-dependent 
metzincin 
protease (BC) 
(Frohlich, 
Albrechtsen et al. 
2006, Kogure, 
Takawa et al. 
2013) 
Log2E stands for the base 2 logarithm of a given expression value. 
 
Table 3.3. Description of up- or down-regulated genes by BCG-challenging in HT1376sT cells. 
Genes modulated by BCG-challenging in HT1376sT cells 
    
Symbol Description Chr 
G
en
B
an
k 
Lo
g2
E
 
(H
T
13
76
sT
) 
Lo
g2
E
 
(a
fte
r 
B
C
G
) 
D
iff
er
en
ce
 
(B
C
G
-s
T
) 
Function Ref 
  Changes decreasing malignancy – Bladder Cancer markers 
    CTSL2 cathepsin L2 9 
N
M
_0
01
33
3 7,2 6,7 -0,5 overexpression 
and release by 
cancerous tissues; 
degradation of 
extracellular matrix 
components (BC) 
(Staack, Koenig 
et al. 2002, 
Staack, Tolic et 
al. 2004, Svatek, 
Karam et al. 
2008) 
    CTSH cathepsin H 15 
N
M
_0
04
39
0 10,6 10,0 -0,5 overexpression 
and release by 
cancerous tissues; 
degradation of 
extracellular matrix 
components (BC) 
(Staack, Koenig 
et al. 2002, 
Staack, Tolic et 
al. 2004) 
    POLI polymerase 
(DNA directed) 
iota 
18 
N
M
_0
07
19
5 9,9 9,4 -0,5 overexpressed 
POLI contributes to 
hypermutagenesis 
(BC) 
(Yuan, Xu et al. 
2013) 
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Table 3.3. Description of up- or down-regulated genes by BCG-challenging in HT1376sT cells 
(continued). 
    VEGFA vascular 
endothelial 
growth factor A 
6 
N
M
_0
01
02
53
66
 11,0 10,4 -0,6 stimulates the 
formation of new 
blood vessels and 
tumour growth  
(BC) 
 
(Fauconnet, Bernardini et 
al. 2009, Zaravinos, 
Volanis et al. 2012, 
Kopparapu, Boorjian et 
al. 2013) 
    SERPINE2 serpin peptidase 
inhibitor; clade E 
(nexin; 
plasminogen 
activator inhibitor 
type 1); member 
2 
2 
N
M
_0
01
13
65
29
 8,5 7,7 -0,8 serine peptidase 
inhibitor, pleiotropic 
functions besides 
haemostasis 
(Bergeron, Lemieux et al. 
2010, Nagahara, 
Nakayama et al. 2010, 
Xu, McKee et al. 2010, 
Iwaki, Urano et al. 2012) 
    MMP14 matrix 
metallopeptidase 
14 (membrane-
inserted) 
14 
N
M
_0
04
99
5 10,0 9,1 -0,9 degradation of 
basal membranes 
and of the 
extracellular matrix 
(BC) 
(Chaffer, Dopheide et al. 
2005, Mohammad, 
Ismael et al. 2010, Reis, 
Leite et al. 2012) 
  Changes decreasing malignancy – caretaker genes 
    CENPI centromere 
protein I 
X 
N
M
_0
06
73
3 7,4 8,4 1,0 centromeric 
protein, important 
role in the fidelity of 
chromosome 
segregation 
(Liu, Hittle et al. 2003, 
Izuta, Ikeno et al. 2006, 
Okada, Cheeseman et al. 
2006, Cheeseman, Hori 
et al. 2008) 
    BRIP1 BRCA1 
interacting 
protein C-
terminal helicase 
1 
17 
N
M
_0
32
04
3 7,9 8,8 0,9 BRCA1-associated 
DNA helicase that 
contributes to 
homologous 
recombination and 
cross-link repair 
(BC) 
(Figueroa, Malats et al. 
2007) 
    ORC1L origin 
recognition 
complex, subunit 
1-like (yeast) 
1 
N
M
_0
04
15
3 7,1 7,9 0,8 localized in the 
centrosomes 
preventing Cyclin 
E-dependent 
reduplication of 
centrioles and 
centrosomes 
during the cell 
division 
(Hemerly, Prasanth et al. 
2009, Ferguson, 
Pascreau et al. 2010, 
Hossain and Stillman 
2012) 
    XRCC2 X-ray repair 
complementing 
defective repair 
in Chinese 
hamster cells 2 
7 
N
M
_0
05
43
1 8,1 8,8 0,7 a member of the 
RecA/Rad51-
related protein 
family that 
participates in 
homologous 
recombination (BC) 
(Matullo, Guarrera et al. 
2005, Figueroa, Malats et 
al. 2007) 
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Table 3.3. Description of up- or down-regulated genes by BCG-challenging in HT1376sT cells 
(continued). 
    RAD54B RAD54 homolog 
B (S. cerevisiae) 
8 
N
M
_0
12
41
5 6,6 7,2 0,7 involved in 
recombination 
repair of DNA 
damage, including 
DNA double-strand 
breaks during 
homologous 
recombination 
(Romanowicz-
Makowska and 
Smolarz 2006, 
Murzik, 
Hemmerich et al. 
2008, Sarai, 
Kagawa et al. 
2008) 
    CENPH centromere 
protein H 
5 
N
M
_0
22
90
9 6,2 6,8 0,7 centromeric 
protein, important 
role in the fidelity of 
chromosome 
segregation 
(Izuta, Ikeno et 
al. 2006, Okada, 
Cheeseman et 
al. 2006, 
Cheeseman, Hori 
et al. 2008) 
    CENPK centromere 
protein K 
5 
N
M
_0
22
14
5 8,8 9,4 0,6 centromeric 
protein, important 
role in the fidelity of 
chromosome 
segregation 
(Foltz, Jansen et 
al. 2006, Okada, 
Cheeseman et 
al. 2006, 
Cheeseman, Hori 
et al. 2008) 
    CENPO centromere 
protein O 
2 
N
M
_0
24
32
2 7,9 8,5 0,6 centromeric 
protein, important 
role in the fidelity of 
chromosome 
segregation 
(Foltz, Jansen et 
al. 2006) 
    RAD54L RAD54-like (S. 
cerevisiae) 
1 
N
M
_0
03
57
9 7,5 8,0 0,6 recombination 
protein associated 
with RAD51, 
involved in NER of 
double-strand 
break 
(Li, Frazier et al. 
2006, Nowacka-
Zawisza, Brys et 
al. 2006, 
Romanowicz-
Makowska and 
Smolarz 2006) 
    BUB1B budding 
uninhibited by 
benzimidazoles 
1 homolog beta 
(yeast) 
15 
N
M
_0
01
21
1 8,7 9,3 0,5 important role in 
the spindle 
checkpoint, 
reduction of 
BUB1B results in 
premature 
chromatid 
separation and 
aneuploidy 
(Hernando, 
Orlow et al. 
2001, Bohers, 
Sarafan-Vasseur 
et al. 2008, 
Izumi, 
Matsumoto et al. 
2009) 
    BRCA2 breast (C) 2, 
early onset 
13 
N
M
_0
00
05
9 8,3 8,7 0,5 important role in 
the homologous 
recombination 
pathway for 
double-strand DNA 
repair and in the 
G2 checkpoint 
following DNA-
damage (BC) 
(Goode, Ulrich et 
al. 2002, Wild, 
Catto et al. 2007, 
Catto, Abbod et 
al. 2010) 
Log2E stands for the base 2 logarithm of a given expression value. 
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Owing to the particular relevance of MHC genes in BCG response, the behaviour of 
MHC genes which exhibit modulation by BCG in HT1376 cells is shown in Figure 3.8.  
In HT1376NC cells BCG induced up-regulation of one class I and two class II MHC genes.  
 
a) MHC genes modulated by BCG in HT1376NC cells 
 
b) MHC genes modulated by BCG in HT1376sT cells 
 
Figure 3.8. Modulation of MHC genes by BCG internalization in HT1376 cells. Percentage of 
expression variation of MHC related genes in a) HT1376NC, b) HT1376sT, after BCG-challenging.  
Only variations greater then ± 0.5 were considered. Data are the mean of 3 experiments. * p ≤ 0.05. 
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Effect of ST6GALNAC1 expression – Gene Signatures of MCR cells 
Like ST3GAL1 expression in HT1376 cells, ST6GALNAC1 expression in MCR cells 
resulted in down-regulation of a set of genes, which can be defined as “caretaker genes”, 
involved in maintaining genetic stability (Figure 3.9a). Genes HAUS6 and ERCC6L, both 
involved in proper chromosomal segregation, and XRCC4 involved in repair of double 
strand breaks, display the most prominent down-regulation (at least a factor 2) in MCRsTn 
cells. Other genes involved in chromosomal segregation (CDCA5, KNTC1, CSPP1, 
HAUS3, SGOL1) also show down-regulation, although at a lower extent.  
Other down-regulated genes are involved in different mechanisms of DNA repair.  
In particular, XRCC2 and BRCA1 are both involved in HR, NBN in both HR and non 
homologous end joining (NHEJ), while ERCC8 and ERCC6 are involved in NER.  
It is worth mentioning that homologues of many of these down-regulated genes are also 
down-regulated in HT1376sT (Table 3.4).  
 
Table 3.4. Genes with analogous or identical functions showing parallel down-regulation in 
sialyltransferase-transduced bladder cancer cell lines. 
Down-regulated in HT1376sT Down-regulated in MCRsTn 
HAUS7 HAUS3 
HAUS6 
CDCA5 CDCA5 
BRCA2 BRCA1 
XRCC3 XRCC2 
XRCC4 
ERCC2 ERCC8 
ERCC6 
  
 
In MCRsTn cells, we observed a parallel and concomitant up-regulation of three of the 
four members of the ERBB family of membrane receptors (ERBB4, ERBB3 and ERBB2). 
Although ERBB2 showed a good level of expression also in MCRNC cells and little 
increased in MCRsTn cells, the expression of both ERBB3 and of ERBB4 in MCRNC cells 
were very low and the ST6GALNAC1-dependent up-regulation had the effect of a  
switch-on. The overexpression of ERBB3 and ERBB4 in the presence of high levels of 
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ERBB2 can result in a strong activation of ERBB receptor signaling. In addition, the  
up-regulation of the tumour protein p63 and a slight decrease of Rb were also observed in 
MCRsTn cells. Although the latter remains highly expressed also in MCRsTn cells, its 
limited down-regulation could corroborate the increased cell growth fuelled by the  
up-regulation of receptors of the ERBB family. The overall protease activity of MCR 
appears to be up-regulated in MCRsTn cells. In fact, cathepsin L2 and H (CTSL2 and 
CTSH) as well as kallikrein-related peptidase 5 (KLK5) display up-regulation which is 
accompanied by a strongly decreased expression of the serine protease inhibitors 
SERPINE1 and SERPINE2. Interestingly, the latter two genes show modulation also in 
HT1376sT cells. A literature search for the global contribution of the modulated genes to 
the neoplastic phenotype has revealed that the modulation of 24 genes is toward a more 
malignant phenotype while only 3 genes were modulated toward a less malignant 
phenotype. Eleven of the genes modulated toward increased malignancy are reported in 
the literature as “bladder cancer markers” (ERBB4, TP63, H19, CTSL2, KLK5, ERBB3, 
BIRC7, CTSH and ERBB2 were up-regulated while and RB1 and SERPINE1 were  
down-regulated), while 13 “caretaker genes” (CDCA5, KNTC1, CSPP1, HAUS3, SGOL, 
ERCC6L, HAUS6, XRCC2, NBN, ERCC8, ERCC6, BRCA1 and XRCC4) genes were 
down-regulated). On the other hand, 3 genes reported as “bladder cancer markers” were 
modulated toward decreased malignancy (CEACAM1 gene was up-regulated, while 
VEGFA and SERPINE2 genes were down-regulated). When MCRNC cells (Figure 3.9b) 
were challenged with BCG, only 3 genes were specifically modulated, all toward a less 
malignant phenotype; two of the genes were caretakers. However, when MCRsTn cells 
were challenged with BCG (Figure 3.9c), 11 caretaker genes were modulated in the sense 
of decreased malignancy, while gene BIRC3 which, according to the literature,  
is associated with bladder cancer, moved toward increased malignancy.  
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a) Genes modulated by ST6GALNAC1 expression  
in MCR cells 
 
b) Genes modulated by BCG-challenging  
in MCRNC cells 
 
c) Genes modulated by BCG-challenging 
in MCRsTn cells 
 
Figure 3.9. Gene signatures in MCR cells. Expression variation of relevant genes in a) MCRsTn cells vs. 
MCRNC cells in b) MCRNC cells and in c) MCRsTn cells after BCG-challenging. Genes were grouped in  
"BC markers" and "caretaker" according to their putative effect on malignancy. Only differential variations 
greater then ± 0.5 were considered. Data are the mean of 3 experiments. * p ≤ 0.05. 
 
In Tables 3.5 to 3.7 are presented the selected signature genes presented in figure 3.9 with 
gene description, hosting chromosome, GenBank code and a short outline of the function. 
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Table 3.5. Description of up- or down-regulated genes in MCRsTn cells vs. MCRNC cells. 
Gene Signatures modulated by ST6GALNAC1 expression 
    
Symbol Description Chr 
G
en
B
an
k 
Lo
g2
E
 
(M
C
R
N
C
) 
Lo
g2
E
 
(M
C
R
sT
n)
 
D
iff
er
en
ce
 
(s
T
n-
N
C
) 
Function Ref 
  Changes increasing malignancy – Bladder Cancer markers 
    ERBB4 v-erb-a 
erythroblastic 
leukemia viral 
oncogene 
homolog 4 
(avian) 
2 
N
M
_0
05
23
5 5,8 7,6 1,7 important in diverse 
cellular functions, 
including cell proliferation, 
differentiation, and 
survival of normal cells, 
increased expression has 
been reported in cancer 
(BC) 
(Junttila, Laato 
et al. 2003, 
Gunes, Sullu et 
al. 2013) 
    TP63 tumour 
protein p63 
3 
N
M
_0
03
72
2 4,7 5,8 1,1 plays a role in the 
regulation of epithelial 
morphogenesis (BC) 
(Choi, Shah et 
al. 2012, 
Sjodahl, Lovgren 
et al. 2013) 
    H19 H19, 
imprinted 
maternally 
expressed 
transcript 
(non-protein 
coding) 
11 
N
R
_0
02
19
6
 9,1 10,1 1,0 an imprinted oncofoetal 
gene abundantly 
expressed in 
embryogenesis and shut 
off in most tissues after 
birth (BC) 
(Matouk, 
DeGroot et al. 
2007, Luo, Li et 
al. 2013, Luo, Li 
et al. 2013) 
    CTSL2 cathepsin L2 9 
N
M
_0
01
33
3 6,3 7,2 0,9 overexpression and 
release by cancerous 
tissues; degradation of 
extracellular matrix 
components (BC) 
(Staack, Koenig 
et al. 2002, 
Staack, Tolic et 
al. 2004, Svatek, 
Karam et al. 
2008) 
    KLK5 kallikrein-
related 
peptidase 5 
19 
N
M
_0
12
42
7 6,7 7,6 0,9 secreted enzyme 
belonging to the serine 
protease family (BC) 
(Shinoda, Kozaki 
et al. 2007) 
    ERBB3 v-erb-b2 
erythroblastic 
leukemia viral 
oncogene 
homolog 3 
(avian) 
12 
N
M
_0
01
98
2 5,7 6,4 0,7 important in diverse 
cellular functions, 
including cell proliferation, 
differentiation, and 
survival of normal cells, 
increased expression 
have been identified in 
cancer (BC) 
(Junttila, Laato 
et al. 2003, 
Gunes, Sullu et 
al. 2013) 
    BIRC7 baculoviral 
IAP repeat-
containing 7 
20 
N
M
_1
39
31
7 5,7 6,4 0,7 involved in the regulation 
of apoptosis (BC) 
(Gazzaniga, 
Gradilone et al. 
2003, Song, 
Hong et al. 2007, 
Xi, Sheng et al. 
2013) 
    CTSH cathepsin H 15 
N
M
_0
04
39
0 4,9 5,5 0,6 secreted enzyme 
belonging to the serine 
protease family (BC) 
(Staack, Koenig 
et al. 2002, 
Staack, Tolic et 
al. 2004) 
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Table 3.5. Description of up- or down-regulated genes in MCRsTn cells vs. MCRNC cells (continued). 
    ERBB2 v-erb-b2 
erythroblastic 
leukemia viral 
oncogene 
homolog 2, 
neuro/glioblastoma 
derived oncogene 
homolog (avian) 
17 
N
M
_0
01
00
58
62
 7,5 8,0 0,5 important in diverse 
cellular functions, 
including cell 
proliferation, 
differentiation, and 
survival of normal cells, 
increased expression 
has been reported in 
cancer (BC) 
(Chekaluk, Wu et al. 
2013, Chen, Yu et 
al. 2013, Gunes, 
Sullu et al. 2013, 
Sjodahl, Lovgren et 
al. 2013) 
    RB1 retinoblastoma 1 13 
N
M
_0
00
32
1 10,0 9,4 -0,6 tumour suppressor 
protein (BC) 
(Hurst, Tomlinson et 
al. 2008, Lindgren, 
Sjodahl et al. 2012, 
Sjodahl, Lovgren et 
al. 2013) 
    SERPINE1 serpin peptidase 
inhibitor; clade E 
(nexin; 
plasminogen 
activator inhibitor 
type 1); member 1 
7 
N
M
_0
00
60
2 8,5 6,3 -2,2 serine peptidase 
inhibitor, pleiotropic 
functions besides 
haemostasis (BC) 
(Chen, Henry et al. 
2009, Litlekalsoy, 
Hostmark et al. 
2012, Rosser, Ross 
et al. 2013) 
  Changes increasing malignancy – caretaker genes 
    CDCA5 cell division cycle 
associated 5 
11 
N
M
_0
80
66
8 8,7 8,1 -0,5 is involved in 
maintenance of cohesion 
in response to the 
spindle checkpoint 
(Diaz-Martinez, 
Gimenez-Abian et 
al. 2007, Dreier, 
Bekier et al. 2011, 
Wu, Nguyen et al. 
2011) 
    KNTC1 kinetochore 
associated 1 
12 
N
M
_0
14
70
8 7,7 7,2 -0,6 involved in mechanisms 
to ensure proper 
chromosome 
segregation, participate 
in the generation and 
amplification of the “ wait 
anaphase” signal 
(Wang, Hu et al. 
2004, Kops, Kim et 
al. 2005, Famulski, 
Vos et al. 2008) 
    ERCC8 excision repair 
cross-
complementing 
rodent repair 
deficiency, 
complementation 
group 8 
5 
N
M
_0
00
08
2 6,7 6,1 -0,6 has a role in NER (Latini, Frontini et 
al. 2011, Scrima, 
Fischer et al. 2011) 
    NBN nibrin 8 
N
M
_0
02
48
5 7,1 6,5 -0,6 plays a critical role in the 
DSB repair pathway, 
functioning both in the 
NHEJ pathway as a 
sensor for DNA damage 
and in the HR pathway 
(BC) 
(Sanyal, Festa et al. 
2004, Stern, Lin et 
al. 2009, Park, 
Bastani et al. 2010) 
    XRCC2 X-ray repair 
complementing 
defective repair in 
Chinese hamster 
cells 2 
7 
N
M
_0
05
43
1 9,5 8,9 -0,6 a member of the 
RecA/Rad51-related 
protein family that 
participates in 
homologous 
recombination (BC) 
(Matullo, Guarrera 
et al. 2005, 
Figueroa, Malats et 
al. 2007) 
 
Chapter III 
98 Thomsen-Friedenreich antigens in bladder cancer: evaluation of their prognostic value | Paulo Severino 
 
 
Table 3.5. Description of up- or down-regulated genes in MCRsTn cells vs. MCRNC cells (continued). 
    CSPP1 centrosome and 
spindle pole 
associated protein 1 
8 
N
M
_0
01
07
72
04
 7,2 6,4 -0,8 is associated with 
centrosomes and 
microtubules and may 
play a role in the 
regulation of G1/S-phase 
progression and spindle 
assembly 
(Patzke, Hauge et 
al. 2005, Asiedu, 
Wu et al. 2009) 
    HAUS3 HAUS augmin-like 
complex, subunit 3 
4 
N
M
_0
24
51
1 6,8 5,9 -0,8 HAUS disruption results 
in the destabilization of 
kinetochore microtubules 
and the eventual 
formation of multipolar 
spindles 
(Lawo, Bashkurov 
et al. 2009) 
    ERCC6 excision repair 
cross-
complementing 
rodent repair 
deficiency, 
complementation 
group 6 
10 
N
M
_0
00
12
4 8,9 8,1 -0,8 recruits nucleotide 
excision repair factors to 
the DNA damage site 
and plays an important 
role in the repair process 
(BC) 
(Garcia-Closas, 
Malats et al. 2006, 
Chen, Kamat et al. 
2007, Chang, Chiu 
et al. 2009) 
    BRCA1 breast (C) 1; early 
onset 
17 
N
M
_0
07
29
6 7,6 6,7 -0,9 activating DNA repair 
through HR, in 
cooperation with BRCA2, 
RAD51 and RAD52 (BC) 
(Agundez, Grau et 
al. 2011, Font, 
Taron et al. 2011, 
Golka, Selinski et 
al. 2011) 
    SGOL1 shugoshin-like 1 (S. 
pombe) 
3 
N
M
_0
01
01
24
10
 8,7 7,8 -0,9 is required for 
maintenance of 
centromeric cohesion 
from prophase to the 
metaphase‑anaphase 
transition 
(Diaz-Martinez, 
Gimenez-Abian et 
al. 2007, Pouwels, 
Kukkonen et al. 
2007, Kang, 
Chaudhary et al. 
2011) 
    XRCC4 X-ray repair 
complementing 
defective repair in 
Chinese hamster 
cells 4 
5 
N
M
_0
22
55
0 8,4 7,4 -1,0 involved in DNA DSB 
repair by NHEJ 
recombination (BC) 
(Figueroa, Malats et 
al. 2007, Chang, 
Chang et al. 2009, 
Mittal, Gangwar et 
al. 2012)  
    ERCC6L excision repair 
cross-
complementing 
rodent repair 
deficiency; 
complementation 
group 6-like 
X 
N
M
_0
17
66
9 7,7 6,7 -1,0 plays an important role in 
maintaining 
prometaphase 
chromosome 
architecture and in the 
segregating sister 
centromeres during 
anaphase 
(Kurasawa and Yu-
Lee 2010, Ke, Huh 
et al. 2011, 
Rouzeau, 
Cordelieres et al. 
2012) 
    HAUS6 HAUS augmin-like 
complex, subunit 6 
9 
N
M
_0
17
64
5 8,2 7,0 -1,2 HAUS disruption results 
in the destabilization of 
kinetochore microtubules 
and the eventual 
formation of multipolar 
spindles 
(Lawo, Bashkurov 
et al. 2009) 
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Table 3.5. Description of up- or down-regulated genes in MCRsTn cells vs. MCRNC cells (continued). 
  Changes decreasing malignancy – Bladder Cancer markers 
    CEACAM1 carcinoembryonic 
antigen-related cell 
adhesion molecule 1 
(biliary glycoprotein) 
19 
N
M
_0
01
71
2 6,2 7,1 0,9 is a member of the 
carcinoembryonic 
antigen family, as a 
tumour-suppressive role 
by inhibiting tumour 
angiogenesis (BC) 
(Oliveira-Ferrer, 
Tilki et al. 2004, 
Tilki, Oliveira-
Ferrer et al. 2007, 
Tilki, Singer et al. 
2010) 
    VEGFA vascular endothelial 
growth factor A 
6 
N
M
_0
01
02
53
66
 9,8 9,2 -0,7 stimulates the formation 
of new 
blood vessels and 
tumour growth (BC) 
(Fauconnet, 
Bernardini et al. 
2009, Zaravinos, 
Volanis et al. 2012, 
Kopparapu, 
Boorjian et al. 
2013) 
    SERPINE2 serpin peptidase 
inhibitor; clade E 
(nexin; plasminogen 
activator inhibitor 
type 1); member 2 
2 
N
M
_0
01
13
65
29
 8,8 7,1 -1,7 serine peptidase 
inhibitor, pleiotropic 
functions besides 
haemostasis 
(Bergeron, 
Lemieux et al. 
2010, Nagahara, 
Nakayama et al. 
2010, Xu, McKee 
et al. 2010, Iwaki, 
Urano et al. 2012) 
Log2E stands for the base 2 logarithm of a given expression value. 
 
 
Table 3.6. Description of up- or down-regulated genes by BCG-challenging in MCRNC cells. 
Gene Signatures modulated by BCG-challenging in MCRNC cells 
    
Symbol Description Chr 
G
en
B
an
k 
Lo
g2
E
 
(M
C
R
N
C
) 
Lo
g2
E
 
(a
fte
r 
B
C
G
) 
D
iff
er
en
ce
 
(B
C
G
-N
C
) 
Function Ref 
  Changes decreasing malignancy – caretaker genes 
    CHEK2 CHK2 checkpoint 
homolog (S. 
pombe) 
22 
N
M
_0
01
00
57
3 5 7,0 7,5 0,5 cell cycle control gene 
encoding a pluripotent 
kinase, can cause 
arrest or apoptosis in 
response to 
unrepaired DNA (BC) 
(Slojewski, 
Zlowocka et al. 
2008, 
Zlowocka, 
Cybulski et al. 
2008) 
    CENPC1 centromere 
protein C 1 
4 
N
M
_0
01
81
2 7,4 7,9 0,5 centromeric protein, 
important role in the 
fidelity of chromosome 
segregation 
(Obuse, Yang 
et al. 2004, 
Foltz, Jansen 
et al. 2006, 
Izuta, Ikeno et 
al. 2006) 
  Changes increasing malignancy – Bladder Cancer markers 
    SERPINE1 serpin peptidase 
inhibitor; clade E 
(nexin; 
plasminogen 
activator inhibitor 
type 1); member1 
7 
N
M
_0
00
60
2 8,5 7,8 -0,7 serine peptidase 
inhibitor, pleiotropic 
functions besides 
haemostasis (BC) 
(Chen, Henry 
et al. 2009, 
Litlekalsoy, 
Hostmark et al. 
2012, Rosser, 
Ross et al. 
2013) 
Log2E stands for the base 2 logarithm of a given expression value. 
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Table 3.7. Description of up- or down-regulated genes by BCG-challenging in MCRsTn cells. 
Gene Signatures modulated by BCG-challenging in MCRsTn cells 
    
Symbol Description Chr 
G
en
B
an
k 
Lo
g2
E
 
(M
C
R
sT
n)
 
Lo
g2
E
 
(a
fte
r 
B
C
G
) 
D
iff
er
en
ce
 
(B
C
G
-s
T
n)
 
Function Ref 
  Changes decreasing malignancy – caretaker genes 
    XRCC2 X-ray repair 
complementing 
defective repair in 
Chinese hamster 
cells 2 
7 
N
M
_0
05
43
1 8,9 9,8 0,9 a member of the 
RecA/Rad51-related 
protein family that 
participates in 
homologous 
recombination (BC) 
(Matullo, 
Guarrera et 
al. 2005, 
Figueroa, 
Malats et al. 
2007) 
    BRCA1 breast (C) 1; early 
onset 
17 
N
M
_0
07
29
6 6,7 7,5 0,8 activating DNA repair 
through HR, in 
cooperation with 
BRCA2, RAD51 and 
RAD52 (BC) 
(Romanowicz-
Makowska 
and Smolarz 
2006, Ma, Cai 
et al. 2013) 
    KNTC1 kinetochore 
associated 1 
12 
N
M
_0
14
70
8 7,2 7,9 0,7 involved in 
mechanisms to ensure 
proper chromosome 
segregation, 
participate in the 
generation and 
amplification of the “ 
wait anaphase” signal 
(Wang, Hu et 
al. 2004, 
Kops, Kim et 
al. 2005, 
Famulski, Vos 
et al. 2008) 
    SGOL1 shugoshin-like 1 
(S. pombe) 
3 
N
M
_0
01
01
24
10
 7,8 8,4 0,6 is required for 
maintenance of 
centromeric cohesion 
from prophase to the 
metaphase‑anaphase 
transition 
(Diaz-
Martinez, 
Gimenez-
Abian et al. 
2007, 
Pouwels, 
Kukkonen et 
al. 2007, 
Kang, 
Chaudhary et 
al. 2011) 
    CENPJ centromere protein 
J 
13 
N
M
_0
18
45
1 6,8 7,4 0,6 centromeric protein, 
important role in the 
fidelity of chromosome 
segregation 
(Foltz, Jansen 
et al. 2006) 
    CHEK2 CHK2 checkpoint 
homolog (S. 
pombe) 
22 
N
M
_0
01
00
57
35
 7,0 7,6 0,6 key cell cycle control 
gene encoding a 
pluripotent kinase that 
can cause arrest or 
apoptosis in response 
to unrepaired DNA 
damage (BC) 
(Slojewski, 
Zlowocka et 
al. 2008, 
Zlowocka, 
Cybulski et al. 
2008) 
    CENPV centromere protein 
V 
17 
N
M
_1
81
71
6 8,5 9,1 0,6 centromeric protein, 
important role in the 
fidelity of chromosome 
segregation 
(Foltz, Jansen 
et al. 2006) 
    CENPQ centromere protein 
Q 
6 
N
M
_0
18
13
2 5,6 6,2 0,6 centromeric protein, 
important role in the 
fidelity of chromosome 
segregation 
(Foltz, Jansen 
et al. 2006) 
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Table 3.7. Description of up- or down-regulated genes by BCG-challenging in MCRsTn cells 
(continued). 
    CSPP1 centrosome and 
spindle pole 
associated protein 1 
8 
N
M
_0
01
07
72
04
 6,4 6,9 0,6 is associated with 
centrosomes and 
microtubules and may 
play a role in the 
regulation of G1/S-
phase progression and 
spindle assembly 
(Patzke, Hauge et 
al. 2005, Asiedu, 
Wu et al. 2009) 
    EME1 essential meiotic 
endonuclease 1 
homolog 1 (S. 
pombe) 
17 
N
M
_1
52
46
3 6,4 7,0 0,5 catalyses with MUS81 
coordinate bilateral 
cleavage of model 
Holliday-junction 
structures 
(Forment, Blasius et 
al. 2011, Zhao, Liu 
et al. 2013) 
    ERCC6L excision repair 
cross-
complementing 
rodent repair 
deficiency; 
complementation 
group 6-like 
X 
N
M
_0
17
66
9 6,7 7,2 0,5 plays an important role 
in maintaining 
prometaphase 
chromosome 
architecture and in the 
segregating sister 
centromeres during 
anaphase 
(Kurasawa and Yu-
Lee 2010, Ke, Huh 
et al. 2011, 
Rouzeau, 
Cordelieres et al. 
2012) 
  Changes increasing malignancy – Bladder Cancer markers 
    BIRC3 baculoviral IAP 
repeat-containing 3 
11 
N
M
_0
01
16
5 8,4 9,1 0,7 regulator of apoptosis; 
its overexpression may 
make tumours 
resistant to apoptosis 
(BC) 
(Che, Yang et al. 
2012, He, Wang et 
al. 2012) 
Log2E stands for the base 2 logarithm of a given expression value. 
 
 
Like for HT1376 cells, the behaviour of MHC genes in response to BCG-challenging in MCR 
cells was accessed and is shown in Figure 3.10. In MCRNC cells, BCG induced up-regulation of 
two class I and two class II MHC genes, while in MCRsTn only the two MHC class II genes 
displayed up-regulation. 
 
a) MHC genes modulated by BCG in MCRNC cells 
 
b) MHC genes modulated by BCG in MCRsTn cells 
 
Figure 3.10. Modulation of MHC genes by BCG internalization. Percentage of expression variation of 
MHC genes in a) MCRNC, b) MCRsTn cells after BCG-challenging. Only variations greater then ± 0.5 were 
considered. Data are the mean of 3 experiments. * p ≤ 0.05. 
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Altogether, microarray results indicate that groups of genes involved in specific functions 
are regulated in parallel in the two cell lines, regardless the type of sialyltransferase 
expressed. 
 
Cytokine secretion by BCG-challenged bladder cancer cells 
The impact of ST3GAL1 or ST6GALNAC1 sialyltransferase expression and  
BCG-challenge on cytokine secretion was evaluated in the conditioned medium of 
bladder cancer cell lines. The following cytokines: IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, 
IL-12, IL-17, IFNγ and TNFα were measured in the conditioned media of  
BCG-challenged or unchallenged bladder cancer cell lines 16 hours after  
Connaught-BCG-challenge and compared with unchallenged cells.  
Only IL-6 and IL-8 were secreted by HT1376 cells (Figure 3.11). In both, unchallenged 
HT1376NC or HT1376sT cells, IL-6 secretion was negligible, while a slight induction was 
observed after BCG-challenge. IL-8 was produced by both HT1376 cell variants; and 
slightly more pronounced in HT1376sT. BCG-challenge increased IL-8 secretion by about 
50%. 
 
[IL-6] pg.mL
-1
 
 
[IL-8] pg.mL
-1
 
 
Figure 3.11. Cytokine secretion by HT1376 cells. An induction of both IL-6 and IL-8 was found in both 
HT1376NC (pink bars) and HT1376sT (orange bars) 12 h after BCG-challenging. IL-8 induction in HT1376sT 
cells was stronger than in HT1376NC cells. Data are the mean ± SD of 3 experiments. *** p < 0.0001;  
* p < 0.05. 
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Also in MCR cells, only IL-6 and IL-8 were detected (Figure 3.12). Similar levels of IL-6 
were produced by both unchallenged MCR variants. BCG-challenge left unaltered IL-6 
production by MCRNC, while it induced a statistically significant increase in MCRsTn.  
The secretion of IL-8 was negligible by unchallenged cells but increased dramatically, 
especially in the sTn variant, after BCG-challenging. 
 
[IL-6] pg.mL
-1
 
 
[IL-8] pg.mL
-1
 
 
Figure 3.12. Cytokine secretion by MCR cells. Twelve hours after BCG-challenging, a significant 
induction of both IL-6 and IL-8 secretion was observed in MCRsTn (dark blue bars), but not in MCRNC  
(light blue bars). Data are the mean ± SD of 3 experiments. *** p < 0.0001; ** p < 0.001. 
 
No significant differences in cytokine secretion were found just after BCG-challenging 
(data not shown).  
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III.3 Response of Macrophages to BCG-challenged BC cell Lines 
 
Cytokine secretion by macrophages in response to bladder cancer secretome 
After the characterization of the cytokine content of the microenvironment of our cell 
models, the effect of the conditioned medium from bladder cancer cell lines on first line 
defence immune cells, such as macrophages, was studied. To assess the macrophage 
response to the tumour microenvironment, the same set of cytokines was measured in the 
culture medium of macrophages stimulated for 24 hours with the secretome of  
BCG-challenged or unchallenged cell lines. Unstimulated macrophages secreted at high 
levels only IL-8. (Figures 3.13 and 3.14). Unstimulated HT1376 cells failed to induce 
cytokine secretion by macrophages. However, the secretome from BCG-challenged cells 
induced a significant secretion of IL-6, IL-8, IL-1β, TNFα and IL-10. With the exception 
of IL-8, whose secretion was stimulated at similar levels by both HT1376NC and 
HT1376sT, the induction of cytokine secretion was markedly stronger when  
BCG-challenged cells expressed the sT antigen (HT1376sT) (Figure 3.13).  
Cytokines IL-2, IL-4, IL-12, and IL-17 were never expressed by macrophages. 
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Figure 3.13. Cytokine secretion by 
macrophages stimulated by HT1376 
secretome. Secretome from BCG-challenged 
HT1376sT (dark orange bars) induced stronger 
secretion than that of HT1376NC (pink bars) of all 
cytokines except IL-8. Gray bars represent 
cytokine secretion by unstimulated macrophages. 
Data are the mean ± SD of 3 experiments.  
*** p < 0.0001; ** p < 0.001; * p < 0.05. 
 
When macrophages were stimulated with the secretome of unchallenged MCR cells, 
TNFα, IL-6 and IL-8 cytokines were slightly induced (Figure 3.14). The stimulation with 
the secretome of both BCG-challenged cell variants induced a strong secretion of IL-6, 
IL-1β, TNFα and IL-10. Interestingly the induction was much higher with the secretome 
from MCRsTn cells. Secretion of IL-8 was not affected either by BCG-challenging or 
ST6GALNAC1 expression of MCR cells.  
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Figure 3.14. Cytokine secretion by Macrophages 
stimulated by MCR secretome. Secretome from 
unchallenged MCRsTn (dark blue bars) or MCRNC 
(light blue bars) cells induced little secretion of  
IL-6 and TNFα and higher levels of IL-8. 
Secretome from BCG-challenged MCR cells 
induced all five cytokines with stronger induction 
of IL-10, IL-1β, IL-6 and TNFα when secretome 
from MCRsTn was tested. Gray bars represent 
cytokine secretion by unstimulated macrophages. 
Data are the mean ± SD of 3 experiments.  
*** p < 0.0001; ** p < 0.001; * p < 0.05. 
 
In general, the secretome of BCG-challenged cells, in particular those expressing either 
the sT or the sTn antigen, potentiated markedly the secretion of cytokines such as IL-6 
and TNFα, and to a lower extent IL-1β and IL-10. 
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Phagocytosis of apoptotic bladder cancer cell lines by macrophages 
A crucial step in the process of bladder cancer antigen presentation by APC to  
T lymphocytes is represented by the phagocytosis of apoptotic cancer cells by 
mononuclear phagocytes. To assess whether BCG-challenge and/or the expression of 
sT/sTn antigens by bladder cancer cells affected their uptake by macrophages, we induced 
apoptosis in BCG-challenged or unchallenged bladder cancer cell lines and measured 
their phagocytosis by monocyte-derived macrophages (Figure 3.15). No significant 
differences were seen in the propensity to undergo apoptosis by the different cell lines 
(data not shown). The phagocytosis of apoptotic HT1376 cells was not affected by  
BCG-challenging while it was higher for HT1376sT cells (Figure 3.15a). On the contrary, 
phagocytosis of MCR cells was not affected either by BCG-challenging or sTn expression 
(Figure 3.15b). 
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Figure 3.15. Phagocytosis of apoptotic bladder cancer cell lines by macrophages. a) Phagocytosis of 
apoptotic BCG-challenged or unchallenged HT1376NC (pink bars) or HT1376sT (orange bars) cells. 
Phagocytosis was not affected by BCG-challenging but was higher with HT1376sT cells. b) Phagocytosis of 
apoptotic BCG-challenged or -unchallenged MCRNC (light blue) or MCRsTn cells (dark blue). Phagocytosis 
was not affected either by BCG-challenging or sTn expression. Data are the mean ± SD of 3 experiments.  
* p < 0.05. 
 
These results suggest that the sT could facilitate the phagocytosis of apoptotic bladder 
cancer cells by macrophages, while the previous contact with BCG does not appear to 
play a role. The presence of sTn antigen didn’t show significant differences in the 
capacity of induction of phagocytosis of apoptotic bladder cancer cells by macrophages. 
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The aim of this thesis was the investigation of the response of bladder cancer cells to 
BCG in the context of a differential expression of Thomsen-Friedenreich related antigens 
sialyl-T (sT) and sialyl-Tn (sTn) and to investigate the response of macrophages to the 
secretome of BCG-challenged bladder cancer cells. To this aim, a bladder cancer model 
of cell lines permanently expressing the cDNA of ST3GAL1 or of ST6GALNAC1  
was refined to obtain cell populations homogenously expressing the cognate carbohydrate 
antigens sT and sTn. Besides these studies, the expression of sT and sTn and  
their relationship in the clinic was studied in collaboration with groups of the  
University of Porto. 
 
 
IV.1 Cellular Models of Bladder Cancer 
 
The isolation of cell populations expressing homogeneously the sTn antigen from the 
bladder cancer cell line MCR was successfully achieved through magnetic sorting using 
an anti-sTn antibody. Owing to the lack of an anti-sT antibody, the same strategy was not 
applicable to the sorting of sT expressing cells from the cell line HT1376. Any attempt to 
pursue a negative selection, through the removal of cell populations reactive with the  
T-specific lectin PNA turned out to be unsuccessful because the population of cells 
unbound by the lectin was still containing a large percentage of PNA-positive cells  
(i.e. still expressing the T antigen). For this reason it was decided to adopt a cloning 
strategy based on single cell cloning through which homogeneous populations of  
PNA-negative cells were obtained. Lectin analysis of neuraminidase-treated cells 
HT1376sT cells indicated that the masking of T antigen by α2,3-linked sialic acid is 
reverted by neuraminidase treatment. Expression of ST6GALNAC1 in MCR cells induced, 
beside the expected appearance of sTn antigen, also profound changes in other  
Thomsen-Friedenreich related antigens. In particular, beside the Tn also the T antigen 
appeared to be profoundly inhibited by α2,6-sialylation, as revealed by the strong 
inhibition of PNA reactivity observed in MCRsTn. The notion that the T antigen is present 
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but almost completely masked by α2,6-sialylation is confirmed by our data in 
collaboration with investigators of the University of Porto (Lima et al. 2013), showing 
that treatment with β1,3-galactosidase of bladder cancer tissue sections unmasked the 
presence of sTn antigen. The reliability of our model of bladder cancer was confirmed by 
the expression of the transduced sialyltransferases at both the mRNA and  
enzyme activity. The expression microarray technique was used to study the 
transcriptome of the two bladder cancer cell lines used and the impact of sialyltransferase 
expression on whole gene expression. According to a recent study on molecular 
classification of bladder cancer (Sjodahl, Lovgren et al. 2013), three types can be 
identified on the basis of the expression of a set of genes: the urobasal (Uro, which is 
further divided in subtypes A and B), the squamous cell cancer-like (SCCL) and the 
genomically unstable (GU).  This classification has prognostic value in that UroA 
tumours are associated with a good prognosis, while UroB and SCCL tumours are 
associated with the worst outcome (Sjodahl, Lovgren et al. 2013). Unlike UroA, SCCL 
tumours show high expression of CDH3 (coding for P-cadherin), EGFR, KRT5, KRT14, 
but not FGFR2, ERBB2 and KRT20 (Chan, Espinosa et al. 2009, Volkmer, Sahoo et al. 
2012, Sjodahl, Lovgren et al. 2013). UroB tumours demonstrate features shared by both 
UroA and SCCL subtypes.  In contrast to SCCL tumours, GU tumours showed high 
CDH1 (coding for E-cadherin), ERRB2, CCNB1, MKI67, low CDH3 expression, while 
genes FGFR3, EGFR, KRT5, KRT6 and KRT14 were not expressed. Moreover, it was 
found that the transition from UroA to SCCL and GU is accompanied by a change from 
high expression of early cell cycle genes, in particular CCND1, to high expression of late 
cell cycle genes, e.g., CCNE1 (Sjodahl, Lauss et al. 2012). In Table 4.1 are presented the 
expression levels detected by microarray analysis in both cell models of genes marking 
the described molecular subtypes. A group of genes showed high expression in HT1376 
cells and very low expression in MCR cells: gene CDH1 and five genes belonging to the 
cytokeratin group (KRT5, KRT6A, KRT6B, KRT6C and KRT14). In HT1376, the high 
CDH1 expression is consistent with a GU phenotype, while high expression of KRT 
genes is consistent with a SCCL phenotype. Cyclin genes were expressed at a good level 
by both cell lines, although in MCR is prevalent the expression of an early cell cycle 
cyclin, like CCND1, while in HT1376 a late cell cycle cyclin, like CCNE2 prevails. This 
feature is consistent with literature data indicating an invasive SCCL or GU phenotype for 
both cell lines (Rasheed, Gardner et al. 1977, Zoli, Ricotti et al. 2004), rather than an 
UroA or UroB phenotype. Even though transduction with either sialyltransferase causes 
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profound changes in gene expression, no significant changes were observed for the genes 
listed in Table 4.1. 
 
Table 4.1. Molecular classification of HT1376 and MCR bladder cancer cells according to  
Sjodahl et al. 
molecular 
subtype 
HT1376 
(Log2E) 
Gene 
symbol 
Gene product 
MCR 
(Log2E) 
molecular 
subtype 
SCCL or GU 
9.0 CCND1 cyclin D1 11.2 
SCCL 
9.8 CCND3 cyclin D3 9.7 
9.8 CCNB1 cyclin B1 9.5 
9.6 CCNB2 cyclin B2 10.0 
8.0 CCNE1 cyclin E1 8.4 
9.4 CCNE2 cyclin E2 7.9 
GU 11.1 CDH1 cadherin 1, or E-cadherin (epithelial) 5.0 SCCL 
SCCL or GU 8.8 CDH3 cadherin 3, or P-cadherin (placental) 8.2 SCCL or GU 
SCCL or GU 7.6 FGFR3 fibroblast growth factor receptor 3 8.4 SCCL or GU 
SCCL 11.3 EGFR epidermal growth factor receptor 10.7 SCCL 
GU 8.4 ERBB2 
v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2 
7.5 SCCL 
SCCL 10.4 KRT5 keratin 5 5.6 GU 
SCCL 
9.9 
7.1 
10.9 
KRT6A 
KRT6B 
KRT6C 
keratin 6 
5.8 
6.3 
6.5 
GU 
SCCL 11.7 KRT14 keratin 14 6.5 GU 
GU 10.6 MKI67 
MKI67 (FHA domain) interacting 
nucleolar phosphoprotein 
10.4 GU 
 
The maintenance of life requires that DNA replication is exceptionally accurate. Errors in 
these processes result in mutations that might cause cancer. The fact that the DNA in 
cancer cells is different from the DNA in normal cells indicates that carcinogenesis 
involves substantial errors in DNA replication, deficits in DNA repair, and alterations in 
chromosomal segregation (Loeb 2001). Once the rarity of mutations in normal cells 
cannot explain the large numbers of mutations observed in human cancers, it has been 
suggested that cancer cells are frequently characterized by an intrinsic tendency to 
accumulate mutations (Schmitt, Prindle et al. 2012, Datta, Gutteridge et al. 2013). 
Microsatellite instability and chromosomal instability are two types of genetic instability 
(Lengauer, Kinzler et al. 1997, Orr-Weaver and Weinberg 1998). Aneuploidy and DNA 
errors represent a general feature of bladder cancer malignancy (Phillips and Richardson 
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2006, Puntoni, Zanardi et al. 2007). Cancers that exhibit extensive microsatellite 
instability are those with mutations or inactivation of mismatch repair genes; those that 
exhibit predominantly chromosomal instability are those with mutations that affect the 
segregation of chromosomes during mitosis (Loeb 2001). Many genes, including those 
involved in maintaining genome stability, chromosomal segregation, DNA repair genes, 
cell cycle checkpoints, if changed could induce a mutator phenotype (Loeb 2001).  
Constitutive expression of ST3GAL1 in HT1376 cells led to a decreased expression of 
several genes whose common feature is the preservation of genomic stability.  
In particular, we found down-regulated genes involved in different mechanisms of DNA 
repair, including homologous recombination (HR), nucleotide excision repair (NER), 
base excision repair (BER). Moreover, we found down-regulated several genes involved 
in the accuracy of chromosomal segregation during mitosis. Interestingly, constitutive 
expression of ST6GALNAC1 in MCR cells also results in a down-regulation of several 
genes involved in different mechanisms of DNA repair and in chromosomal segregation. 
Strikingly, the two sialyltransferases affect in a parallel manner groups of genes with 
similar functions. These data suggest that the expression of either sialyltransferase in the 
two cell lines leads to a decreased ability to fix mutations and to an inherent tendency to 
aneuploidy, resulting in genetic instability and tumour progression. In MCR cells, 
ST6GALNAC1 turns on genes ERBB3 and ERBB4, in the presence of good levels of 
expression of ERBB2.  It should be remembered that the human gene ERBB2 (or HER-2) 
encodes a 185 kDa cell surface transmembrane glycoprotein (p185
erbB2
) with intrinsic 
tyrosine kinase activity that is frequently amplified or over-expressed in breast cancer and 
other epithelial cancers. Most studies have linked ERBB2 over-expression with poor 
clinical prognosis in breast cancer patients (Slamon, Clark et al. 1987, Eccles 2001).  
Members of the ERBB family undergo ligand-induced heterodimerization.  
Although ERBB2 is unique within this family as having no known ligand, it is 
nevertheless the favoured heterodimerization partner of the other three family members.  
It has been shown that ERBB2 is normally expressed in an activated conformation,  
i.e. ready for heterodimer formation (Cho, Mason et al. 2003). In contrast, activation of 
the other ERBB family members is dependent on ligand binding. Therefore, rather than 
being a growth factor receptor per se, the role of ERBB2 may be that of an essential 
common subunit of ERBB receptor signal transduction. Thus, in the presence of ERBB2, 
the higher expression of other ERBB family members would have the effect of strengthen 
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the ligand-induced ERBB signalling. These changes, in addition with an increase of the 
tumour protein p63 coding gene (TP63) and a decrease of the tumour suppressor RB in 
MCRsTn cells are consistent with a moderate positive effect on cell growth.  
Another functional group of genes affected by ST6GALNAC1 expression is represented 
by those encoding proteases. The up-regulation of cathepsin L2 and H (CTSL2 and CTSH) 
as well as kallikrein-related peptidase 5 (KLK5) in association with the down-regulation 
of the serine protease inhibitors SERPINE1 and SERPINE2 is consistent with an increase 
of the overall protease activity in MCRsTn cells. 
In a recent study in collaboration with investigators of the University of Porto  
(Ferreira et al. 2013), we have shown that MCRsTn cells display slightly increased 
proliferation, increased cell motility and increased Matrigel invasion, data which are fully 
consistent with the changes in gene expression profile. Also consistent with current data 
are those of clinical specimens (Ferreira, Videira et al. 2013), showing that the sTn 
antigen is preferentially expressed by high-grade and muscle invasive cancers. 
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IV.2 Response of Bladder Cancer to BCG 
 
The interaction of BCG with urothelial endothelium is a key step in the development of 
anti-tumour response. Thus, after instillation of BCG, it accumulates near the wall of the 
bladder, allowing the establishment of specific and unspecific contacts to urothelial cells. 
The lumen of the bladder allows to accumulate BCG, specifically without adhering to the 
cell wall of the bladder (Bevers, Kurth et al. 2004). In clinical studies, intravesical BCG 
treatment has reduced bladder cancer recurrence rates by inducing a series of complex 
systemic humoral and cellular immune responses (Agarwal, Agrawal et al. 2010).  
It has been reported that the internalization process is dependent on the dose of BCG and 
time of incubation, as well as the state of differentiation of tumour cells, being that cells 
poorly differentiated (high grade) have a higher rate of internalization (de Boer, Bevers et 
al. 1996). Data from a large clinical study suggest that the five most commonly used 
strains Connaught, RIVM, Pasteur, Tice and A. Frappier do not differ in terms of 
preventing tumour progression (Sylvester, van der Meijden et al. 2002) even though 
recent in vitro studies on bladder cancer cell lines suggest that different commercial BCG 
strains could exert different anti-tumour activities (Secanella-Fandos, Luquin et al. 2013).  
In this study is shown that internalization of BCG occurs for both cell lines in a  
time-dependent manner, independently on sTn or sT expression. Nevertheless, it should 
be noticed that the strain RIVM of BCG showed a tendency to be more internalized by 
HT1376sT or MCRsTn when confronting with non expressing sT or sTn antigen cells.  
A higher internalization of BCG might be correlated with the higher internalization of 
BCG, by sTn expressing bladder cancer cells, was concurrent with a higher loss of 
viability of these cells after BCG internalization. The observations that sTn cancer cells 
are more susceptible to BCG may be one of the mechanisms associated with the fact that 
bladder cancer patients expressing sTn respond better BCG (Lima, Severino et al. 2013). 
Lima, Severino et al paper is presented in Supplement II section. After internalization by 
tumour cells, BCG is processed and degraded and its antigens are presented at the cell 
surface in the context of MHC complex. This response of bladder cancer cells to  
BCG-challenging is complex and only partially understood. Among the functional 
consequences of BCG interaction is the modulation of the expression of MHC molecules 
(Ikeda, Toida et al. 2002) and the secretion of cytokines (Bevers, de Boer et al. 1998, 
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Bevers, Kurth et al. 2004). Consistently, gene expression analysis revealed increased 
expression of some transcripts encoding for class I or II MHC antigens upon  
BCG-challenging in both cell lines. 
The analysis of transcriptome changes in BCG-challenged HT1376 and MCR cells 
reveals that the number of genes modulated by BCG-challenging is much higher in the 
cell lines expressing ST3GAL1 or ST6GALNAC1. Among the genes which are 
consistently up-regulated only in sialyltransferase expressing cells are "caretaker" genes, 
suggesting a BCG-induced turn toward increased genomic stability, but only in 
sialyltransferase expressing cells. The mechanism(s) leading a cell surface change, such 
as the expression of Thomsen-Friedenreich related antigens on one or more glycoproteins, 
to a change in gene expression can be at the moment only hypothesized.  
However, the "outside-in" flow of information going from the cell membrane to the 
nucleus, triggered by the stimulation of membrane receptor and eventually leading to 
gene transcription can be conceivably modulated by postranslational modifications 
(including glycosylation) of these receptors. 
Among the ten cytokines whose presence we investigated in the secretome of our bladder 
cancer cell lines, only IL-6 and IL-8 were expressed and modulated by BCG-challenging. 
IL-6 was produced by HT1376 cells only after BCG-challenging, regardless of ST3GAL1 
expression. By contrast, unchallenged MCR cells produced good levels of IL-6, which 
were doubled by BCG-challenging only in ST6GALNAC1 expressing cell population.  
IL-6 is a multifunctional proinflammatory cytokine, playing multiple functions in 
angiogenesis and vascular modelling that may contribute to tumour cell proliferation and 
differentiation (Wei, Kuo et al. 2003, Culig 2011). Several studies have suggested that  
IL-6 is associated with a number of biological functions in bladder cancer, including cell 
proliferation, cell transformation, inflammation, and detrusor smooth muscle contractility  
(Han, Lee et al. 2009, Weng, Wu et al. 2009, Escudero-Lourdes, Medeiros et al. 2010, Li, 
Li et al. 2010). IL-6 levels in serum and urine have been also associated with progression 
in bladder cancer (Andrews, Shariat et al. 2002, Chen, Lin et al. 2013). Previous studies 
have indicated that BCG also increased IL-6 production in human and murine bladder 
cancer cell lines; however the mechanisms by which IL-6 affects human bladder 
carcinoma cells remain unclear (Chen, Crist et al. 2002, Chen, Zhang et al. 2009). 
Recently Tsui et al reported that IL-6-knockdown experiments in T24 cells and IL-6 
overexpression experiments in HT1376 cells resulted in IL-6 reduced cell proliferation, 
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migration, and invasion in vitro. Xenograft studies indicated that the overexpression of 
IL-6 down-regulated tumourigenesis of bladder cells and that IL-6 knockdown reversed 
this effect (Tsui, Wang et al. 2013). IL-8 was expressed at a good level by HT1376 cells 
but not by MCR cells. BCG-challenging turned on IL-8 production only in cells 
expressing either sialyltransferase. IL-8 is a neutrophil chemoattractant and an inducer of 
angiogenesis (Koch, Polverini et al. 1992, Mukaida 2000). Some authors have found that 
high levels of IL-8 production early during the treatment of bladder cancer are associated 
with better clinical responses to BCG and are responsible for immune cells recruitment  
(Rabinowitz, Smith et al. 1997, Kumar, Dubey et al. 2002). However, others reported 
high urinary IL-8 levels during intravesical instillation in patients who developed 
recurrence compared with the levels in those in remission (Sheryka, Wheeler et al. 2003, 
Sagnak, Ersoy et al. 2009). Recently, Secanella-Fandos et al reported that IL-6 and IL-8 
inhibited tumour growth in a dose dependent manner. When both interleukins were 
present at low concentrations, a synergistic effect on growth inhibition was observed. 
However, at higher concentrations inhibition was increased only with respect to the IL-8 
dose alone (Secanella-Fandos, Luquin et al. 2013). The apparently contradictory 
relationship between IL-6 and IL-8 production and anti-tumoural response should be 
considered in the context of the relationship between inflammation and cancer which is 
double edge. In fact, on one hand the inflammatory reaction is useful to eradicate the 
tumour while on the other hand the inflammatory environment is the necessary soil for 
cancer growth and progression. The finding that both cytokines are preferentially released 
by ST3GAL1- or ST6GALNAC1- expressing cells strongly indicates that the expression of 
these sialyltransferases might profoundly influence the clinical response to BCG.  
This could happen through different and not mutually exclusive mechanisms.  
First, at the level of the BCG interaction with bladder cells; second, at the level of a 
differential activity of receptors decorated by Thomsen-Friedenreich related antigens; and 
third, indirectly through a differential pattern of gene expression. 
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IV.3 Response of Macrophages to BCG-challenged BC cell lines 
 
Although the mechanism of action of BCG immunotherapy has not been fully elucidated, 
it is clear that it induces a local immune response characterized by massive inflow and 
infiltration of inflammatory cells to the lining and bladder lumen, which results in the 
production of various cytokines and in the development of a robust cellular response 
(Lockyer and Gillatt 2001, Kresowik and Griffith 2009). A key role in these processes is 
played by macrophages, a cell population present in almost all tissues which provides a 
link between innate and adaptive immunity (Gordon and Taylor 2005, Hao, Lu et al. 
2012). Macrophages can be activated by a variety of stimuli and polarized to functionally 
different phenotypes. Two distinct subsets of macrophages have been described: 
classically activated M1 and alternatively activated M2 macrophages (Hao, Lu et al. 
2012). M1 macrophages are classically activated by microbial products, secrete cytokines 
such as IL-12, which through the cooperation of other cell types, polarize the 
differentiation of T helper cells toward the Th1 phenotype whose hallmark is the cytokine 
IFNγ. This response leads to antimicrobial responses. On the other hand,  
M2 macrophages are involved in type 2 responses, during which T helper 2 lymphocytes 
secrete IL-4, IL-5 and IL-10. M2 macrophages are mainly involved in angiogenesis and 
tissue repair and are thought to provide help to tumour growth (Balkwill, Charles et al. 
2005, Mantovani, Allavena et al. 2008). However, M1 and M2 phenotypes are extremes 
in a continuum spectrum of functional conditions. The hallmark of M1 or M2 phenotypes 
can be considered the IL-12/IL-10 ratio, which is high for M1 and low for M2 
macrophages. The expression of other cytokines such as IL-1β, IL-6 or TNFα can be 
shared by macrophages of both phenotypes (Mantovani, Allavena et al. 2004).  
In our unstimulated monocyte-derived macrophages, the level of IL-10 is low while IL-12 
is undetectable. Moreover, cytokines IFNγ and IL-4, which are the hallmarks of Th1 and 
Th2 lymphocyte differentiation, respectively, are barely or not detectable.  
On the contrary, inflammatory cytokines, such as IL-1β, IL-6 and TNFα and the  
anti-inflammatory IL-10 are induced only by the secretome of BCG-challenged bladder 
cancer cells, particularly when expressing either sialyltransferase. IL-8 was produced at a 
high level even by unstimulated macrophages and exhibited little variations upon  
BCG-challenging. Altogether, these results indicate that the macrophages used in our 
model system, after secretome from BCG-challenged and sT or sTn expressing bladder 
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cancer cells, display a phenotype oriented toward a M1 type accordingly to ability to 
produce inflammatory cytokines like M1 type. Nevertheless, the expression of IL-10 
suggests an intermediate phenotype between M1 and M2. The stimulation of 
inflammatory cytokine production by macrophages is crucially dependent on the 
secretome of BCG-challenged bladder cancer cells expressing sialylated  
Thomsen-Friedenreich related antigens, and in the case of sTn antigens, this may also 
explain the better response to BCG observed in sTn positive bladder cancer patients. 
Particularly the expression of sT in our bladder cancer model showed also a tendency for 
higher phagocytosis level of apoptotic bladder cancer cells by macrophages. In fact, in the 
latest publication of Lima et al., clinical data correlated a worst response to BCG when 
M2 type macrophages were present (Lima, Oliveira et al. 2013), and accordingly to our 
most recent results, it was found that the expression of sTn and of s6T antigens  
(the biosynthesis of both is dependent on ST6GALNAC1) is predictive of BCG response 
and is associated with a better recurrence free survival (Lima, Severino et al. 2013).  
Lima, Severino et al paper is presented in Supplement II section. Thus, BCG treatment 
turns the expression of sTn/s6T from an unfavourable condition associated with increased 
progression to a favourable condition associated with a better prognosis. Current results 
are fully consistent with these clinical data because they show how the whole gene 
expression profile is modulated by the expression of either sialyltransferase and that the 
secretion of inflammatory cytokines, a crucial step in the establishment of an effective 
anti-tumour response, is dramatically dependent on sT or sTn expression. 
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IV.4 Conclusions 
 
In conclusion, it appears that the expression of either sialyltransferase in the two cell lines 
induces the down-regulation of several genes involved in proper chromosomal 
segregation and repair of DNA alterations. Although the level of modulation is rarely 
high, it is reasonable to expect that the concomitant and parallel down-regulation of many 
genes involved in the same cellular function results in a phenotype more prone to 
chromosomal instability. The changes of expression of genes encoding members of the 
ERBB family we observed in ST6GALNAC1-transduced cells are consistent with a more 
sustained cell growth. Moreover, these cells display also a modulation of the protease 
genes and of their inhibitors which is consistent with the recently observed increased 
proteolytic activity of these cells (Ferreira, Videira et al. 2013). The effect of BCG on 
gene expression appears to be remarkably stronger on cells expressing either 
sialyltransferase rather than on mock-transduced cells, while the cytokine production and 
the ability to induce cytokine secretion by macrophages are also crucially dependent on 
sTn or sT antigens. Together with the clinical studies showing that carbohydrate antigens 
are major determinants in predicting successful BCG therapy, Thomsen-Friedenreich 
related antigens emerge as key determinants in the biology of bladder cancer and in the 
clinical response to BCG immunotherapy. 
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Effect of ST3GAL1 expression 
In Figure I.1 is presented, as a heat-map, the ST3GAL1-dependent modulation of genes in 
HT1376 cells. Up- or down-regulation refer to the change in HT1376sT compared with 
HT1376NC cells.   
Genes modulated by ST3GAL1 expression in HT1376 cells 
-3,0  3,0 
-2,7 HLA-DMA -1,6 MYH15 -1,3 HK2 -1,1 PSMB7 -1,0 LY6K -0,9 VDR -0,9 TFPI 
-2,7 RHOXF2 -1,6 S100A4 -1,3 KCNJ15 -1,1 TACC3 -1,0 CDRT1 -0,9 HIST1H3B -0,9 LMNB2 
-2,6 FRMD3 -1,6 RAI14 -1,3 CPNE2 -1,1 LDLRAD3 -1,0 KCND2 -0,9 GDA -0,9 SLC2A6 
-2,3 ALCAM -1,6 POM121L1P -1,3 SCIN -1,1 ATXN1 -1,0 SCARNA22 -0,9 TRERF1 -0,9 QSOX2 
-2,3 TGFB2 -1,6 EFNA5 -1,2 EMP3 -1,1 MGST3 -1,0 POP7 -0,9 SPANXC -0,9 CEL 
-2,3 KCNJ2 -1,5 FGF12 -1,2 COL1A2 -1,1 XYLT1 -1,0 SLC45A4 -0,9 ATP1B1 -0,9 SNORD32A 
-2,2 LASS6 -1,5 FBN2 -1,2 NR3C2 -1,1 HMGN2 -1,0 NMNAT2 -0,9 NDUFS6 -0,9 AK1 
-2,2 GSTM4 -1,5 FBN1 -1,2 HIST1H4K -1,1 HIST2H2AB -1,0 GPR177 -0,9 CDYL2 -0,9 GPSM2 
-2,1 IGFL4 -1,5 ANTXR1 -1,2 PTPRM -1,1 FAM25B -1,0 ATP5I -0,9 TCEB2 -0,9 PTTG1 
-2,1 DEPDC6 -1,5 FRY -1,2 PLXDC2 -1,1 PPAP2C -1,0 MFAP5 -0,9 CCNF -0,9 TNFAIP2 
-2,1 GAGE12C -1,5 LGALS1 -1,2 TLE4 -1,1 GCOM1 -1,0 LOC389832 -0,9 KIAA1671 -0,9 CCNB1 
-2,0 STC1 -1,5 SNORD68 -1,2 TRIM58 -1,1 EPB41L2 -1,0 MALT1 -0,9 C21orf70 -0,9 PLAC8 
-2,0 REXO1L1 -1,5 ZNF462 -1,2 DDR1 -1,1 THOP1 -1,0 OIP5 -0,9 FAM64A -0,9 TNFRSF10D 
-2,0 MXRA7 -1,4 RNF152 -1,2 TERC -1,1 CDH18 -1,0 CD177 -0,9 CHST6 -0,9 EPHA4 
-1,9 CCL2 -1,4 NPTX1 -1,2 MCC -1,1 DYNLT1 -1,0 CD200 -0,9 NDUFA8 -0,9 SNORD24 
-1,9 PLLP -1,4 LOXL4 -1,2 HAUS7 -1,1 ADAMTS1 -1,0 CYP2J2 -0,9 SNORA52 -0,9 SNORD35A 
-1,9 PAGE4 -1,4 FAM90A7 -1,2 METTL11A -1,1 NOTCH1 -1,0 ENAH -0,9 SSNA1 -0,9 SIVA1 
-1,8 AKR1C1 -1,4 THBD -1,2 LOC100130876 -1,1 KIAA1467 -1,0 KIFC1 -0,9 MTSS1L -0,9 LMNB1 
-1,8 CT47A1 -1,4 CFH -1,2 ALDH1B1 -1,1 FEZ1 -1,0 DKFZP564O0823 -0,9 PRUNE2 -0,9 NUAK2 
-1,7 SPOCK1 -1,4 NXN -1,2 GRB10 -1,1 AKR1C2 -1,0 SNORA65 -0,9 FSCN1 -0,9 CST6 
-1,7 THBS1 -1,3 MXRA7 -1,2 DOK4 -1,0 CAPN6 -1,0 RNU2-1 -0,9 TMEM183A -0,9 MRPS7 
-1,7 SERPINE1 -1,3 KIAA0922 -1,2 HIST1H2AB -1,0 MND1 -1,0 C9orf102 -0,9 GALNT6 -0,9 SSX4 
-1,7 EDIL3 -1,3 KHDRBS3 -1,2 RPL35 -1,0 KIAA0802 -1,0 ASAP3 -0,9 TEAD2 -0,9 CDCA5 
-1,7 KRT5 -1,3 FAM101B -1,2 HDGFRP3 -1,0 PFN2 -1,0 COBRA1 -0,9 WNT7A   
-1,7 ANK3 -1,3 COL14A1 -1,1 FBXW5 -1,0 CXXC5 -1,0 C6orf129 -0,9 SURF6   
-1,7 KCNJ16 -1,3 HIST1H2AJ -1,1 KIF4A -1,0 ACOT1 -1,0 TLN1 -0,9 KIF3C   
-1,7 XG -1,3 TBC1D9 -1,1 CHST15 -1,0 CGA -1,0 RPS24 -0,9 NDUFS7   
-1,7 OLFML3 -1,3 CDC2L1 -1,1 MEGF6 -1,0 SPC24 -1,0 GLRX -0,9 HSPB8   
-1,7 LY6E -1,3 ANKH -1,1 ABLIM1 -1,0 PHACTR2 -1,0 MRPS34 -0,9 ROPN1L   
 
0,9 SUPT3H 0,9 RBMS1 1,0 ELOVL6 1,1 KDELR3 1,2 hCG_18385 1,3 IL1RAPL2 1,7 SH3BGRL 
0,9 CDK8 0,9 HLA-DQA2 1,0 SESN3 1,1 NIPAL2 1,2 EPS8 1,3 CD24 1,7 NPIPL3 
0,9 ZFAND1 0,9 ANKRD20A1 1,0 C20orf194 1,1 ANKRD36B 1,2 PDK4 1,3 RGL2 1,7 ICA1 
0,9 MTSS1 0,9 C2orf34 1,0 LOC220115 1,1 GUSBL2 1,2 FAM20C 1,3 SIAE 1,7 LY6G6C 
0,9 STARD3NL 0,9 RPS27 1,0 VIPR2 1,1 TMOD2 1,2 RLIM 1,4 SNORD28 1,8 RPS3A 
0,9 PTGES3 0,9 MANEA 1,0 PMS2L5 1,1 ERV3 1,2 SNORD27 1,4 KRT19P2 1,8 AIM2 
0,9 STOM 0,9 C11orf63 1,0 ZNF117 1,1 CBWD1 1,2 ZNF626 1,4 PROS1 2,0 LRRC37A 
0,9 RPL22L1 0,9 NDN 1,0 FAM164A 1,1 SNORD26 1,2 GRAMD1C 1,4 RPL21P28 2,3 TPTE 
0,9 SMG1 0,9 EVI5 1,0 SNORD25 1,1 SMG1 1,2 TGIF1 1,5 SATB2 2,3 CCDC72 
0,9 PSCA 0,9 PRCP 1,0 SIAE 1,1 ZNF675 1,2 ARP11 1,5 ZNF730 2,5 SLC39A2 
0,9 HSP90AB3P 0,9 PHKA1 1,1 AGAP4 1,1 ZNF525 1,2 UBLCP1 1,5 RFC1 3,0 CALB1 
0,9 MEIS2 1,0 ARL8B 1,1 SNORA40 1,2 TCN1 1,2 TPTE2 1,5 AVIL   
0,9 LOC729992 1,0 RAB18 1,1 ZNF257 1,2 POLR2J3 1,3 RNASE7 1,6 SNORD54   
0,9 TSPAN6 1,0 NDUFV2 1,1 AMY2A 1,2 PGLYRP3 1,3 POF1B 1,6 CHAC1   
0,9 RAB1C 1,0 PROS1 1,1 PGLYRP4 1,2 TMED10P 1,3 TMSB4X 1,6 PRKAR2B   
0,9 OCLM 1,0 PMS2L1 1,1 FLJ16171 1,2 SNORD47 1,3 SNORD13 1,7 MBNL3   
Figure I.1. Genes showing up- or down-regulation in HT1376sT cells compared with HT1376NC cells. 
Heat-maps are presented for the 2log expression ratio (≤ -0.9 in green or ≥ 0.9 in red) between HT1376sT 
cells and HT1376NC cells. Constitutive expression of ST3GAL1 induced significant (p ≤ 0.05) 
overexpression of 197 genes and down-regulation of 107 genes. Data are the mean of 3 experiments. 
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In HT1376sT cells, constitutive ST3GAL1 overexpression induced the down-regulation of 
197 genes and the up-regulation of 107 genes. 
 
Effect of BCG challenging on HT1376 cells transcriptome 
The impact of BCG challenging on gene expression of HT1376 cells (HT1376NC and 
HT1376sT cells) is shown in Figure I.2. The analysis was restricted to genes modulated by 
BCG but not modulated by the ST3GAL1 overexpression (i.e. the genes which showed 
modulation by both ST3GAL1 overexpression and BCG treatment were excluded from 
this analysis). BCG induced up-regulation of 68 genes and down-regulation of 18 genes. 
 
Genes modulated by BCG in both HT1376NC and HT1376sT cells 
-1,0  1,0 
-1,1 FAM115A -0,7 ANKRD36B -0,6 CCDC85C -0,6 HSD17B14 -0,5 ZNF585A -0,5 ZNF852 -0,5 FAM108C1 
-0,9 TBC1D3D -0,7 TNFRSF11B -0,6 BMP8B -0,5 GPC2 -0,5 CUZD1 -0,5 UBE2MP1 -0,5 TSHZ1 
-0,8 CYP1B1 -0,6 LOC80154 -0,6 PSG3 -0,5 WIPF2       
 
0,5 ATP2B2 0,5 GJD4 0,5 FAM55C 0,5 FOXL1 0,5 LOC339742 0,6 CRNN 0,7 REEP1 
0,5 APLNR 0,5 FGF17 0,5 IRX5 0,5 FLJ40536 0,5 ARHGDIG 0,6 ADAMTS2 0,7 HLA-C 
0,5 SH3RF3 0,5 RAMP3 0,5 PYY 0,5 LILRB3 0,5 ART1 0,6 FAM148A 0,7 GABBR1 
0,5 CYS1 0,5 SLC6A13 0,5 FBXL16 0,5 GP6 0,6 SYCE2 0,6 XPNPEP2 0,7 GS85 
0,5 TMPRSS6 0,5 KRT37 0,5 CALHM3 0,5 GDF10 0,6 RASAL3 0,6 ZNF618 0,7 C21orf63 
0,5 MEOX1 0,5 PGLYRP2 0,5 UNC93A 0,5 SNAI1 0,6 LEFTY2 0,6 SAMD11 0,8 CDSN 
0,5 LAMC3 0,5 NYX 0,5 TMEM132D 0,5 FAM27L 0,6 BATF 0,6 CCDC153 0,9 FUT5 
0,5 CTRB1 0,5 KCNK3 0,5 TOX2 0,5 HEPACAM 0,6 TPRX1 0,6 PMP22 1,1 NT5C3 
0,5 RUNDC3A 0,5 ACP5 0,5 RAB44 0,5 LOC400931 0,6 LTA 0,6 FABP5   
0,5 C20orf185 0,5 CCR10 0,5 KRTAP10-8 0,5 ISG15 0,6 TMEM82 0,6 C19orf26   
Figure I.2. Genes showing up- or down-regulation in both HT1376NC and HT1376sT after BCG 
challenging. Heat-maps are presented for the 2log expression ratio (≤ -0.5 in green or ≥ 0.5 in red) between 
BCG-challenged and unchallenged HT1376 (NC and sT) cell lines. BCG challenging induced  
down-regulation of 18 genes and up-regulation of 68 genes. Data are the mean of 3 experiments. p ≤ 0.05. 
 
These results showed an overall up-regulation of the transcriptome of HT1376 cells after 
BCG challenging. When HT1376NC or HT1376sT were analysed separately for their 
response to BCG, we found that 25 genes were modulated only in HT1376NC  
(Figure I.3a) (13 genes down-regulated and 12 genes up-regulated), whereas 107 genes 
were modulated (80 genes down-regulated and 27 up-regulated) only in BCG-challenged 
HT1376sT cells (Figure I.3b). 
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a) 
Genes modulated by BCG only in HT1376NC cells 
-2,0  2,0 
-1,9 CDC2L1 -1,2 P704P -1,1 UGT2B7 -1,1 SGK269 -1,0 S100A12 -1,0 S100A9 -1,0 CARD17 
-1,3 C15orf48 -1,1 MOG -1,1 SLCO2A1 -1,0 TNFAIP3 -1,0 FLJ45950 -1,0 CFC1B   
 
1,0 CDSN 1,1 SNORA70 1,2 TRIM73 1,3 DND1 1,4 CD177 1,6 TMPRSS11E 1,6 UBTFL2 
1,0 MBD3L2 1,1 CCDC72 1,2 PRB1 1,4 BAT3 1,5 USP17L6P     
b) 
Genes modulated by BCG only in HT1376sT cells 
-3,0  3,0 
-2,9 PHGDH -1,5 SLC43A1 -1,3 FBXO32 -1,2 HIST2H2BF -1,1 SARS -1,0 RNU4-2 -1,0 CDCA7L 
-2,5 NUPR1 -1,5 VCAN -1,3 PSG4 -1,2 ZNF493 -1,1 IL20RB -1,0 THBS3 -1,0 MAP2 
-2,1 LRRC37A4 -1,5 ATP12A -1,3 FTL -1,1 TMEM120B -1,1 JMY -1,0 PAIP2B -1,0 RPL10A 
-1,9 PSAT1 -1,5 PSG2 -1,2 LOC642587 -1,1 TRIB3 -1,1 EIF4EBP1 -1,0 ZNF587 -1,0 RAPGEFL1 
-1,8 GAGE12C -1,4 CYP1A1 -1,2 SLC16A12 -1,1 TMEM154 -1,1 NPY5R -1,0 SLC16A13 -1,0 HBP1 
-1,8 CBS -1,4 GPT2 -1,2 CIR1 -1,1 IGHA1 -1,1 AARS -1,0 MKNK2 -1,0 ZBTB4 
-1,7 ASNS -1,4 TESK2 -1,2 PAGE2 -1,1 PCDHA3 -1,1 SLC9A9 -1,0 PIK3IP1 -1,0 PSG6 
-1,7 RNU5B-1 -1,4 SKIV2L -1,2 ADHFE1 -1,1 SLC6A9 -1,1 PPFIBP2 -1,0 PPP1R1C -1,0 DUX4 
-1,7 PCK2 -1,3 N4BP2L1 -1,2 SLC1A4 -1,1 ZNF615 -1,1 C9orf150 -1,0 TBL1X -1,0 NDRG1 
-1,7 ENPP2 -1,3 KLHL24 -1,2 CHP2 -1,1 CEBPB -1,1 ZNF737 -1,0 SCARNA9 -1,0 TUBE1 
-1,6 ASS1 -1,3 SLC37A2 -1,2 ARHGAP26 -1,1 TMPRSS13 -1,0 ACSL5 -1,0 PSPH -1,0 DKK3 
-1,5 KIAA0746 -1,3 STC2 -1,2 TCP11L2         
 
1,0 CLEC18A 1,0 CLSPN 1,0 ORC6L 1,0 TPPP3 1,1 DSCC1 1,1 FLJ25715 1,3 MAPK8IP1 
1,0 SNORA70B 1,0 FKBP5 1,0 MAGEA9 1,0 KRT6B 1,1 SMA5 1,2 OBP2B 1,3 GOLGA9P 
1,0 ERI1 1,0 CENPI 1,0 ST6GALNAC5 1,0 RP5-1022P6,6 1,1 SLITRK5 1,2 PDSS1 1,4 PPP2R3B 
1,0 LRP8 1,0 CCNE2 1,0 PCDHA12 1,0 MXRA8 1,1 KRTAP23-1 1,2 CTGF   
Figure I.3. Genes showing differential modulation after BCG-challenging in HT1376NC or HT1376sT 
cells. Heat-maps are presented for the 2log expression ratio (≤ -1.0 in green or ≥ 1.0 in red) between  
BCG-challenged HT1376NC or HT1376sT cells and unchallenged cells. a) Group of genes modulated by 
BCG challenging in HT1376NC, but not in HT1376sT cells. b) Group of genes modulated by BCG 
challenging in HT1376sT, but not in HT1376NC cells. Twenty five genes showed modulation  
(12 up-regulation, 13 down-regulation) in HT1376NC, cells, but not in HT1376sT. On the contrary, 107 genes 
displayed modulation in HT1376sT cells but not in HT1376NC. Of these, 27 displayed up-regulation and  
80 down-regulation. Data are the mean of 3 experiments. p ≤ 0.05. 
 
This finding is consistent with the notion that ST3GAL1 expression makes the genome of 
bladder cancer cells more prone to BCG-induced modulation.  
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Effect of ST6GALNAC1 expression  
In Figure I.4 is presented as a heat-map the modulation of genes whose expression was 
modulated by ST6GALNAC1. In MCRsTn cells, the constitutive ST6GALNAC1 
overexpression induced the down-regulation of 114 genes and the up-regulation of  
83 genes. 
 
Genes modulated by ST6GALNAC1 expression in MCR cells 
-3,0  3,0 
-2,7 PLCB1 -1,5 ZNF675 -1,3 NMD3 -1,1 PSG3 -1,0 ACSL4 -0,9 EEA1 -0,9 PTGES3 
-2,7 LOX -1,5 ZNF141 -1,3 FRAS1 -1,1 FBN2 -1,0 LAMA1 -0,9 PIK3R1 -0,9 SUGT1P 
-2,5 GLIPR1 -1,4 CD302 -1,2 PAPPA -1,1 SLC16A7 -1,0 MAN2B1 -0,9 NCF1 -0,9 FLRT2 
-2,3 MME -1,4 EMILIN2 -1,2 NID2 -1,1 IMPAD1 -1,0 LPAR3 -0,9 DOCK11 -0,9 GLTP 
-2,3 PSG6 -1,4 SYT14 -1,2 ZNF717 -1,1 ZNF542 -1,0 ITGB3 -0,9 ANKRD1 -0,9 ZNF850P 
-2,1 SLC17A8 -1,4 SRPX2 -1,2 FAR2 -1,1 OCIAD2 -1,0 BXDC1 -0,9 FOXRED2 -0,9 MRPL42 
-2,0 SERPINE1 -1,4 C1orf85 -1,1 LUM -1,1 PSAT1 -1,0 HS3ST3B1 -0,9 hCG_1757335 -0,9 C9orf23 
-1,9 KIAA1217 -1,4 NFIA -1,1 UAP1 -1,0 CTGF -1,0 STAC -0,9 PLLP -0,9 C18orf54 
-1,8 NTN4 -1,4 CCDC68 -1,1 C18orf19 -1,0 ZNF528 -1,0 EMR2 -0,9 ADAMTS1 -0,9 TM4SF1 
-1,8 F2R -1,3 IGHA1 -1,1 DCTPP1 -1,0 SACS -1,0 ISCA1 -0,9 ZNF91 -0,9 NT5E 
-1,7 PLEK2 -1,3 CCDC72 -1,1 MUC12 -1,0 SAMD9 -1,0 FAM35A -0,9 EPHA4 -0,9 GNAQ 
-1,6 DYSF -1,3 KCNH1 -1,1 PBX2 -1,0 TRIM38 -1,0 DSG2 -0,9 FAM19A2 -0,9 TNC 
-1,5 S100A16 -1,3 SYT1 -1,1 BMP4 -1,0 MARCH3 -1,0 RPP40 -0,9 PTPRG   
-1,5 ZNF474 -1,3 OPHN1 -1,1 DOK6 -1,0 HAUS6 -1,0 FUCA2 -0,9 ARHGAP29   
-1,5 HIST2H2BF -1,3 ANTXR2 -1,1 IFI16 -1,0 CHMP2B -1,0 VGLL3 -0,9 ZNF431   
-1,5 CCDC88C -1,3 IGHD -1,1 ARHGAP18 -1,0 LRRFIP1 -0,9 ELL2 -0,9 RIN3   
-1,5 CCDC3 -1,3 SPARC -1,1 LIPH -1,0 ZNF595 -0,9 ZNF22 -0,9 UBQLN4   
 
0,9 ME3 0,9 H19 0,9 CADM1 1,0 TSPAN33 1,1 CLSTN3 1,3 DDX60 1,6 JAM3 
0,9 STAG3L3 0,9 BHLHE41 1,0 PDGFRA 1,0 ELOVL7 1,1 FOXP2 1,3 BMF 1,6 NR2F1 
0,9 BCL11A 0,9 PSMB8 1,0 SULF2 1,0 SLCO3A1 1,2 CIB2 1,4 CSF1R 1,6 MAP2 
0,9 NR4A1 0,9 ARF5 1,0 TMEFF2 1,1 ABCD2 1,2 MAGI2 1,4 KCNK2 1,6 ERBB4 
0,9 AP1G2 0,9 COL8A1 1,0 PARP12 1,1 EPHA5 1,2 RNF43 1,4 C1QTNF6 1,7 FOSB 
0,9 IGSF3 0,9 TRIM26 1,0 IRF1 1,1 IGF2 1,2 UNC5C 1,4 CPPED1 1,7 TLR3 
0,9 GOLGA8B 0,9 GBP4 1,0 TP63 1,1 COL5A2 1,2 GAGE12C 1,4 MAGED1 1,8 OLR1 
0,9 PDK3 0,9 SMO 1,0 ERO1LB 1,1 BTN3A1 1,2 PBX1 1,4 EGR1 1,9 C12orf59 
0,9 MOSPD3 0,9 PIM2 1,0 FLOT2 1,1 APOL1 1,2 EDARADD 1,5 SCNN1A 2,0 STC1 
0,9 MYO5B 0,9 SLITRK6 1,0 HIP1 1,1 LRRTM1 1,3 KLRC4 1,5 PSMB9 2,2 PDE3A 
0,9 EFNA1 0,9 F11R 1,0 RP1-21O18.1 1,1 PER1 1,3 PKP2 1,6 LPAR6   
0,9 SLC1A3 0,9 DOK4 1,0 KIAA1324L 1,1 CEACAM1 1,3 GPC3 1,6 GPR87   
 
Figure I.4. Genes showing up- or down-regulation in MCRsTn cells compared with MCRNC.  
Heat-maps are presented for the 2log expression difference (≤ -0.9 in green or ≥ 0.9 in red) between 
MCRsTn cells and MCRNC cells. In MCRsTn cells, constitutive ST6GALNAC1 overexpression induced the 
down-regulation of 114 genes and the up-regulation of 83 genes. Data are the mean of 3 experiments.  
p ≤ 0.05. 
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Effect of BCG challenging on MCR cells transcriptome 
The gene expression profile of BCG-challenged MCR (MCRNC and MCRsTn cells) cells 
confronted with that of unchallenged cells is presented in Figure I.5. The analysis was 
restricted to genes modulated by BCG but not modulated by the ST6GALNAC1 
overexpression (i.e. the genes which showed modulation by both ST6GALNAC1 
expression and BCG treatment were excluded from this analysis). BCG induced  
up-regulation of 25 genes and down-regulation of 24 genes. 
 
Genes modulated by BCG in both MCRNC and MCRsTn cells 
-1,5  1,5 
-1,5 RGL2 -0,8 CD177 -0,6 MUC21 -0,5 PCDHA13 -0,5 SPINT1 -0,5 PCDHA1 -0,5 CHAT 
-1,2 OR2A1 -0,8 FLJ25715 -0,5 FAM176A -0,5 SLC5A3 -0,5 KCNK9 -0,5 CPA1 -0,5 FAM21C 
-0,8 BTNL8 -0,7 BAT3 -0,5 CALML5 -0,5 AMOT -0,5 S1PR4 -0,5 TRIB3   
-0,8 SAGE1 -0,6 LOC440518 -0,5 TMPRSS13 -0,5 SCXA       
 
0,5 CENPC1 0,5 EME1 0,5 SNORA14B 0,5 PYROXD1 0,6 TMEM183A 0,8 PDK1 1,1 HLA-DQA2 
0,5 PTBP2 0,5 SDCCAG8 0,5 UNQ3028 0,5 CHEK2 0,6 LRRC37A4 0,9 ZNF737 1,3 LOC727832 
0,5 SVEP1 0,5 GCA 0,5 NCRNA00201 0,5 PLK2 0,7 CSGALNACT1 1,0 SKP1   
0,5 MSH5 0,5 KRAS 0,5 ANKRD32 0,6 GRIP1 0,7 FLJ45950     
 
Figure I.5. Genes showing up- or down-regulation in both MCRNC and MCRsTn after BCG 
challenging. Heat-maps are presented for the 2log expression ratio (≤ -0.5 in green or ≥ 0.5 in red) between 
BCG-challenged and unchallenged MCR (NC and sTn) cell lines. BCG challenging, 24 genes are  
down-regulated and 25 genes are significantly up-regulated. Data are the mean of 3 experiments. p ≤ 0.05. 
 
These results showed an overall equivalent up- and down-regulation of MCR cell 
transcriptome after BCG challenging. When the BCG response of MCRNC or MCRsTn 
cells was analysed separately (Figure I.6) we found that 17 genes were modulated only in 
MCRNC cells (11 genes down-regulated and 6 up-regulated), whereas 38 genes were 
modulated only in MCRsTn cells (29 were up-regulated and 9 down-regulated). 
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a) 
Genes modulated by BCG only in MCRNC cells 
-2,0  2,0 
-1,8 GOLGA8D -1,3 EMP1 -1,2 FAM183B -1,1 C7orf11 -1,0 RLBP1L2 -1,0 DOC2B -1,0 USP17L6P 
-1,7 TM4SF19 -1,3 AJAP1 -1,1 IFFO2 -1,0 XCL1       
 
1,0 ANKRD20B 1,0 PCDHB5 1,0 BATF3 1,1 ARHGDIG 1,2 ANKRD20B 1,4 SLC27A2   
 
 
b) 
Genes modulated by BCG only in MCRsTn cells 
-2,5  2,5 
-2,4 RGPD5 -1,4 CGB2 -1,0 GGT3P -1,0 ESPNP -1,0 AMAC1L3 -1,0 MBD3L2 -1,0 ARHGDIG 
-1,5 KRTAP4-9 -1,3 DUX4           
 
1,0 ETV4 1,0 NT5C3 1,1 TAS2R19 1,2 DNAH14 1,3 GOLGA8E 1,4 SNORD6 1,9 NPIPL3 
1,0 SNORD80 1,0 C21orf63 1,1 PSD3 1,2 SNORD47 1,3 CBWD1 1,5 USP6 2,1 H3F3A 
1,0 SNORA1 1,0 SNRPG 1,1 RAB7A 1,3 AREG 1,3 RNU5B-1 1,6 TMPRSS11E 2,3 SCARNA4 
1,0 ACTR3B 1,0 SCARNA9L 1,1 GNG4 1,3 SNORD45B 1,4 SNORD29 1,6 RFC1 2,3 SNORD25 
 
 
Figure I.6. Genes showing differential modulation after BCG challenging in MCRNC or MCRsTn cells. 
Heat-maps are presented for the 2log expression difference (≤ -1.0 in green or ≥ 1.0 in red) between  
BCG-challenged MCRNC or MCRsTn cells and their respective unchallenged cells. a) Group of genes 
modulated by BCG challenging in MCRNC, but not in MCRsTn cells. b) Group of genes modulated by BCG 
challenging in MCRsTn, but not in MCRNC cells. In MCRsTn bladder cancer cells, after BCG challenging,  
a) 17 genes failed to respond to BCG whether in MCRNC these responded negatively (11 genes) or 
positively (6 genes). On the other hand b) 38 new genes differentially respond to BCG challenging  
(29 genes were up-regulated and 9 were down-regulated). Data are the mean of 3 experiments. p ≤ 0.05. 
 
This finding is consistent with the notion that ST6GALNAC1 expression makes the 
genome of bladder cancer cells more prone to BCG-induced modulation. 
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